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1Abstract
Quinolinate phosphoribosyltransferase (QPRTase, EC 2.4.2.19) is an intriguing
enzyme which appears to catalyse two distinct chemical reactions; transfer of a
phosphoribosyl moiety from 5-phosphoribosyl-1-pyrophosphate to the nitrogen of
quinolinic acid and decarboxylation at the 2-position to give nicotinic acid
mononucleotide. The chemical mechanism of QPRTase is not fully understood. In
particular, enzymatic involvement in the decarboxylation step is yet to be
conclusively proven. QPRTase is neurologically important as it degrades the potent
neurotoxin, quinolinic acid, implicated in diseases such as Huntington’s disease and
AIDS related dementia. Due to its neurological importance and unusual chemistry the
mechanism of QPRTase is important. Described here is a mechanistic study on
human brain QPRTase.
Human brain QPRTase was successfully expressed in E. coli BL21 (DE3) from the
pEHISTEV-QPRTase construct and the protein was efficiently purified by nickel
affinity chromatography. The crystal structure was solved using multiwavelength
methods to a resolution of 1.9 Å. Human brain QPRTase was found to adopt an
energetically stable hexameric arrangement. The enzyme was also found to exist as a
hexamer during gel filtration under physiological conditions.
Kinetic studies allowed the measurement of the kinetic parameters for quinolinic acid.
The data gave a Km of 13.4  1.0 M and a Vmax of 0.92  0.01 M min-1. There was
no evidence for cooperative binding of quinolinic acid to the six subunits of the
QPRTase hexamer. The enzyme showed maximum activity at approximately pH 6.
The active site of human brain QPRTase is a deep pocket with a highly positive
electrostatic surface composed of three arginine residues, two lysine residues and one
histidine residue. Mutation of these residues resulted in either complete loss or
significant reduction in enzymatic activity showing they are important for binding
and/or catalysis. A possible mechanism involving QPRTase in the decarboxylation of
quinolinic acid mononucleotide was proposed.
A series of quinolinic acid analogues were synthesised and tested as inhibitors of
QPRTase. The inhibition studies highlighted some key interactions in the active site.
2Chapter One
Introduction
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1.1 Tryptophan metabolism
In mammals, tryptophan cannot be generated biosynthetically and is therefore
essential in mammalian nutrition. For humans, the average daily requirement for
tryptophan is low; 250 mg and 160 mg per day for men and women, respectively, and
as such is met entirely by dietary intake.1 In lower organisms, however, tryptophan is
generated biosynthetically via a multi-step pathway.
Tryptophan 1 can be metabolised by several pathways to produce a number of
biologically active molecules. Tryptophan metabolites with an intact indole nucleus
arise by way of four possible routes.2 The first route is the serotonin pathway, an
important pathway in mammalian tryptophan metabolism.1 This is a short metabolic
pathway consisting of two enzyme catalysed steps, tetrahydrobiopterin (BH4)
mediated hydroxylation followed by decarboxylation, and leads to the formation of
5-hydroxytryptamine 3 (5-HT or serotonin) (Scheme 1.1).
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Scheme 1.1: The serotonin pathway of tryptophan metabolism.
The second possible pathway involves decarboxylation of tryptophan to form
tryptamine, which in turn acts as a precursor for other compounds including indole,
-carboline and ergoline alkaloids and auxins. This is therefore an important pathway
for tryptophan metabolism in plants and some bacteria but is not important in
mammalian metabolism.
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The third route involves cleavage of the tryptophan side chain to release indole, a
reaction catalysed by tryptophanase (EC 4.1.99.1). This is essentially the reverse of
the final stage of tryptophan biosynthesis in bacteria and plants. Again, this reaction
is not important in mammalian tryptophan metabolism.
The fourth route to indolic tryptophan metabolites involves transamination of
tryptophan to produce indole-3-pyruvate, although this is also a minor pathway in
mammalian tryptophan metabolism.
Tryptophan metabolites that do not contain an intact indole nucleus arise via the
kynurenine pathway, which was first described as a major route for the metabolism of
tryptophan in 1947.3 The kynurenine pathway (Scheme 1.2) begins with the oxidative
cleavage of the heterocyclic ring of tryptophan 1 to give N-formylkynurenine 4. This
reaction is catalysed by one of two different haem-dependent oxygenase enzymes,
tryptophan 2,3-dioxygenase (TDO, EC 1.13.11.11), which in mammals is confined
almost exclusively to the liver,4 or indoleamine 2,3-dioxygenase (IDO,
EC 1.13.11.17), which is found in most other tissues.5 N-Formylkynurine is then
hydrolysed by a formamidase enzyme (EC 3.5.1.9) to give kynurenine 5, with release
of formate. Kynurenine is at a branch point in the pathway and can be metabolised by
three different routes. Firstly, kynurenine can undergo hydrolysis catalysed by
kynureninase (EC 3.7.1.3), a pyridoxal-5’-phosphate (PLP) dependent enzyme,
resulting in the removal of the aliphatic side chain as L-alanine. This yields
anthranilic acid 6 which, in lower organisms, may then be utilised in the biosynthesis
of aromatic amino acids. Alternatively, kynurenine may undergo a transamination
reaction catalysed by another PLP dependent enzyme, kynurenine aminotransferase
(KAT, EC 2.6.1.7), to give kynurenic acid 7, a stable aromatic metabolite sometimes
employed in the biosynthesis of quinolines in lower organisms. The third possibility
involves oxidation of the benzene ring catalysed by kynurenine 3-hydroxylase
(EC 1.14.13.9) to produce 3-hydroxykynurenine 8, which can then be converted
to 3-hydroxyanthranilic acid 9 also by reaction with kynureninase.
3-Hydroxyanthranilic acid then undergoes a rearrangement catalysed by
3-hydroxyanthranilic acid oxidase (3-HAO, EC 1.13.11.6) to form quinolinic acid 10.
Quinolinic acid is then converted to nicotinic acid mononucleotide 11 by the
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action of quinolinate phosphoribosyltransferase (QPRTase, EC 2.4.2.19). Further
transformations may then follow, leading to the nicotinamide coenzymes.
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Scheme 1.2: The kynurenine pathway of tryptophan metabolism.
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Scientific interest in the kynurenine pathway was primarily centred around both its
importance as a source of nicotinamide, an important intermediate in the synthesis of
the essential co-factor nicotinamide adenine dinucleotide (NAD) and also as the first
metabolic pathway to be affected by vitamin B-6 deficiency.6 Vitamin B-6 12 is
oxidised and phosphorylated in the body to pyridoxal-5’-phosphate (PLP) 13, which
is an essential cofactor for a number of enzymes involved in the kynurenine pathway
i.e. kynureninase and kynurenine aminotransferase.
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With the discovery that neurons and other cells release 5-hydroxytryptamine (5-HT)
as a neurotransmitter or local hormone respectively, the major focus of tryptophan
research shifted to the investigation of its role as a precursor of 5-HT via the serotonin
pathway. 5-HT is involved in controlling sleep, appetite, mood and behaviour.7
Dysfunction of the serotonin pathway can lead to reduced levels of cerebral 5-HT,
which can result in disorders such as insomnia and depression. It was initially
thought that such illnesses could be treated simply by the administration of high doses
of tryptophan. However, due to the complex metabolism of tryptophan this would not
only augment levels of 5-HT, but also the biosynthesis of various kynurenines via the
kynurenine pathway, which are thought to be implicated in a number of neurological
disorders (section 1.3). Consequently, tryptophan is no longer used to treat 5-HT
deficient disorders.8
The discovery that some kynurenine metabolites possess interesting biological
properties triggered a resurgence of interest in the kynurenine pathway. The most
important work concerns the neurological activity of quinolinic acid (section 1.2).
The kynurenine pathway, once perceived to be less important than the serotonin
pathway, is in fact the quantitatively dominant pathway for mammalian tryptophan
metabolism. In peripheral tissue, only 1% of dietary tryptophan is actually converted
to 5-HT, while greater than 95% is metabolised to kynurenines.9
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1.2 Neurological activity of quinolinic acid
The N-methyl-D-aspartic acid (NMDA) receptor is abundant and ubiquitously
distributed throughout the brain. Activation of the receptor mediates
neurotransmission across most excitatory synapses in the mammalian central nervous
system (CNS). In 1981, it was discovered that one member of the kynurenine
pathway, quinolinic acid, could excite neurons in the CNS by acting as an agonist at
the NMDA receptor.10 This first report of the excitatory activity of quinolinic acid
resulted from experiments in the cerebral cortex of anaesthetised rats, in which it was
demonstrated that quinolinic acid could excite all 54 neurons tested with an
apparently similar potency to NMDA itself. By comparing the structures of
quinolinic acid 10 and NMDA 14 it can be seen that they share a similar backbone,
shown in red, hence quinolinic acid is able to interact with the NMDA receptor.
Me
N
H
CO2H
CO2H
H
N
CO2H
CO2H
10 14
The NMDA receptor is important because it is implicated in key aspects of brain
function such as development, learning and memory. These functions are mediated
by calcium entry through the NMDA receptor-associated calcium channel upon
activation of the receptor by NMDA. However, over-activation of NMDA receptors
by agonists such as quinolinic acid triggers an excessive entry of Ca2+ ions into the
cell.11 Uncontrolled calcium influx overloads the transport systems and buffers which
normally act to reduce the concentration of free Ca2+ in the cell. The excess Ca2+
triggers a series of processes that promote neuronal cell death12,13 and hence quinolinic
acid possesses neurotoxic activity.10 The ways in which quinolinic acid-induced Ca2+
influx through NMDA-coupled ion channels leads to neuronal cell death are outlined
in Figure 1.1.
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Figure 1.1: Quinolinic acid induced neurotoxicity – the intracellular cascade of
biochemical events leading to excitotoxic cell death.14
Firstly, excessive Ca2+ influx leads to an elevation of the intracellular free Ca2+
concentration to a point that results in Ca2+ overload of mitochondria (Figure 1.1, 1).
The excess Ca2+ causes depolarization of the mitochondrial membrane potential,
malfunction of the mitochondrial electron transport chain and a decrease in ATP
synthesis.15 The resulting dramatic decrease in cellular ATP concentrations means
that energy requiring processes are severely compromised, leading to cell dysfunction
and ultimately neuronal cell death (Figure 1.1, A).
Secondly, studies have shown that oxidative/nitrosative stress is involved in NMDA
receptor-mediated excitotoxic neuronal cell damage by quinolinic acid. Quinolinic
acid-induced Ca2+ influx into cells triggers a series of processes that lead to increased
production of the highly toxic compound peroxynitrite (ONOO-) (Figure 1.1).
Peroxynitrite is formed in biological systems by the reaction of nitric oxide (NO) with
superoxide (O2-). It has been shown that stimulation of NMDA receptors leads to the
Ca2+-dependent activation of nitric oxide synthase (NOS, EC 1.14.13.39), resulting in
the increased production of nitric oxide in neurons (Figure 1.1, 2).16,17 Also the
increased entry of Ca2+ into the mitochondria, and subsequent malfunctioning of the
Chapter One Introduction
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mitochondrial electron transport chain, leads to increased production of reactive
oxygen species such as superoxide (O2-) (Figure 1.1, 3).18 The most powerful cellular
antioxidant system protecting against superoxide is the enzyme superoxide dismutase
(SOD, EC 1.15.1.1). However, it has been shown that the activity of superoxide
dismutase is significantly reduced in the presence of quinolinic acid and this further
contributes to the build up of superoxide.19 This simultaneously enhanced production
of nitric oxide and superoxide leads to the rapid formation of the highly toxic
compound peroxynitrite (Figure 1.1).
Peroxynitrite is a powerful oxidant and reacts with a variety of biomolecules to
produce a wide array of tissue damaging effects.20,21 Peroxynitrite is a particularly
effective oxidant of aromatic molecules and organosulfur compounds including free
amino acids and peptide residues. Peroxynitrite oxidises cysteine to the disulfide and
methionine to the sulfoxide. Tyrosine and tryptophan undergo single-electron
oxidations to radical cations, which are competitively hydroxylated, nitrated and
dimerised.22,23 These changes may lead to the dysfunction of essential proteins, for
instance tyrosine nitration has been suggested as a key factor in the case of reduced
superoxide dismutase activity.24
The reaction of peroxynitrite with lipids leads to lipid peroxidation (malondialdehyde
and 4-hydroxynonenal formation)25 and formation of nitrito-, nitro-, nitrosoperoxo-
and/or nitrated lipid oxidation adducts,26 all of which cause damage to cellular
membranes. Quinolinic acid (100 M) has been shown to produce an 80% increase
in lipid peroxidation, evidence that quinolinic acid-induced toxicity involves the early
formation of peroxynitrite.27
In addition, peroxynitrite causes damage to DNA since purine nucleotides are
vulnerable to oxidation and adduct formation, resulting in the production of
8-hydroxydeoxyguanosine or 8-nitroguanine. Peroxynitrite is also a potent trigger of
DNA strand breakage.28
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Peroxynitrite therefore causes extensive cellular damage leading to cellular
dysfunction. When peroxynitrite-induced cellular damage reaches a level where it
cannot be handled by the repair mechanisms, cells undergo one of the basic cell death
pathways i.e. apoptosis or necrosis (Figure 1.1, B).
Furthermore, quinolinic acid-induced Ca2+ overload of cells can result in sustained
activation of a number of Ca2+-dependent degradative enzymes, the uncontrolled
action of which terminally disrupts cell function (Figure 1.1, 4, B). Calpains are
Ca2+-dependent proteolytic enzymes. The cellular targets for these enzymes are a
number of structural components of the neuronal cytoskeleton, including spectrin,
microtubule-associated proteins, tubulin and neurofilaments.29 The proteolytic
activity of the calpain enzymes disrupts the links that anchor the cytoskeleton to
integral proteins of the plasma membrane, and this may lead to membrane blebbing
and ultimately to the loss of plasma membrane integrity.30 Similarly, phospholipase
activation by sustained increase in intracellular Ca2+ can result in enhanced
breakdown of membrane phospholipids and loss of plasma membrane integrity.31
Ca2+ overload of cells can also trigger endonuclease activation which results in
fragmentation of DNA.32 In addition, Ca2+ overload may stimulate other enzymatic
processes that result in DNA damage. For example, elevated Ca2+ levels can lock the
enzyme topoisomerase II (EC 5.99.1.2) in a form that cleaves but does not re-ligate
DNA, leading to DNA fragmentation.33
Further damage to DNA results from the Ca2+-dependent activation of the cysteine
aspartate specific protease (caspase) cascade, which results ultimately in the
activation of caspase-3 (EC 3.4.22.B9).34 Studies have shown that the caspase
enzymes are important in excitotoxin-induced neuronal apoptosis of cerebrocortical
neurons,35 in particular caspase-3.36 The caspase enzymes have a significant
proteolytic activity and induce the degradation of a series of cytosolic and nuclear
targets. In particular, caspase-3 cleaves poly [ADP-ribose] polymerase-1 (PARP-1,
EC 2.4.2.30), a key DNA repair enzyme that is activated by DNA strand breakage.
The cleavage of PARP-1 by caspase-3 results in the separation of the two zinc-finger
DNA-binding motifs from the automodification and catalytic domains, thus
preventing the recruitment of the enzyme to sites of DNA damage.37 Caspase-3
Chapter One Introduction
11
protease activity leads to chromatin condensation and DNA fragmentation in the
neuronal nucleus, suggesting these proteases play a central role in NMDA-mediated
neuronal apoptosis.
In summary, quinolinic acid exerts its neurotoxic activity by overstimulating NMDA
receptors; the target neurons are overexcited, the result being energy disturbance and
a series of pathobiochemical changes that culminate in nerve cell death. Studies have
shown that micromolar concentrations of quinolinic acid are toxic when cells are
exposed to those concentrations for several hours,38-40 and sub-micromolar
concentrations can produce neurotoxicity in culture if maintained for several weeks,
with some neurons being killed on exposure to only 100 nM quinolinic acid.41
1.3 Quinolinic acid and neurological diseases
Excitotoxicity due to excessive NMDA receptor activation is a final common path for
cell death in a number of neurodegenerative conditions. The observation that
quinolinic acid is an excitotoxic NMDA receptor agonist raises the potential
involvement of this metabolite in many neurodegenerative and convulsant disorders.
Elevation of quinolinic acid to neurotoxic levels has now been observed in a number
of neurological disorders, suggesting quinolinic acid may play an important
pathological role in these conditions.5
1.3.1 Non-inflammatory neurological diseases
1.3.1.1 Huntington’s disease
Huntington’s disease is a progressive neurodegenerative disorder characterised by
specific and regional neuronal cell loss in the striatum and neocortex of the brain. Its
clinical phenotype includes motor and psychiatric manifestations with a decline in
cognitive function, resulting in the progressive development of involuntary
movements and, in its later stages, dementia.
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Quinolinic acid was first proposed to be an important factor in Huntington’s disease
because it produced nerve cell damage very similar to that caused by the disease.42
Animal studies by Schwarcz found that intrastriatal injection of quinolinic acid
resulted in the formation of lesions which closely resemble those observed in the
post-mortem brains of Huntington’s disease victims, suggesting quinolinic acid may
be causally involved in the disease.43
Studies involving the quantification of various kynurenine pathway metabolites have
revealed some interesting pathway alterations in Huntington’s disease. Firstly, a
recent study involving a mouse model of Huntington’s disease has shown that
quinolinic acid levels are elevated in the cortex and striatum, the two brain areas that
suffer the most pronounced neuron loss in Huntington’s disease, further supporting
the idea that quinolinic acid might be involved in the progression of the disease.44
Quinolinic acid is formed from a precursor, 3-hydroxyanthranilic acid, by the enzyme
3-hydroxyanthranilic acid oxidase (3-HAO). Quinolinate phosphoribosyltransferase
(QPRTase) is the only enzyme responsible for the catabolism of quinolinic acid.
Kinetic studies have shown that the maximum enzymatic rate for 3-HAO is
approximately 80-fold higher than that for QPRTase, although the Michaelis-Menten
constant (Km) for both enzymes is about the same.45 QPRTase is therefore the
rate-limiting enzyme in quinolinic acid metabolism. A study of post-mortem brains
of Huntington’s disease victims revealed a 3- to 4-fold increase in the activity of
3-HAO in the corpus striatum, the area of the brain most affected by the disease.46 In
contrast, the activity of QPRTase is relatively unchanged in Huntington’s disease.47
Therefore, if QPRTase was unable to metabolise the excess quinolinic acid, this
would account for the observed increased levels of the neurotoxin.
In addition, reduced levels of kynurenic acid have been observed in both the
post-mortem brain48,49 and cerebrospinal fluid (CSF)50 of Huntington’s disease victims.
Kynurenic acid is an NMDA receptor antagonist and is therefore able to block
neuronal damage induced by neurotoxins.51 It has been proposed that kynurenic acid
and quinolinic acid concentrations must be finely balanced in order to maintain the
NMDA receptor activity at its optimum level. A drop in the level of the
neuroprotectant, kynurenic acid, as observed in the post-mortem brains and CSF of
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Huntington’s disease victims, shifts the balance in favour of the neurotoxin,
quinolinic acid.
A crucial role for quinolinic acid and NMDA receptors in the neuronal dysfunction
and loss which occurs in Huntington’s disease has thus been postulated. In a study of
post-mortem brains of Huntington’s disease victims, Young et al. detected a loss of
NMDA receptors, which is consistent with an increased loss of cells bearing these
receptors in response to an excitotoxic process mediated by quinolinic acid.52
In addition, there is growing evidence for a degree of oxidative stress in Huntington’s
disease which could result from the over-activation of NMDA receptors by quinolinic
acid. In an animal model for Huntington’s disease, a significant increase in lipid
peroxidation has been reported which parallels the neurological phenotype.53 Also,
results from a recent study of Huntington’s disease patients were consistent with
elevated oxidative stress as reflected in the significantly raised (almost eight-fold
higher) plasma levels of lipid peroxidation products compared to control subjects.54
While there is growing evidence for a role for quinolinic acid in Huntington’s disease,
there is also strong evidence that overexpression of the abnormal huntingtin gene
contributes to the induction of Huntington’s disease symptoms in humans and to the
striatal characteristics of Huntington’s disease in mouse models.55 However, the two
situations may be closely linked since it has been shown that administration of
quinolinic acid into the striatum can induce increased expression of huntingtin56 and
as such it has been proposed that perhaps a primary toxicity caused by quinolinic acid
could induce huntingtin expression as a cytoprotective response.57,58
1.3.1.2 Temporal lobe epilepsy
Studies have shown that injection of quinolinic acid into the hippocampus of rats
causes convulsions reminiscent of human temporal lobe epilepsy.59 Examination of
the activity of QPRTase in post-mortem brain tissue from epilepsy victims revealed
reduced activity of the enzyme relative to controls.60 It was inferred that the
decreased QPRTase activity may lead to a build up of quinolinic acid which may be
involved in epileptogenesis.
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1.3.2 Inflammatory neurological diseases
A study by Heyes et al. showed that inflammatory diseases (bacterial, viral, fungal
and parasitic infections, meningitis, autoimmune diseases and septicaemia) are
associated with accumulation of quinolinic acid.50 In this study, the CSF and
post-mortem brain tissue quinolinic acid levels of inflammatory disease patients who
had demonstrable clinical neurological deficits were increased between ten-fold to
one thousand-fold compared to control groups and exceeded the 100 nM
concentrations that are toxic to certain types of neurons in vitro.41
It has been demonstrated that macrophages, cells which are activated and can
infiltrate the brain following an immune response to neutralise the effects of foreign
substances, have a particularly high capacity for synthesising quinolinic acid.61
Similarly microglial cells, the resident immune cells within the brain, are capable of
biosynthesising quinolinic acid.62 Activated microglia and macrophage infiltrates into
the brain might therefore be an important source of quinolinic acid within the CNS in
inflammatory diseases. This is discussed further using specific examples of
inflammatory diseases as case studies.
1.3.2.1 Alzheimer’s disease
Alzheimer’s disease is a progressive neurological disorder which causes defects in
memory, cognition, attention and motivation. It is the most common cause of
dementia in the elderly. Two significant abnormalities occur in the brains of people
affected by Alzheimer’s disease, particularly in the neocortex, hippocampus and
amygdale regions. These are the formation of extracellular plaques, which consist
largely of an insoluble sticky protein called -amyloid, and the formation of
intracellular neurofibrillary tangles, which are made from an abnormal,
hyperphosphorylated state of tau, a protein normally associated with microtubule
formation. Dementia is significantly correlated with the density of -amyloid
deposits and the number of neurofibrillary tangles. However, studies have shown that
isolated plaques do not have direct cytotoxic effects upon neuronal tissues.63
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Microglial clusters around the plaques are a distinctive feature of Alzheimer’s disease
pathology. Studies have shown that microglia and -amyloid deposits appear almost
simultaneously at an early stage in Alzheimer’s disease and the density of plaques and
microglia are strongly correlated.64 Recently, it has been shown that, in culture, the
microglia in contact with the plaques typically have a “reactive” morphology similar
to those found in Alzheimer’s disease tissue.63 It would appear, therefore, that
-amyloid plaques are able to activate microglia, although the way in which this
occurs is unknown. Plaque-stimulated microglia are capable of a range of secretory
functions, and studies suggest that it is these reactive microglia that are the source of
brain neurotoxins in Alzheimer’s disease.63 Activated microglia are capable of
synthesising quinolinic acid in neurotoxic concentrations, raising the possibility that
quinolinic acid could play an important role in the neurodegeneration associated with
Alzheimer’s disease.62 In support of this hypothesis, Guillemin et al. have
demonstrated that -amyloid plaques can induce quinolinic acid production by human
microglia.65 Furthermore, up-regulation of the kynurenine pathway and accumulation
of quinolinic acid have been detected in the cortical microglia and neurons in the
hippocampus of the Alzheimer’s disease brain.66
1.3.2.2 HIV and AIDS
It has been reported that almost 20% of patients with acquired immune deficiency
syndrome (AIDS) develop marked CNS symptoms, with cognitive decline, motor
dysfunction and behavioural abnormalities.67 There is growing evidence, gathered
from both human studies and animal model studies, for a role for quinolinic acid in
this AIDS-dementia complex.
In patients who are affected by AIDS-related dementia, the levels of quinolinic acid in
the CSF are increased up to 20-fold.68 The levels of quinolinic acid observed correlate
with the degree of cognitive and motor dysfunction in the affected patients. The
amount of quinolinic acid in the brain of patients infected with human
immunodeficiency virus (HIV) can increase up to levels 300 times of those measured
in the CSF.69 The quinolinic acid found in the AIDS brain is likely to originate from
cells activated by the immune system as part of the generalised inflammatory reaction
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to the viral invasion. Studies have shown that immune stimulation of
macrophages can activate components of the kynurenine pathway including
indoleamine-2,3-dioxygenase (IDO), kynurenine-3-hydroxylase, kynureninase and
3-hydroxyanthranilic acid oxidase (3-HAO).70 In AIDS-related dementia, there is
evidence for increased activity of IDO.71 Such IDO induction will result in enhanced
tryptophan degradation along the kynurenine pathway, leading to increased generation
of quinolinic acid. It has been demonstrated that the activated macrophages present in
AIDS patients are capable of generating enough quinolinic acid to cause neuronal
damage.72
Studies have shown that the concentration of quinolinic acid declines in parallel with
neurological improvement when AIDS patients are treated with the drug
azidothymine (AZT).73 This drug inhibits the replication of the HIV virus. As a result
the immune response is suppressed, presumably resulting in a decrease in quinolinic
acid biosynthesis by immune stimulated cells and leading to improvement of motor
and cognitive processes.
1.3.2.3 Cerebral malaria
Malaria, caused by Plasmodium falciparum infection, is one of the most important
global health problems, potentially affecting more than one third of the world’s
population. A major, life-threatening complication of malaria infection is cerebral
malaria. Cerebral malaria is characterised by neurological manifestations, such as
convulsions and coma. This condition chiefly afflicts children aged 2-6 years in
sub-Saharan Africa and adults in South East Asia.74
The contribution of excitatory mediators to the initiation and maintenance of seizures
and neurodegeneration during cerebral malaria has been studied in both human
populations75,76 and mouse models.77 The studies showed that quinolinic acid levels
are elevated in the CSF of children suffering from cerebral malaria. For example,
Kenyan children suffering from cerebral malaria exhibit a fourteen-fold increase in
CSF quinolinic acid levels.76 Similarly, elevated levels of quinolinic acid have been
observed in the mouse model of cerebral malaria.77 These studies suggest that
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quinolinic acid may contribute to some of the neurological symptoms of cerebral
malaria.
The increased level of quinolinic acid is thought to arise from activation of the
kynurenine pathway as a result of immune stimulation. Studies on the mouse model
of cerebral malaria have shown that the activity of IDO, the first enzyme of the
kynurenine pathway, is dramatically increased in the brain.77 One of the earliest
events in cerebral malaria pathogenesis appears to be a mild increase in the
permeability of the blood-brain barrier.78 The significance of changes in the
blood-brain barrier in cerebral malaria is that they would allow cytokines and malaria
antigens to enter the brain compartment from which they are normally excluded.
Interferon-, a cytokine known to be produced in malaria infection,79 is a powerful
inducer of IDO expression.80
Currently there is no specific treatment for cerebral malaria. Recently, however,
studies have shown that inhibition of the kynurenine pathway results in prolonged
survival using a murine model of cerebral malaria.81 The enzyme targeted in this
inhibition study was kynurenine-3-hydroxylase. Inhibiting the kynurenine pathway at
this stage prevents synthesis of quinolinic acid and therefore prevents over-activation
of NMDA receptors and subsequent neuronal damage and neurological symptoms
associated with the disease. Therefore, compounds which inhibit the kynurenine
pathway may potentially be effective in the treatment and prevention of human
cerebral malaria.
1.3.2.4 Poliomyelitis
The importance of quinolinic acid in poliomyelitis has been investigated using model
animal studies involving infection of the lumbar spinal cord of macaques with
poliovirus.82 Such an infection causes neurodegeneration and produces inflammatory
lesions within the target areas of the central nervous system. The study found that the
concentration of quinolinic acid in poliovirus-infected spinal cord and CSF was
substantially increased and exceeded levels reported to kill spinal cord neurons
in vitro. As with other inflammatory neurological disorders, the production of
quinolinic acid is believed to reflect local induction of IDO by cytokines in reactive
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cells and inflammatory cell infiltrates within the CNS. All the poliovirus-infected
macaques showed motor impairments, which were classified as either weakness of leg
muscles, partial paralysis or complete paralysis. The magnitude of the increase in
quinolinic acid concentration in the spinal cord was proportional to both the degree of
motor impairment and the severity of lesions. This suggests that quinolinic acid may
contribute to nerve cell death in the spinal cord and other poliovirus target areas.
1.3.2.5 Lyme disease
Neurological dysfunction frequently occurs in patients with Lyme disease, which is
caused by infection with the bacterium Borrelia burgdorferi. The levels of quinolinic
acid are raised significantly in the CSF of Lyme disease patients with CNS
involvement, and those levels correlate strongly with the invasion of the CNS by
leukocytes, cells involved in inflammatory and immune responses.83 The presence of
quinolinic acid may contribute to the neurological and cognitive deficits seen in many
Lyme disease patients.
1.3.2.6 Traumatic CNS damage
It has been demonstrated that quinolinic acid levels are significantly elevated in
the CSF following traumatic brain injury in humans.84 Similarly, in animal studies,
Blight et al. have demonstrated a contributory role for quinolinic acid in secondary
neurological deficits following a compression injury of the spinal cord of guinea
pigs.85 It has been clearly established that an inflammatory reaction occurs in
response to brain injury. A recent study by Mackay et al. showed that increases in
inflammatory indicators were linked to increases in kynurenine pathway metabolites
for patients with chronic brain injury and those patients with more inflammation
showed greater activation of the pathway.86 This is consistent with the view that
activation of the kynurenine pathway is a consequence of inflammation. The results
of this study showed that for brain-damaged patients the raised levels of
inflammation, increased activation of the kynurenine pathway and oxidative stress
continue many years after the original insult, possibly contributing to the continuing
cerebral dysfunction in these patients.
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1.4 Quinolinate phosphoribosyltransferase (QPRTase)
The enzyme quinolinate phosphoribosyltransferase (QPRTase) provides the only
route for the metabolism of the neurotoxin quinolinic acid. QPRTase belongs to a
family of ten phosphoribosyltransferase (PRTase) enzymes, an important group of
enzymes which utilise 5-phosphoribosyl-1-pyrophosphate (PRPP) in substitution
reactions. Each PRTase enzyme is highly specific for a nitrogenous, generally
aromatic, base (Table 1.1). The PRTase enzymes are involved in de novo and salvage
reactions of purine, pyridine and pyrimidine nucleotide biosynthesis,87 as well as in
histidine88 and tryptophan89 biosynthesis.
Enzyme Substrate Enzyme Substrate
Adenine
PRTase
(EC 2.4.2.7)
N
N
NH2
N
N
H
Nicotinamide
PRTase
(EC 2.4.2.12)
N
NH2
O
Anthranilate
PRTase
(EC 2.4.2.18) NH2
CO2H Nicotinate
PRTase
(EC 2.4.2.11) N
CO2H
ATP PRTase
(EC 2.4.2.17)
OPPPiO N
N
NH2
N
N
OH OH
Orotate
PRTase
(EC 2.4.2.10)
NH
N
H
CO2H
O
O
Glutamine-
amido PRTase
(EC 2.4.2.14)
O
N
H2
CO2H
NH2 Quinolinate
PRTase
(EC 2.4.2.19) N
CO2H
CO2H
Hypoxanthine-
guanine
PRTase
(EC 2.4.2.8) N
NH
O
N
N
H N
NH
O
N
N
H NH2
Uracil PRTase
(EC 2.4.2.9) NH
N
H
O
O
Table 1.1: Phosphoribosyltransferase enzymes and their substrates.
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However, QPRTase is an unusual phosphoribosyltransferase enzyme in that it appears
to catalyse a second reaction. QPRTase was first isolated and purified from rat liver
acetone powder by Nakamura et al. in 1963.90 The stoichiometry of the reaction was
determined and found to involve the reaction of one molecule of quinolinic acid 10
with one molecule of PRPP 15 in the presence of Mg2+ to generate one molecule of
nicotinic acid mononucleotide 11, carbon dioxide and pyrophosphate. The reaction
presumably involves the initial formation of quinolinic acid mononucleotide 16 which
is subsequently decarboxylated to form the nicotinic acid mononucleotide product 11
(Scheme 1.3). No quinolinic acid mononucleotide 16 was detected. Thus a single
enzyme, QPRTase, appeared to be responsible for two consecutive chemical
reactions, phosphoribosyl transfer and decarboxylation.
N
CO2
O
OHOH
PiO
N
CO2
CO2
H
O
OHOH
PiO
OPPi
N
CO2
O
OHOH
PiO
CO2 +
QPRTase
Mg2+
--
-
+
+ - CO2- PPi
+
-
- QPRTase
10
11
15
16
Scheme 1.3: Metabolism of quinolinic acid.
Since its initial discovery, QPRTase has been isolated and purified from many
sources. QPRTase is widely distributed in micro-organisms, fungi and plants
including Pseudomonas fluorescens, E. coli, Neurospora crassa, yeast, persimmon
leaf, shiitake mushroom, Pseudomonas riboflavin,91 castor bean endosperm,92
Mycobacterium tuberculosis, Salmonella typhimurium93 and the root and leaves of the
tobacco plant Nicotiniana tobaccum.94 In addition, hog liver95,96 and kidney,97,98 rat
brain, liver and kidney99 and human brain and liver100 have all been identified as
sources of QPRTase. In all systems investigated to date, both the
phosphoribosyltransferase activity and the decarboxylation are catalysed by a single
protein.
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1.5 Mechanism of QPRTase
QPRTase is an intriguing enzyme which appears to catalyse two distinct chemical
reactions; the Mg2+-dependent transfer of a phosphoribosyl moiety from PRPP to the
nitrogen of quinolinic acid and decarboxylation at the 2-position to give nicotinic acid
mononucleotide. The mechanism of the QPRTase catalysed reaction is not well
understood. The elucidation of the mechanism is important because of the unusual
chemistry and neurological significance of the QPRTase reaction.
1.5.1 Kinetic mechanism of QPRTase
Essentially, there are two main possibilities for the kinetic mechanism of QPRTase.
The first possibility is the ping-pong mechanism which is a two-step process whereby
PRPP binds first and reaction takes place to eliminate pyrophosphate and leave a
reactive phosphoribosyl intermediate at the active site. The quinolinic acid then binds
and reacts with this intermediate to form the mononucleotide (Scheme 1.4).
E PRPP E.PRPP+
PPi
E*
QA
E*.QA E + NAMN + CO2
Scheme 1.4: Two-step kinetic mechanism for QPRTase.
Such a kinetic mechanism has been observed for three members of the PRTase
family; adenine PRTase,101 orotate PRTase102,103 and uracil PRTase.104 However,
kinetic studies on QPRTase from E. coli by Calvo et al. have ruled out a ping-pong
mechanism for QPRTase.105 They reported that the true enzyme substrate was the
magnesium complex of PRPP and showed that a double reciprocal plot of initial rate
as a function of the concentration of quinolinic acid at various fixed concentration
levels of MgPRPP3- resulted in an intersecting pattern. These results indicate a
sequential mechanism in which both PRPP and quinolinic acid bind before
pyrophosphate, carbon dioxide or nicotinic acid mononucleotide is released.
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A sequential kinetic mechanism involves simultaneous binding of PRPP and
quinolinic acid at the enzyme active site, giving a ternary complex, and the transfer
reaction then takes place in one step. Three possible orders of substrate binding to
form the ternary complex may be proposed (Scheme 1.5).
A. Ordered sequential mechanism with PRPP leading.
E
PRPP
E.PRPP
QA
E + NAMN + PPi + CO2E
.QA
.PRPP
B. Ordered sequential mechanism with QA leading.
E
PRPPQA
E + NAMN + PPi + CO2E
.QA
.PRPPE.QA
C. Random sequential mechanism.
E E + NAMN + PPi + CO2E
.QA
.PRPP
E.QA
E.PRPP
Scheme 1.5: Sequential kinetic mechanism for QPRTase.
Having deduced a sequential kinetic mechanism for QPRTase, Calvo et al. then
carried out inhibition studies on QPRTase from E. coli to establish the order of
substrate binding.106 Inhibition by phthalic acid was found to be competitive with
respect to quinolinic acid and uncompetitive with respect to PRPP. The
uncompetitive pattern was explained by the formation of a dead-end complex between
QPRTase.PRPP and phthalic acid. This requires that PRPP binds to QPRTase first
followed by quinolinic acid to form a ternary complex (Scheme 1.5, A).
Fructose-1,6-bisphosphate was found to be a competitive inhibitor with respect to
PRPP and noncompetitive with respect to quinolinic acid. These inhibition patterns
were interpreted in terms of the formation of a dead-end binary complex of
QPRTase.fructose-1,6-bisphosphate, again supporting the ordered addition of PRPP
followed by quinolinic acid (Scheme 1.5, A).
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Recently, Grubmeyer et al. carried out a more detailed study on the kinetic
mechanism of Salmonella typhimurium QPRTase.107 Firstly, equilibrium gel filtration
experiments were employed to assess substrate binding to the enzyme. The results
showed that both quinolinic acid and PRPP can bind to free QPRTase, but did not
indicate whether the resultant binary complexes are catalytically competent. This was
determined by performing isotope trapping experiments, which measured the
partitioning of binary and ternary enzyme-substrate complexes in the reaction
pathway. Complexes of QPRTase with radiolabeled substrate were formed and then
injected into a chase solution containing the second substrate, together with a large
concentration of the non-radioactive form of the substrate whose behaviour was to be
analysed. When QPRTase.[-32P]-PRPP complexes were injected into chase mixtures
containing quinolinic acid and non-radioactive PRPP, no [-32P]-PRPP was trapped as
pyrophosphate. However, [3H]-quinolinic acid was trapped as [3H]-nicotinic acid
mononucleotide when the QPRTase.[3H]-quinolinic acid complexes were injected into
buffer containing PRPP and non-radioactive quinolinic acid. These results are
inconsistent with an ordered sequential mechanism with PRPP as the leading substrate
(Scheme 1.5, A) in which the QPRTase.[-32P]-PRPP complex should be trapped.
They are consistent with an ordered sequential mechanism with quinolinic acid as the
leading substrate (Scheme 1.5, B) or the random sequential mechanism (Scheme 1.5,
C) if PRPP is able to dissociate rapidly from the QPRTase.PRPP.QA ternary complex.
To differentiate between random and ordered sequential mechanisms, the partitioning
of the QPRTase.PRPP.QA ternary complex was examined by steady-state isotope
trapping experiments with [3H]-quinolinic acid and [5-32P]-PRPP. In these
experiments, mixtures of QPRTase and radioactive substrates allowed to reach the
steady state were injected into a quench solution or a trap solution containing a vast
excess of the non-radioactive substrates. Trap samples were then allowed to react for
10 additional turnover times, and then the reactions were quenched. The amount of
radioactive substrate bound in the steady state and committed to catalysis was
indicated by the difference between the trap and quench samples. The results clearly
indicated that nearly all the [3H]-quinolinic acid and about one-third of the
[5-32P]-PRPP in QPRTase.PRPP.QA ternary complexes partition forward to product
formation. Therefore, in contrast to the kinetic mechanism previously determined by
Calvo et al., the conclusion from this study was that Salmonella typhimurium
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QPRTase follows an ordered substrate binding mechanism in which binding of
quinolinic acid precedes that of PRPP (Scheme 1.5, B).
To resolve some of the differences between their conclusions and those previously
reported Grubmeyer et al. carried out selected steady-state kinetic measurements. It
was found that PRPP behaves as an inhibitor at high concentrations. This is
consistent with the observation that the QPRTase.PRPP complex is catalytically
non-productive since QPRTase.PRPP complexes deplete the concentration of free
QPRTase. Substrate inhibition was not observed by Calvo as the range of
concentrations examined was too low to cause inhibition. Thus the major
discrepancies result from the existence of a non-productive side branch on the
reaction pathway, leading to the formation of a dead-end QPRTase.PRPP complex
(Scheme 1.6).
E
PRPPQA
E + NAMN + PPi + CO2E
.QA
.PRPPE.QA
E.PRPP
Non-productive
Scheme 1.6: Kinetic mechanism for QPRTase proposed by Grubmeyer et al.
This mechanism is consistent with the structural data for this enzyme, which show
quinolinic acid is buried much deeper in the active site than PRPP, which is closer to
the surface.108 In addition, the binding of PRPP in the active site appears to block
access for quinolinic acid.
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1.5.2 Chemical mechanism of QPRTase – Phosphoribosyl transfer
Phosphoribosyltransferase enzymes catalyse the transfer of a phosphoribosyl moiety
from PRPP to the nucleophilic nitrogen of purines, pyridines and pyrimidines. The
coupling reaction requires a divalent metal ion, usually Mg2+. In all cases the reaction
proceeds with inversion of stereochemistry at the anomeric C-1 of PRPP,109 although
the chemical mechanism for this reaction has been disputed for many years. A direct
SN2-type displacement, shown in Scheme 1.7 for the QPRTase catalysed reaction, is
possible given the inversion of the configuration at the anomeric carbon position of
PRPP. This is compatible with the ternary complex kinetic mechanism where both
reactants bind to the active site simultaneously.
N
CO2H
CO2H
O P O P O
O O
O O
O
OH OH
PiO
CO2H
O
OH OH
N
PiO
CO2H
10
15 16
+
Scheme 1.7: SN2 mechanism.
However, the pyrophosphate leaving group is among the most acidic found in
biological glycosides and the furanose ring oxygen can readily stabilise positive
charge.110 Both of these factors will favour carbocation SN1-type mechanisms over
SN2-type mechanisms. If it is the case that QPRTase catalysed phosphoribosyl
transfer proceeds via a two step SN1-type mechanism (Scheme 1.8), then the active
site must shield the oxocarbonium ion 17 such that nucleophilic attack by quinolinic
acid 10 can only occur from one face to give the observed stereochemistry.
OPPi
O
OH OH
PiO N
CO2H
CO2H
O
OH OH
PiO
CO2H
O
OH OH
N
PiO
CO2H10
15 16
+ +
17
Scheme 1.8: SN1 mechanism.
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Determination of the kinetic isotope effects (KIE) for an enzyme catalysed reaction
provides a powerful tool for the elucidation of the chemical mechanism for the
reaction. Isotope effects are caused by the substitution of a lighter atom for a heavier
one, for example replacing hydrogen with deuterium or tritium, or replacing 12C with
13C or 14C. A KIE is the ratio of reaction rates for molecules containing the lighter
and heavier atoms. A primary isotope effect is observed when the bond to the heavy
atom is being cleaved or formed during the rate-determining step of the reaction. An
-secondary isotope effect occurs when the heavy atom is directly attached to the
atom undergoing bond cleavage or formation, while a -secondary isotope effect
occurs when there is a further bond between the heavy atom and the site of reaction.
Secondary hydrogen isotope effects can often be used to obtain an insight into the
changes in hybridisation at the site of substitution as a reaction proceeds from the
ground state to the rate limiting transition state. One situation in which they have
been frequently employed is in attempts to distinguish between SN1 and SN2
mechanisms. -Secondary hydrogen isotope effects arise from changes in the
zero-point energy of normal vibrations. The changes in zero-point energy are a result
of changes in hybridisation of the carbon atom in going from the ground state to the
transition state. Primarily, changes in C-H bending vibration are involved. In going
from an sp3 to an sp2 hybridised carbon, the out-of-plane bending frequency decreases
from 1350 cm-1 to 800 cm-1. Therefore, if the transition state arising from an
sp3 ground state closely resembles the sp2 structure, it will generally have less total
zero-point vibrational energy compared to the ground state. Consequently, the
activation energy for reaction of a molecule containing a heavier hydrogen isotope
bonded to the reaction centre is larger, resulting in slower reaction for the substituted
molecule. In contrast, SN2 reactions generally exhibit much smaller -secondary
KIEs. This is because the SN2 transition state has more nearly equal total zero-point
vibrational energy compared to the sp3 ground state, resulting in more nearly equal
reaction rates for substituted and unsubstituted molecules. Thus determination of
-secondary hydrogen isotope effects is useful in differentiating between SN1 and SN2
mechanisms.
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However, a problem may arise in enzyme catalysed reactions if the -secondary
hydrogen KIE is suppressed by steady state features of the enzymatic reaction, so that
an SN1 reaction could be mistaken for SN2. This ambiguity often can be resolved by
determination of the primary 14C KIE for the same enzymatic reaction. For an SN1
reaction, a small primary 14C isotope effect would be expected because of the
asymmetric transition state. However, the SN2 transition state is more symmetrical
and a larger primary 14C isotope effect should be observed. Thus the primary and
-secondary kinetic isotope effects tend to be complementary. Carbocation-like
transition states exhibit large -secondary isotope effects and small primary effects,
whereas SN2-like transition states exhibit smaller -secondary isotope effects and
larger primary effects (Table 1.2).111 Thus, in a reaction that demonstrates an
-secondary deuterium or tritium isotope effect near 1.00, observation of a significant
primary 14C isotope effect eliminates the possibility that a significant -secondary
effect was suppressed by steady state factors. This would unambiguously identify the
catalytic mechanism as being SN2-like. Thus a combination of primary and secondary
isotope effects is required to fully elucidate a reaction mechanism.
Reaction type 2H  - Secondary KIE 14C Primary KIE
SN1 1.15 – 1.25 1.00 – 1.08
SN2 1.00 – 1.06 1.09 – 1.15
Table 1.2: Comparison of kinetic isotope effects for SN1 and SN2 reactions.
Such an approach has been used in studies on the chemical mechanism of the PRTase
family.112 In a study by Goitein et. al, PRPP was synthesised with 14C at C-1 or with
3H bonded to the C-1 or C-5 carbon atoms. Appropriate pairs of these compounds
were then used to determine the primary 14C and -secondary 3H kinetic isotope
effects on three PRTase reactions (Table 1.3).
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PRTase 3H Secondary KIE 14C Primary KIE
Hypoxanthine-guanine PRTase 1.30 1.05
Orotate PRTase 1.17 1.03
ATP PRTase 1.11 1.01
Table 1.3: Comparison of the primary and secondary KIEs for three PRTase enzymes.
By itself, the observation of a moderate -secondary tritium KIE of 1.11, which
corresponds to an -secondary deuterium effect of 1.08, for the ATP PRTase reaction
makes it probable that this enzyme utilises a carbocation mechanism. However, this
KIE is near the upper limit of that expected for SN2-like reactions (Table 1.2) and
some uncertainty might exist as to the real mechanism were it not for the additional
information available from the primary 14C KIE. A primary 14C KIE of 1.01 suggests
that the ATP PRTase reaction utilises a carbocation intermediate. The
hypoxanthine-guanine PRTase and orotate PRTase catalysed reactions exhibited large
-secondary tritium kinetic isotope effects, which clearly indicate that these enzymes
also utilise carbocation SN1-type mechanisms.
Furthermore, computational studies have been used to model the transition state
structure for which the calculated KIE values match the measured KIE values for the
orotate PRTase reaction.113 The results strongly suggest that the reaction undergoes
an SN1-like mechanism, with a substantially developed oxocarbonium ion in the
transition state.
Since all three of the PRTases examined utilised carbocation SN1-type catalytic
mechanisms, it seems likely on chemical grounds that this is the case for all PRTase
reactions, including QPRTase, although this is as yet unconfirmed.
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1.5.3 Chemical mechanism of QPRTase – Decarboxylation
QPRTase is an unusual PRTase enzyme in that it appears to catalyse a second
reaction, decarboxylation of the quinolinic acid mononucleotide 16 to form the
corresponding nicotinic acid mononucleotide 11. This decarboxylation reaction is
considered to have an analogous mechanism to that observed for the decarboxylation
of pyridine carboxylic acids in chemical studies. The mechanism proposed by
Hammick et al. involves loss of carbon dioxide to form a nitrogen ylide, which is then
protonated to give the product (Scheme 1.9).114 In the model studies, the intermediate
ylide was trapped with a suitable electrophile, such as acetone or benzaldehyde
(Scheme 1.9).
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Scheme 1.9: Mechanism for the decarboxylation of pyridine carboxylic acids.
An analogous mechanism can be envisaged for the decarboxylation of quinolinic acid
mononucleotide 16, proceeding via the nitrogen ylide 18 (Scheme 1.10).
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Scheme 1.10: Decarboxylation of quinolinic acid mononucleotide.
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However, enzymatic involvement in the decarboxylation step is yet to be conclusively
proven. As similar reactions were observed to occur spontaneously, it was suggested
that QPRTase played no part in the decarboxylation step and it occurred after the
mononucleotide had been released from the active site. In order to test this theory,
experiments were conducted involving the non-enzymatic decarboxylation of pyridine
carboxylic acids.115 Quinolinic acid was the most rapidly decarboxylated of all the
pyridine carboxylic acids studied, but the reaction was still very slow and required
harsh conditions. Quinolinic acid was shown to decarboxylate in aqueous
hydrochloric acid (pH 1) at 95 °C, with a half life of ca. 3 days. Clearly the harsh
conditions whereby decarboxylation was observed are quite remote from the
physiological conditions (pH 7 and 37 °C) under which the QPRTase catalysed
reaction takes place. Some enzymatic involvement would therefore seem to be
necessary. Ideally, examination of the non-enzymatic decarboxylation of quinolinic
acid mononucleotide would solve this problem. However, to date this has not been
possible since quinolinic acid mononucleotide has proved to be a very difficult
compound to synthesise.
Orotidine 5’-monophosphate decarboxylase (OMP decarboxylase, EC 4.1.1.23)
carries out a very similar decarboxylation reaction to QPRTase and thus information
on the mechanism of this enzyme can be used as a guide in evaluating the
mechanism of QPRTase. OMP decarboxylase catalyses the decarboxylation of
orotidine 5’-monophosphate (OMP) 19 to form uridine 5’-monophosphate 20 in the
final step of de novo pyrimidine nucleotide biosynthesis. The previous step in the
biosynthesis involves the transfer of a phosphoribosyl group to orotate 21 to
form orotidine 5’-monophosphate 19. This reaction is catalysed by orotate
phosphoribosyltransferase (OPRTase, EC 2.4.2.10). Therefore the two enzymes
(OPRTase and OMP decarboxylase) catalyse the transfer of a phosphoribosyl group
to the nitrogen of a heterocycle followed by decarboxylation (Scheme 1.11), the same
two reactions catalysed by the single QPRTase protein.
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Scheme 1.11: Conversion of orotate to uridine 5’-monophosphate.
A mechanism involving a nitrogen ylide intermediate has been proposed for OMP
decarboxylase.116 On the basis of the observation of rates of non-enzymatic
decarboxylation of various OMP analogues and other heterocyclic acids resembling
OMP, Beak and Siegel suggested that the active site of OMP decarboxylase might
function to catalyse the formation of a zwitterionic intermediate 22, followed by
decarboxylation to a stabilised nitrogen ylide 23 (Scheme 1.12). Protonation of the
ylide would then give the product 20.
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Scheme 1.12: Ylide mechanism for OMP decarboxylase.
This ylide mechanism is supported by results from inhibition studies.117 Levine et al.
observed that 1-(phosphoribosyl)barbituric acid (BMP) 24 was a very strong inhibitor
of OMP decarboxylase and suggested that this compound might act as a transition
state analogue because of its resemblance to the nitrogen ylide intermediate that Beak
and Siegel had proposed.
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O O
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However, on the basis of model studies, Silverman and Groziak proposed an
alternative mechanism for OMP decarboxylase.118 They proposed a covalent catalytic
mechanism involving addition of an enzymic nucleophile across the C5-C6 double
bond of the pyrimidine ring system (Scheme 1.13, A) followed by the concerted
elimination of CO2 and the enzymic nucleophile to give the product (Scheme 1.13, C).
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Scheme 1.13: Covalent catalytic mechanism for OMP decarboxylase.
In an effort to distinguish between these two possible mechanisms, Acheson et al.
synthesised the inhibitor BMP 24 enriched in 13C at C-5 of the pyrimidine ring and
examined its interaction with OMP decarboxylase by NMR.119 Formation of a
covalently bound adduct with either substrate or inhibitor would result in a change in
geometry at C-5 from trigonal (sp2) to tetrahedral (sp3), and a significant upfield shift
of the 13C NMR C-5 resonance would be expected. In the nitrogen ylide mechanism,
however, C-5 remains trigonal throughout the catalytic sequence. When OMP
decarboxylase was titrated with the 13C enriched BMP, a new resonance at 78.5 ppm
was observed. The signal was situated only 0.6 ppm downfield from the resonance of
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the free inhibitor and so it seems unlikely that covalent attack by an enzymic
nucleophile occurs at C-5 of the inhibitor. Consistent with this conclusion, the UV
difference spectrum of the enzyme-inhibitor complex was virtually identical with the
spectrum of the inhibitor-free solution.
As an additional test for a change in geometry at C-5, Acheson et al. synthesised the
substrate OMP with deuterium substituted for hydrogen at C-5 and determined the
effect of this substitution on the rate constants for enzymatic decarboxylation. No
significant secondary hydrogen isotope effect was observed. Similarly, Smiley et al.
measured 13C kinetic isotope effects for the enzymatic reaction.120 The observation of
large 13C isotope effects for OMP decarboxylase suggests that no covalent chemical
step is occurring prior to decarboxylation. Only an unusually fast covalent step could
allow the decarboxylation step to be fully rate-limiting. Therefore, these experiments
do not support the existence of covalently bound intermediates on the reaction
pathway catalysed by OMP decarboxylase. The results appear, instead, to be
consistent with a mechanism involving a nitrogen ylide intermediate.
More recently, Harris et al. determined the structure of OMP decarboxylase from
E. coli co-crystallised with the inhibitor BMP and used their structural results to
evaluate the different catalytic mechanisms.121 The structural studies strongly
supported the ylide-type mechanism and identification of the active site enabled the
elucidation of the residues involved in the mechanism (Scheme 1.14). Site-directed
mutagenesis studies on yeast OMP decarboxylase have confirmed Lys73 is an
essential catalytic residue.122
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Scheme 1.14: Ylide mechanism for OMP decarboxylase.
The decarboxylative step catalysed by QPRTase is similar in many respects to that
catalysed by OMP decarboxylase and therefore it is possible that QPRTase catalyses
the decarboxylation of quinolinic acid mononucleotide in an analogous manner.
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1.6 Inhibition of QPRTase
Investigation into the inhibition of an enzyme system is an extremely important part
of understanding the enzyme. The use of inhibitors is vital, not just to prevent the
enzyme from functioning, but also to examine possible mechanisms for the catalysed
reaction. Several inhibition studies have been reported for QPRTase.
1.6.1 Quinolinic acid analogues
Studies involving the inhibition of QPRTase by quinolinic acid analogues may
provide useful mechanistic information. Phthalic acid 25 is a potent competitive
inhibitor of QPRTase, which suggests that the ring nitrogen is not essential for
binding at the active site.99,106,107,123 Picolinic acid 26 is also a good competitive
inhibitor. In contrast, nicotinic acid 27 is not an inhibitor, which implies that the
carboxylic acid function at the 2-position is absolutely necessary for binding. The
methyl esters of phthalic acid and picolinic acid also do not inhibit, implying that the
free acid is required at the 2-position for binding at the active site.92
CO2H
CO2H N
CO2H
N CO2H
25 26 27
In order to gain more information on the mechanism, a series of 2-substituted
nicotinic acids and 2-substituted 3-nitropyridines were investigated as inhibitors of
QPRTase from ATCC strain 23269 by Calvo et al..105 The 2-hydroxy and
2-thiopyridines used in the study were all shown to inhibit QPRTase, with the
2-thio-3-nitropyridine derivative 31 showing the greatest inhibitory effect (Table 1.4).
The type of inhibition was determined for this compound and was found to be
competitive with respect to quinolinic acid.
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The 2-hydroxypyridines exist mostly in a tautomeric form where the oxygen is
present as a carbonyl and the ring is really an unsaturated lactam (Scheme 1.15). The
same is true for the 2-thiol derivatives. It was estimated based on NMR studies that
only about 4% of compound 28 is present as the hydroxypyridine. The corresponding
2-thiopyridine 29 was found to have slightly larger amounts of the thiol tautomer, 8%
based on NMR studies. It was shown that the general effect of the nitro substituent at
the 3-position of the pyridine ring was to increase the amount of the hydroxyl or thiol
form relative to the lactam or thiolactam (Table 1.4).
N XH
R
N
H
X
R
R = CO2H, NO2
X = O, S
Scheme 1.15: Tautomerisation of 2-hydroxy and 2-thiopyridines.
Compound
N OH
CO2H
28
N SH
CO2H
29
N OH
NO2
30
N SH
NO2
31
% Inhibition 0 (pH 7)
6.3 (pH 9)
8.3 (pH 7)
20 (pH 9)
16 (pH 7)
23 (pH 9)
95 (pH 7)
pKa Not
determined
Not
determined
10.3 6.9
Summary
decreasing (thio)lactam form
decreasing pKa
increasing inhibitory effect
Table 1.4: Inhibitors of QPRTase.
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Due to the strong electron withdrawing ability of the nitro group, the pKa of a
hydroxyl or thiol at the 2-position would be expected to be lower than in the case of
the pyridine with a carboxylate at the 3-position (Table 1.4). Based upon this
argument, it can be concluded that the pyridines with a 3-nitro substituent will exist to
a greater extent in the hydroxyl or thiol form relative to the lactam or thiolactam, and
the hydroxyls and thiols at the 2-position will be more acidic. The fact that the
compound with the lowest pKa, 31, was also the best inhibitor implies that negative
charge on the 2-substituent is an important contributor to tight binding to the enzyme.
Furthermore, the percentage inhibition was found to be pH dependent, a result
consistent with a requirement for a negative charge at C-2 of the pyridine ring (Table
1.4).
This evidence supports the postulated decarboxylation mechanism. It is envisaged
that these inhibitors mimic the intermediate ylide 18 that is formed immediately
following decarboxylation.
NO
OHOH
PiO
CO2H
N
R
X+
-
18
R = CO2H, NO2
X = O, S
1.6.2 PRPP analogues
1-Phosphorothioate analogues of PRPP, in which a non-bridging oxygen atom is
replaced with sulfur, have been prepared.124 Such analogues of PRPP have direct
application as mechanistic probes, and in particular probes of the structure of the
Mg2+-PRPP complex at the active site of QPRTase. The analogues prepared
were 5-phosphoribosyl 1-O-(2-thiodiphosphate) (PRPPS) and the Sp and Rp
diastereomers of 5-phosphoribosyl 1-O-(1-thiodiphosphate) (PRPPS). In a study by
Kunjara et al., these compounds were tested as substrates for QPRTase from hog
kidney.125 The study showed that with Mg2+ as the divalent cation, the order of
effectiveness as substrates was PRPP  PRPPS  PRPPS. The Sp diastereomer of
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PRPPS was a better substrate than the Rp diastereomer with Mg2+, whereas with
Cd2+ as the activating metal ion the Rp diastereomer was better. The apparent
reversal of enzyme stereospecificity with the change of the divalent cation suggests
that the metal ion remains ligated to the 1-phosphate moiety in the rate determining
step. This rationale is based on the preferential ligation of hard metal ions (Mg2+) to
oxygen, and of soft metal ions (Cd2+) to sulfur (Figure 1.2).
OP
O
Mg O
P
O-Rib-Pi
S
OP
O
Cd S
P
O-Rib-Pi
O
PRPPS
Sp diastereomer
PRPPS
Rp diastereomer
Figure 1.2: Simplified structures of the metal ion – PRPP analogue complexes.
Although these compounds were tested as substrates for QPRTase, the fact they
bound to the enzyme implies they could also be inhibitors of the reaction.
Fructose-1,6-bisphosphate 32 is one of the few analogues of PRPP 15 to be examined
as an inhibitor of QPRTase. Kinetic studies by Calvo et al. showed that this
compound was a competitive inhibitor with respect to PRPP and a noncompetitive
inhibitor with respect to quinolinic acid.106
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32 3315
HO
5-Phosphoribosyl-1-(-methylene)pyrophosphate (PRPCP) 33 is a stable analogue of
PRPP 15. PRPCP has been employed in crystallisation studies and has proved useful
in probing binding interactions at the active site of QPRTase (section 1.7).108
However, this compound has not yet been examined as an inhibitor in kinetic studies.
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1.6.3 Other applications of QPRTase inhibitors
As discussed in sections 1.6.1 and 1.6.2, inhibitors of QPRTase are useful mechanistic
tools for the elucidation of the chemical mechanism of QPRTase. Inhibitors of
QPRTase may also allow the neurological effects of quinolinic acid to be investigated
by blocking the active site of the enzyme, inhibiting its action and therefore
artificially raising quinolinic acid levels. The biological effect of this increase could
be investigated and compared with neurological disorders. Thus inhibitors of
QPRTase may also be important as biological tools.
In addition to their use as tools for mechanistic and biological studies, inhibitors of
QPRTase may also possess antimycobacterial properties.108 Mycobacterium
tuberculosis is the single most deadly human pathogen and is responsible for nearly
three million deaths every year. Recent elucidation of the mode of action of isoniazid,
a frontline antimycobacterial drug, suggests that nicotinamide adenine dinucleotide
(NAD) metabolism is extremely critical for this microorganism. QPRTase is a key
enzyme in the de novo biosynthesis of NAD, which is an essential coenzyme that
functions as a hydrogen transfer agent. In addition to the de novo synthesis of NAD,
salvage pathways (pyridine nucleotide cycles) exist that allow recycling of NAD,
usually via degradation of NAD 34 in several steps to nicotinic acid 27, followed by
conversion of nicotinic acid to nicotinic acid mononucleotide 11 by nicotinate
phosphoribosyltransferase (NPRTase) (Scheme 1.16).
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Scheme 1.16: NAD metabolism.
Despite the similarity between their enzymatic reactions, QPRTase and NPRTase
exhibit exclusive specificity for their respective substrates.109 In Mycobacterium
tuberculosis, unlike most organisms, the salvage pathway appears to be disrupted.
This is proposed to be a consequence of the lack of detectable NPRTase activity and
results in secretion of nicotinic acid 27, as NAD 34 cannot be recycled, although the
NAD degradation enzymes remain very active.127 Thus Mycobacterium tuberculosis
depends solely on the de novo pathway to meet its NAD demand, making this
organism extremely vulnerable to drugs targeted against QPRTase. Subtle differences
between the active sites of the mycobacterial and human enzymes – in the
quinolinic acid binding site (Leu170  Met) or PRPP binding site (Arg48  Lys,
Ala268  Ser, Ala271  Met and His274  Gln) - could be exploited in the design
of drugs specific for mycobacterium QPRTase.108
Similarly, fungi rely entirely on the de novo pathway for their NAD requirements.
Therefore, compounds which block this biosynthetic pathway, including analogues of
quinolinic acid as inhibitors of QPRTase, could act as anti-fungal agents.128
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1.7 Crystal structure of QPRTase
The availability of the crystal structures of QPRTase with and without its substrates
and products would provide a detailed perspective for the active site interactions in
pre-catalytic, catalytic and post-catalytic stages of the enzyme. Hence useful
information could be obtained concerning the mechanism of the QPRTase reaction.
In addition, knowledge of the design of the QPRTase active site and of any substrate
induced conformational changes could be exploited in designing novel inhibitors for
the enzyme.
1.7.1 QPRTase apoenzyme structure
Structural studies have been carried out on bacterial QPRTase from both
Mycobacterium tuberculosis108 and Salmonella typhimurium.129 The structure of the
apoenzyme from Mycobacterium tuberculosis has been solved at high-resolution
(2.4 Å). Mycobacterium tuberculosis QPRTase is a homodimer with each 29 kDa
subunit consisting of 285 amino acids. Each subunit was found to be comprised of
eleven -strands and ten -helices arranged into two structural domains. The
N-terminal open-face -sandwich domain is composed of a four stranded anti-parallel
-sheet stacked against three -helices and the C-terminal /-barrel domain is
composed of seven -strands and six -helices. The connection between the two
domains is through the longest -helix.
Similarly, QPRTase from Salmonella typhimurium is a dimer of identical 32 kDa
subunits. The X-ray crystal structure of this enzyme has also been solved at high
resolution and revealed an analogous two-domain structure for each subunit.129
The QPRTase /-barrel is unlike any other /-barrel structure reported to date. A
conventional /-barrel involves eight -strands and eight -helices arranged in a
regular ()8 topology. The seven stranded /-barrel observed in QPRTase differs
significantly, following an ()4 topology.
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Furthermore, QPRTase shows a completely novel fold for a PRTase enzyme.
QPRTase belongs to a family of ten enzymes that catalyse phosphoribosyltransfer
reactions. The crystal structures of several PRTase enzymes are known and include
the structures of orotate PRTase,130 hypoxanthine-guanine PRTase,131 glutamine-amido
PRTase132 and uracil PRTase.133 All these enzymes possess a common fold composed
of a central parallel five-stranded -sheet surrounded by four -helices. These
PRTase enzymes contain a conserved motif of thirteen residues that serves to bind the
ribose-phosphate moiety of the substrate PRPP and is found at the centre of the
PRTase fold. The phosphoribosyltransferase enzymes can therefore be divided into
two structurally distinct groups, type I, the most commonly observed PRTase fold,
and type II, of which QPRTase is the only known example. This observation shows
that members of the PRTase group of enzymes have evolved convergently to perform
similar enzymatic functions utilising different protein architectures.
The QPRTase dimer is formed by a twofold symmetry that places the N-terminal
domain of one subunit next to the C-terminal domain of the other (Figure 1.3). The
two active sites are located at the interfaces between the /-barrel of one subunit and
the -sandwich of the second subunit and are composed of residues from both
subunits. A dimeric structure is therefore essential for activity of the enzyme.
Figure 1.3: Mycobacterium tuberculosis QPRTase dimer. For one of the monomers
the /-barrel is shown with helices in red and strands in blue, and the open face of
the -sandwich is shown with purple helices and yellow strands; the second monomer
is shown in cyan.108
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The asymmetric unit of the crystal of Mycobacterium tuberculosis QPRTase was
found to contain three dimers, which are related by a threefold noncrystallographic
symmetry (Figure 1.4). The interface between dimers is largely solvent accessible and
hydrated in character. Stacking interactions between the side chains of Arg48 and
Trp227 were identified as the major protein – protein contact at this interface.
Figure 1.4: Mycobacterium tuberculosis QPRTase hexamer. Each subunit is shown in
a different colour.108
1.7.2 QPRTase complex structures
In addition to the Mycobacterium tuberculosis QPRTase apoenzyme structure, the
structures of three binary complexes (with substrate quinolinic acid 10, product
nicotinic acid mononucleotide 11 and inhibitor phthalic acid 25) and a ternary
complex (with bound phthalic acid 25 and 5-phosphoribosyl-1-(-
methylene)pyrophosphate (PRPCP) 33) have been determined.108
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The quinolinic acid binding site of Mycobacterium tuberculosis QPRTase is a deep
pocket located at the centre of the /-barrel with a highly positive electrostatic
surface. This surface is composed of three arginine residues (Arg139, Arg162 and
Arg105’), two lysine residues (Lys140 and Lys172) and one histidine residue
(His161). These residues are highly conserved among QPRTase enzymes and adopt
similar conformations in the structures of Mycobacterium tuberculosis QPRTase and
Salmonella typhimurium QPRTase.
The orientations of quinolinic acid and phthalic acid are essentially identical in their
respective complexes with QPRTase. Both of the carboxylate groups are involved in
hydrogen bonding interactions with the active site residues (Figure 1.5). The C-3
carboxylate group forms hydrogen bonds with the sidechain atoms N and N of
Arg162 and N of Arg139, whereas the C-2 carboxylate group is within hydrogen
bonding distance of the mainchain NH of Arg139, the sidechain of Arg105’ and the
sidechain Nof Lys172. In addition, the sidechains of the residues Thr138, His161,
Leu170 and Leu220 are within van der Waals distance of the substrate.
Figure 1.5: Active site of Mycobacterium tuberculosis QPRTase with phthalic acid
bound.
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By comparing the structures of the QPRTase apoenzyme and the QPRTase-quinolinic
acid complex, it was noticed that the binding of quinolinic acid is accompanied by
substantial structural changes in the active site of Mycobacterium tuberculosis
QPRTase. These include reorientation of the sidechains of a number of binding site
residues such as His161, Leu170, Lys172 and Leu220. In particular, the
conformational flexibility in the sidechain of residue Lys172, which orients in an
altogether different fashion in the two structures, results in significant structural
changes. In the structure of the apoenzyme, the sidechain of Lys172 hydrogen bonds
with the sidechains of residues Asn174 and Glu104’, whereas in the structure with
quinolinic acid bound it orients towards the C-2 carboxylate. This results in a 5 Å
movement of the Lys172 sidechain N atom and a 2 Å displacement of its C atom.
The enzyme conformational changes are retained in the ternary QPRTase-phthalic
acid-PRPCP complex. Use of phthalic acid and PRPCP, stable analogues of
quinolinic acid and PRPP, respectively, enables examination of the binding of the
ternary complex in the active site without turnover. Phthalic acid binds in a
conformation identical to that seen in its binary complex with QPRTase. A divalent
cation is required for PRPP binding as well as catalysis, and the structural studies
showed that one divalent metal ion is coordinated by two ribose hydroxyl groups, two
pyrophosphate oxygen atoms and two water molecules, while another divalent metal
ion is coordinated by two PRPCP oxygen atoms and four water molecules. The
5-phosphate interacts with the backbone amide of Gly270, the backbone carbonyl of
Gly249 and the sidechains of residues Lys140 and His274. The hydroxyl groups of
the ribose ring form hydrogen bonds with the sidechains of Glu201, Asp222 and
Lys172. The pyrophosphate group of PRPCP is within hydrogen bonding distance of
Arg105’, Arg173, Lys140, Asp222 and Asp173.
The alteration in the conformation of Lys172 on quinolinic acid binding has several
implications for the specificity and mechanism of the QPRTase reaction. The
interaction of Lys172 with the negatively charged C-2 substituent appears to
determine the specificity of QPRTase for quinolinic acid. In terms of mechanism,
kinetic data107 for Salmonella typhimurium QPRTase implied an ordered sequential
mechanism with quinolinic acid binding prior to PRPP and this is consistent with the
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structural data, which show the quinolinic acid bound more deeply in the active site.129
Moreover, comparison of the various complex structures suggests that the
conformational changes in the active site brought about by the binding of quinolinic
acid appear to facilitate PRPP binding and the subsequent reaction.108
The structure of Mycobacterium tuberculosis QPRTase with the product nicotinic acid
mononucleotide (NAMN) bound in the active site has also been determined. In this
binary complex, NAMN was found to adopt a conformation such that the nicotinate
ring occupies a very similar position to quinolinic acid in the QPRTase-quinolinic
acid complex (Figure 1.6). The C-3 carboxylate provides the only hydrogen bonding
interactions for the nicotinate ring with the protein (to the side chains of residues
His161 and Arg162). The lack of a C-2 carboxylate and a planar geometry at the
positively charged nitrogen atom results in the movement of the pyridine ring by 1 Å
relative to the QPRTase-quinolinic acid complex. The ribose hydroxyl group oxygen
atoms of NAMN are within hydrogen bonding distance of Asp222, Glu201, Gly249,
Ser248 and Gly270. Similarly, the oxygen atoms of the phosphate group hydrogen
bond with residues Gly270, Ala271, His274 and Lys140.
Figure 1.6: Active site of Mycobacterium tuberculosis QPRTase with NAMN bound.
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By comparing the structures with PRPCP and NAMN in the QPRTase binding site, it
was noticed that the two complexes differ substantially with respect to the position of
the common phosphoribosyl moiety. In both cases the 5-phosphate is located in the
phosphate binding site and forms an equal number of hydrogen bonds with the active
site residues. At the ribose group, however, there is a large difference in position
between the substrate and the product. In comparison to NAMN, the ribose ring of
PRPCP is displaced across the binding cavity by a rotation of almost 90.
The overall conformation of the active site in the QPRTase-NAMN complex is more
similar to that of the apoenzyme and the conformational changes observed in the
QPRTase-quinolinic acid complex are absent in the QPRTase-NAMN complex. It
would appear, therefore, that QPRTase has two conformers: a relaxed conformer,
observed in the structures of the apoenzyme and its complex with the product
nicotinic acid mononucleotide, and an active conformer, seen in its complex with
substrate quinolinic acid or inhibitor phthalic acid and in a non-productive ternary
complex with phthalic acid and PRPCP.
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2.1 Introduction
To enable the study of an enzymatic reaction, it is essential to have access to good
quantities of pure protein. QPRTase has been isolated from a number of sources such
as shiitake mushroom,1 castor bean endosperm2 and mammalian liver and kidney.3-5
However, such extractions are often very laborious, requiring several different
chromatographic techniques to obtain the pure enzyme. Furthermore, isolation of
sufficient protein for analysis requires access to significant quantities of the protein
source. For example, 50 kg of shiitake mushroom were required to obtain sufficient
QPRTase for analysis.
More recently, QPRTase from Salmonella typhimurium6 and Mycobacterium
tuberculosis7 were obtained by cloning the QPRTase gene into a suitable vector, then
expressing the target protein in bacterial host cells. However, the methods employed
for the purification of the over-expressed protein were still reasonably lengthy and
required a number of steps involving different chromatographic techniques.
Nevertheless, good quantities of pure protein were obtained which enabled kinetic and
structural studies to be undertaken. The mechanistic studies that were carried out on
the bacterial enzymes were discussed in sections 1.5 and 1.7.
Despite the studies on the bacterial enzymes, there were still many unanswered
questions regarding the mechanism of the QPRTase catalysed reaction. Furthermore,
although interest in QPRTase had been fuelled by the involvement of quinolinic acid
in CNS disease,8 the human enzyme had yet to be studied. With this in mind, a
project aimed at carrying out a thorough mechanistic study on human brain QPRTase
was initiated in our laboratory in 2001.
The human QPRTase cDNA was isolated and characterised from a human brain DNA
library by Fukuoka et al.9 The partial amino acid sequences for purified porcine
kidney QPRTase were used to design oligonucleotide probes, which were screened
against the human brain cDNA library. QPRTase was isolated as a single positive
clone which encodes 1182 nucleotides and has a single open reading frame of
891 base pairs (291 amino acids). Confirmation that the isolated cDNA clone
encoded QPRTase came from studies of its functional expression in a bacterial host.
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It was found that introduction of the human cDNA into a QPRTase defective E. coli
strain brought about an abrupt increase in QPRTase activity and allowed the cells to
grow in the absence of nicotinic acid. However, despite the enzyme being detected
sufficient protein was not produced for isolation.
In our laboratory,10 using the cDNA for human brain QPRTase which was kindly
donated by Professor S.I. Fukuoka (Research Institute for Food Science, Kyoto
University, Uji, Japan), the human brain QPRTase gene was amplified by PCR. The
expression vector pEHISTEV-QPRTase was then constructed by ligating the
QPRTase gene into the pEHISTEV plasmid. Active human brain QPRTase was then
successfully over-expressed in E. coli strain BL21 (DE3) host cells from the
pEHISTEV-QPRTase construct.
A significant advantage of using the pEHISTEV plasmid is the high expression levels
of the target protein. The pEHISTEV plasmid is comprised of 5365 base pairs, which
includes a gene for resistance to the antibiotic kanamycin (Appendix 1). The DNA
encoding human brain QPRTase was cloned into the multiple cloning site of the
plasmid downstream from a T7 promoter. The expression of the QPRTase gene is
therefore under the transcriptional control of the exceptionally strong T7 promoter.
The transcription of a gene encoding T7 RNA polymerase in the host is controlled by
the lac promoter and the lac operator. A repressor is present which binds to the lac
operator and blocks transcription of T7 RNA polymerase. The repressor is a variant
of the lac repressor and binds the operator more tightly than the wild-type repressor.
This helps tighten regulation of transcription so that premature expression is
prevented. Once the cells have reached the mid- to late-exponential stage of growth,
the inducer isopropyl--D-thiogalactoside (IPTG) is added to bind the lac repressor
and induce its dissociation from the lac operator, allowing expression of T7 RNA
polymerase in the host, E. coli BL21 (DE3). The T7 RNA polymerase then binds to
the T7 promoter and transcribes the QPRTase gene. Thereafter, the mRNA binds to
the ribosome and is translated to QPRTase. As T7 RNA polymerase is highly active
and extremely promoter-selective, the desired protein can make up more than 30% of
the total cell proteins.
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A further advantage of using the pEHISTEV plasmid is that protein purification is
simple. When the expression vector is constructed, the target gene sequence is
inserted adjacent to a short sequence encoding a 6-histidine tag and a TEV protease
recognition site. As a result, the target protein is expressed with a polyhistidine
affinity tag on the N-terminus and the protein can be easily purified by nickel
affinity chromatography. The histidine-tag can then be selectively cleaved by
digestion with TEV protease. TEV protease recognises a seven amino acid sequence
Glu-X-X-Tyr-X-Gln-Gly, where X can be various amino acid residues. The sequence
used in this study was Glu-Asn-Leu-Tyr-Phe-Gln-Gly, which is the most commonly
used TEV protease recognition sequence (Appendix 1). Cleavage occurs selectively
between the glutamine and glycine residues of the sequence. TEV protease is a
cysteine protease and utilises a catalytic triad of residues (Cys-Asp-His) to catalyse
peptide hydrolysis. Once the histidine tag has been cleaved from the target protein, a
second nickel column can be used to isolate the pure protein.
This chapter describes the expression and purification of wild-type human brain
QPRTase and the kinetic and structural studies that were carried out on the purified
enzyme.
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2.2 Expression and purification of human brain QPRTase
Human brain QPRTase was successfully expressed in E. coli strain BL21 (DE3) cells
from the pEHISTEV-QPRTase construct. The E. coli cells were grown in L-broth
medium containing kanamycin to a cell density of OD600 0.4 at 37 C. The
temperature was then reduced to 20 C and the cells were grown to OD600 0.6 prior to
induction with IPTG. The cultures were then incubated at 20 C for 15 hours
post-induction. The expressed protein comprised human QPRTase with a 6-histidine
tag separated by a TEV protease cleavage site. This was confirmed by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) which showed a
large protein band at the expected mass of ~34 kDa (Figure 2.1).
kDa 1 2 3 4 5
Figure 2.1: Coomassie stained SDS-PAGE gel. Lane 1 – Molecular weight standards
and Lanes 2-5 – E. coli crude extracts.
The first stage in the purification of the protein was to separate the HISTEV-QPRTase
from all the E. coli proteins. This was achieved by nickel affinity chromatography.
Metal chelate affinity chromatography is routinely employed in the purification of
proteins.11 This technique involves immobilisation of a chelating ligand on to a
polymer support. The resin bound ligand can then be charged with metal ions which
are capable of coordinating to proteins. The chelating ligand employed in these
studies was nitrilotriacetic acid which binds to four of the six coordination sites on
nickel. The remaining sites are free to bind to exposed histidine residues in the
protein (Scheme 2.1).
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Scheme 2.1: Binding of HISTEV-QPRTase to a nickel affinity column.
(HISTEV-QPRTase is represented as blue bar: 6 x histidine affinity tag, green bar:
TEV protease recognition site and red bar: QPRTase)
It has been reported by Hochuli et al. that binding to a metal chelate affinity column
is favoured by proteins which have two or more adjacent histidine residues.12
Therefore, when the crude protein extract was passed through the nickel affinity
column, HISTEV-QPRTase bound to nickel via the 6-histidine tag attached to the
N-terminus of the protein while the E. coli proteins passed through relatively
unhindered and were simply washed off the column. The nickel-protein interaction is
reversible and the pure HISTEV-QPRTase was eluted by passing a buffer containing
excess imidazole through the column.
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The next stage in the purification process is the cleavage of the histidine tag. This
was achieved by treating the pure HISTEV-QPRTase with TEV protease. The TEV
protease used also has a histidine tag attached to the N-terminus which aids its
removal in the final stage of purification.
Following digestion with TEV protease, a second nickel affinity column was used to
isolate the pure QPRTase from the cleaved histidine tag and the TEV protease. Both
the histidine tag and the TEV protease bound to the nickel column while the pure
QPRTase passed through unhindered. The histidine tag and the TEV protease were
subsequently eluted by passing a buffer containing excess imidazole through the
column.
The purity of the final protein was confirmed by SDS-PAGE which showed a single
protein band (Figure 2.2).
kDa 1 2
Figure 2.2: Coomassie stained SDS-PAGE gel. Lane 1 – Molecular weight standards
and Lane 2 – Pure QPRTase.
The protein was concentrated and the final concentration was determined by
performing Bradford’s assay.13 Purified human brain QPRTase was isolated in a
yield of 8 mg/litre culture.
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However, the overall isolated yield of pure QPRTase could have been significantly
higher were it not for the problems encountered during the TEV protease digestion
step of the purification process. The cleavage of the histidine tag from the pure
HISTEV-QPRTase was monitored by SDS-PAGE which showed that approximately
only 50% cleavage was attained, even after the addition of more TEV protease
(Figure 2.3). It was found that the cleavage of the histidine tag was most successful
when freshly expressed and purified TEV protease was used, but even then complete
cleavage was never achieved.
kDa 1 2
Figure 2.3: Coomassie stained SDS-PAGE gel. Lane 1 – Molecular weight standards
and Lane 2 – HISTEV-QPRTase and QPRTase.
Since a lot of protein was being lost at this stage, it was decided to leave the histidine-
tag attached to the N-terminus of QPRTase and examine whether its presence affects
the function of the protein. If the histidine-tag was found to have no effect on the
activity of QPRTase then this would increase the amount of protein available for
kinetic studies and also reduce the time required to obtain the protein since the need
for the troublesome TEV digestion step and the second nickel column would be
eliminated.
175
83
62
47.5
32.5
25
16
HISTEV-QPRTase
QPRTase
Chapter Two Studies on Wild-type QPRTase
63
2.3 Structural studies on wild-type human brain QPRTase
2.3.1 Crystal structure of human brain QPRTase
Previously in our laboratory,10 initial crystallisation conditions were obtained with
sitting-drop diffusion using Crystal Screen Kits (Hampton research) at 20 C with a
protein concentration of 10 mg/mL. Crystals appeared within 5 days in condition 29
of Hampton screen 1. Refinement of these conditions yielded a single crystal from a
mixture of 2 L of the protein (10 mg/mL, 50 mM Tris, pH 7.5) and 2 L of
precipitant (0.6 M K, Na tartrate, 0.1 M Na Hepes, pH 7.6). The crystal of native
human brain QPRTase was diffracted at the European Synchrotron Radiation Facility
(ESRF) to a resolution of 1.9 Å (Dr Huanting Liu, The Centre for Biomolecular
Science, University of St Andrews).
Attempts to solve the structure of human brain QPRTase by molecular replacement
using the bacterial enzymes as search models failed. Therefore, selenomethionine
labelled QPRTase was expressed, purified and crystallised (Figure 2.4). The
selenomethionine labelled QPRTase crystal was diffracted at ESRF to a resolution of
2.4 Å. The structure of human brain QPRTase was solved by a combination of
multi-wavelength anomalous dispersion phasing and non-crystallographic averaging
(Dr Huanting Liu, The Centre for Biomolecular Science, University of St Andrews).
The crystallographic space group was identified as P212121 and the unit cell
dimensions were a=111.5 Å, b=179.5 Å, c=194.7 Å and ===90.
Figure 2.4: Crystals of selenomethionine labelled QPRTase.
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Figure 2.5 shows the structure of the human brain QPRTase monomer, which
comprises twelve -helices and twelve -strands arranged into two structural
domains. The N-terminal domain (residues 1-112 and 279-291) is composed of a
four-stranded (1, 3, 5 and 12) anti-parallel -sheet stacked against helices 1,
2, 3, 4 and part of the 33 residue long 5. The strands 1 and 3 are followed by
two short strands 2 and 4 which form a small two-stranded anti-parallel -sheet.
The C-terminal domain (residues 113-278) is an /-barrel structure consisting of the
remaining -strands (6, 7, 8, 9, 10 and 11) and eight -helices (5, 6, 7,
8, 9, 10, 11 and 12) arranged in (/)2(/)4 topology. The two domains
are connected by helices 5 and 12.
Figure 2.5: Human brain QPRTase monomer.
The overall structure of the human brain QPRTase monomer is very similar to that of
the bacterial enzymes. The sequence alignment of the QPRTase homologues is
shown in Figure 2.6 together with the secondary structure elements of human brain
QPRTase and Mycobacterium tuberculosis QPRTase. The sequence homology of
human brain QPRTase and the bacterial enzymes is quite low; 28% to Salmonella
typhimurium QPRTase and 39% to Mycobacterium tuberculosis QPRTase.
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Figure 2.6: Sequence alignment of the QPRTase homologues. Conserved residues are
shown as white letters on a black background. The secondary structure elements of
human brain QPRTase are shown above the alignment (red) while those of
Mycobacterium tuberculosis QPRTase are shown below (blue). -Helices are
represented as rectangles and -strands as arrows.
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In the crystalline form, the human brain QPRTase monomers associate to form a
dimer (Figure 2.7). The dimer is formed by a twofold symmetry that places the
N-terminal domain of one subunit next to the C-terminal domain of the other.
(a) (b)
Figure 2.7: Structure of the human brain QPRTase (a) monomer and (b) dimer.
The two active sites are located at the interfaces between the /-barrel of one subunit
and the -sandwich of the second subunit and are composed of residues from both
subunits. The active site is a deep pocket with a highly positive electrostatic surface
(Figure 2.8). This surface is composed of three arginine residues (Arg161, Arg138,
Arg102’ (‘ denotes residues from the other subunit of the dimer)), two lysine residues
(Lys139 and Lys171) and one histidine residue (His160). These residues are highly
conserved among QPRTase enzymes (Figure 2.6) and adopt similar conformations in
the structures of Mycobacterium tuberculosis QPRTase and Salmonella typhimurium
QPRTase.
Figure 2.8: Active site of human brain QPRTase.
Lys139
His160 Arg161
Lys171
Arg138
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In the human brain QPRTase structure, the quinolinic acid binding site was occupied
by a tartrate molecule (Figure 2.9). Tartrate 35 was present at a concentration of
0.6 M in the precipitant used to crystallise the protein. Tartrate 35 and quinolinic acid
possess a similar backbone consisting of a 1,2-dicarboxylic acid functionality, which
explains the binding of tartrate in the active site.
Figure 2.9: Active site of human brain QPRTase with a tartrate molecule bound.
The asymmetric unit of the human brain QPRTase crystal in fact contained twelve
monomers of protein. Essentially the QPRTase dodecamer is an arrangement of two
hexameric rings (Figure 2.10a). Each QPRTase hexamer contains three dimers which
are related by a three-fold rotation axis (Figure 2.10b).
(a) (b)
Figure 2.10: Structure of the human brain QPRTase (a) dodecamer and (b) hexamer.
Each subunit is shown in a different colour.
OH
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H
H
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Chapter Two Studies on Wild-type QPRTase
68
In the human brain QPRTase hexamer, each subunit makes quite extensive contacts
with four other monomers. Each hexamer buries in total over 26000 Å2 of available
surface area. Analysis of the hexamer by the program PISA confirmed the hexameric
assembly is energetically stable (Dr Huanting Liu, The Centre for Biomolecular
Science, University of St Andrews). The contacts between the hexamers are only of
the order of 100’s of Å2 and the program PISA indicated the dodecameric assembly is
unstable. Therefore, it would appear that human brain QPRTase is a hexamer.
The hexameric arrangement adopted by human brain QPRTase is very different from
the hexameric arrangement seen in the crystal of the Mycobacterium tuberculosis
enzyme.7 In the bacterial enzyme, the contacts in the hexamer are much less
extensive and are formed by entirely different regions of the protein compared to
human brain QPRTase (Figure 2.11). Furthermore, the hexameric arrangement in
Mycobacterium tuberculosis QPRTase was found to be energetically unstable by
PISA, suggesting the bacterial enzyme is a dimer and the hexamer is simply an
artefact of crystal packing.
Figure 2.11: Hexameric arrangement seen in the crystal structure of human brain
QPRTase and Mycobacterium tuberculosis QPRTase. The dimer of the human
QPRTase hexamer (coloured monomer A green, monomer B cyan) is superimposed
with the Mycobacterium tuberculosis QPRTase dimer (also coloured monomer A
green, monomer B cyan). The dimer, in the middle of the image is structurally
conserved between human and bacterial enzymes. To the left are the other four
subunits of the human brain QPRTase hexamer (monomers C, D, E and F are
coloured deep red, salmon, yellow and orange respectively). The additional
subunits of the Mycobacterium tuberculosis QPRTase “hexamer” are shown and
are on the right of the dimer (monomer C light blue, monomer D deep blue,
monomer E purple and monomer F indigo). As is immediately obvious, the
hexameric arrangements bear no relationship to each other.
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2.3.2 Human brain QPRTase in the solution phase
Having established that human brain QPRTase adopts an energetically stable
hexameric arrangement in the crystal structure, the next stage was to determine the
degree of association of human brain QPRTase in solution. This was achieved by
performing a series of gel filtration experiments under physiological conditions.
In gel filtration chromatography, the stationary phase consists of porous beads with a
well-defined pore size. In this study a Superose column was used, which has a
crossed-linked agarose matrix. The rate of movement of a molecule through the
column depends on the ability of the molecule to enter the gel pores, which ultimately
depends on the size of the molecule. Large molecules, which can never enter the
stationary phase, move through the chromatographic bed fastest. Smaller molecules,
which can enter the gel pores, move more slowly through the column, since they
spend a proportion of their time in the stationary phase. The partition coefficient, Kav,
represents the fraction of the stationary gel volume that is available for diffusion of a
given species.
Kav = Vt - Vo
Ve - Vo
Vt is the total volume of the packed column (column length 30 cm, column diameter
1 cm, Vt = 23.6 mL). Vo is the void volume and is fully accessible for all molecules,
independent of size. Vo was determined by passing blue dextran through the column
and measuring its elution volume (Vo = 7.4 mL). Blue dextran, which is composed of
the protein dextran (MW > 106 Da) attached to a polycyclic chromophore, is larger
than the pores in the gel and is therefore only distributed in the mobile phase.
Vi is the internal volume of the gel and is only accessible for smaller molecules
(Vi = Vt-Vo = 16.2 mL). Ve is the elution volume of the species of interest.
Vo Vi = Vt -VoVt
Figure 2.12: Diagrammatic representation of Vt, Vo and Vi for a gel filtration column.
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To determine the oligomeric state of human brain QPRTase in solution, a series of
protein standards of known molecular weight were passed through the gel filtration
column and for each the elution volume (Ve) and hence Kav were determined
(Table 2.1). The data were used to construct a calibration graph of Kav versus
molecular weight (Figure 2.13).
Protein Molecular Weight
(kDa)
Elution Volume
(Ve, mL)
Kav
SBTI 21 19.1 0.72
Carbonic anhydrase 29 18.7 0.70
DA 40 18.0 0.65
BSA 66 17.4 0.62
Alcohol
dehydrogenase
150 16.5 0.56
-amylase 200 15.9 0.52
Table 2.1: Elution volume and Kav determined for a series of proteins of known
molecular weight.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 50 100 150 200 250
Molecular weight (kDa)
K
av
Figure 2.13: Gel filtration calibration graph of Kav versus molecular weight (Protein
standards: SBTI (21 kDa), carbonic anhydrase (29 kDa), DA (40 kDa), BSA
(66 kDa), alcohol dehydrogenase (150 kDa) and -amylase (200 kDa)).
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Next, a sample of pure human brain QPRTase was passed through the column in
50 mM KH2PO4/K2HPO4 buffer at pH 7.2. The resulting UV detector trace showed a
single symmetrical peak, indicating human brain QPRTase exists in a single
oligomeric state in solution. As before, the elution volume (Ve = 16.2 mL) and
Kav (0.54) were determined. From the calibration graph, the Kav value corresponds
to a protein with a molecular weight of approximately 174 kDa. This most
closely resembles the molecular weight of the human brain QPRTase hexamer
(Table 2.2).
QPRTase oligomer Molecular weight (kDa)
Monomer 30.9
Dimer 61.9
Hexamer 185.6
Dodecamer 371.3
Table 2.2: Molecular weights of possible QPRTase oligomers.
Therefore it would appear that human brain QPRTase also exists as a hexamer in
solution. This is consistent with QPRTase from other mammals, such as hog14 and
rat,15 where hexameric QPRTase structures have also been reported. In contrast,
Mycobacterium tuberculosis QPRTase was found to exist as a dimer during gel
filtration under physiological conditions, which is consistent with the instability of the
hexamer observed in the crystal structure.7 The hexameric form observed in the
crystal structure of Mycobacterium tuberculosis QPRTase may be a result of the high
protein concentrations and ionic strengths used in crystallisation.
Human brain QPRTase however, was found to exist as a stable hexamer in both the
crystal structure and during gel filtration under physiological conditions.
Similarly, HISTEV-QPRTase was found to exist as a hexamer during gel filtration
under the same conditions (Kav = 0.51). Therefore, it can be concluded that the
presence of the histidine tag does not affect the oligomeric state of the protein.
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2.3.3 Characterisation of protein conformation by circular dichroism
Circular dichroism (CD) is a sensitive spectroscopic technique that can be used to
characterise protein conformation. CD gives information about the unequal
absorption of left- and right-handed circularly-polarised light by optically active
molecules. Optical activity originates in the absorption bands of asymmetric
compounds. The absorption coefficients for left and right circularly-polarised light
are different if the electrons participating in the transition to the excited state sense an
asymmetric environment.
Proteins are optically active because they are asymmetric. Two kinds of asymmetry
are present in proteins, configurational and conformational. Amino acid residues
other than glycine have intrinsic optical activity because of the L-configuration at their
-carbon atom. Threonine and isoleucine possess an additional asymmetric centre.
Electronic interactions between different residues in a protein also contribute to
optical activity. The right-handed screw sense of an -helix, for example, gives rise
to a large conformational contribution to optical activity.
CD has become a standard technique to measure the optical activity of proteins. CD
bands of proteins occur in two spectral regions. The far-UV region (180 – 260 nm) is
dominated by contributions of the peptide bonds, whereas CD bands in the near-UV
region (260 – 320 nm) originate from aromatic amino acids. In addition, disulfide
bonds give rise to several CD bands in the near-UV region. The two spectral regions
give different kinds of information about protein structure.
The CD in the far-UV region reports on the backbone structure of a protein and is
used to characterise the secondary structure and changes therein. Measurements of
synthetic polypeptides and proteins of known structure have defined the CD spectra of
-helices, -structure motifs and random coils (Figure 2.14).16
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Figure 2.14: CD spectra of an -helix (red), -pleated sheets (green) and random coil
region (black).17
CD data in the far-UV region can be used to determine the relative amounts of the
different secondary structure elements of a protein. The -helix makes a dominant
contribution with negative CD bands at 208 nm and 222 nm and a positive band at
192 nm (Figure 2.14). A randomly arranged polypeptide chain, by contrast, has a
negative CD band centred at 199 nm. Estimates of the -helix content of proteins
derived from CD spectra agree well with values obtained from X-ray crystallographic
studies. The content of -structures can also be estimated from CD spectra but the
uncertainty is greater because -structures are less regular than the -helices and
contribute less to the CD spectrum.
CD bands in the near-UV region (260 – 320 nm) originate from aromatic amino acids
and are observed when, in a folded protein, aromatic side chains are immobilised in
an asymmetric environment. The CD of the aromatic residues is virtually zero in the
absence of ordered structure. The signs and wavelengths of the aromatic CD bands
cannot be calculated; they depend on the immediate structure and electronic
environment of the immobilised chromophores. Therefore the individual peaks in the
very complex near-UV CD spectrum of a protein cannot be assigned to transitions in
the vicinity of specific amino acid side chains. However, the near-UV CD spectrum
represents a highly sensitive criterion for the native state of a protein. It can thus be
used as a fingerprint of the correctly folded conformation.
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The near-UV (260-320 nm) CD spectra of QPRTase and HISTEV-QPRTase were
measured using a Jasco J-8.10 spectropolarimeter (Figure 2.15). By comparing the
CD spectra of QPRTase and HISTEV-QPRTase, it can be seen that CD bands of the
same sign and magnitude were observed at the same wavelengths in both spectra.
Therefore, it can be concluded that the presence of the histidine tag does not cause
gross changes in enzyme structure.
Figure 2.15: Near-UV CD spectra of QPRTase (green) and HISTEV-QPRTase (blue)
measured using a Jasco J-8.10 spectropolarimeter (Band width, 1nm; Response, 1 s;
Data pitch, 0.2 nm; Scanning speed, 20 nm/min; Accumulation, 4; Cell length,
0.5 cm; Solvent, 50 mM potassium phosphate buffer; Concentration, 1 mg/mL;
Temperature, room temperature).
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2.4 Kinetic studies on wild-type human brain QPRTase
2.4.1 Introduction
2.4.1.1 Assays for the measurement of QPRTase activity
QPRTase is an intriguing enzyme which appears to catalyse two distinct chemical
reactions; the Mg2+-dependent transfer of a phosphoribosyl moiety from PRPP 15 to
the nitrogen of quinolinic acid 10 and decarboxylation at the 2-position to give
nicotinic acid mononucleotide (NAMN, 11) (Scheme 2.2).
NO
OHOH
PiO
CO2H
N
CO2H
CO2H
O
OHOH
PiO
OPPi
+
QPRTase
Mg2+
+ CO2PPi
10 1115
++
Scheme 2.2: QPRTase catalysed reaction.
A number of assays have been developed for the measurement of QPRTase activity
including a radioactive assay which monitors the loss of 14C-carbon dioxide
from 14C-labelled quinolinic acid,18 an HPLC assay which measures the
formation of NAMN19 and two different spectrophotometric assays.20,21 The first
spectrophotometric assay involves the determination of a cyanide adduct formed by
NAMN.20 Following the QPRTase reaction, cyanide is added to react with NAMN 11
and generate a molecule which is more UV active and therefore easier to measure at
low concentrations. However, a significant disadvantage of this assay is that the
kinetic data are deduced from only single point measurements. Furthermore, the
toxicity of cyanide makes the assay problematic. The second spectrophotometric
assay that has been reported for the measurement of QPRTase activity is a continuous
UV assay based on the difference in extinction coefficients between quinolinic
acid 10 and NAMN 11 at 266 nm (Δ266 = 920 M-1cm-1).21 This assay involves
measuring the change in absorbance at this wavelength over a 30 minute period at
37 ºC and therefore allows continuous measurement of product formation.
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Previously in our laboratory,10 an HPLC assay was initially employed to confirm the
over-expressed human brain QPRTase was active. Steady-state kinetic analysis was
then carried out using a continuous spectrophotometric assay which monitored the
appearance of product.21 This involved measuring the change in absorbance at
266 nm over a 30 minute period, at 37 ºC. Each reaction was initiated by the addition
of QPRTase. A typical UV trace for the conversion of quinolinic acid to NAMN by
QPRTase is shown in Figure 2.16. From this plot, the change in absorbance, the
change in concentration of NAMN and hence the rate of product formation can be
determined. The slight delay in NAMN formation was observed from 0 to 3 minutes
in every assay and therefore the rate of formation of NAMN was measured from this
point.
Figure 2.16: Typical UV trace for the conversion of quinolinic acid to NAMN by
QPRTase.
The cyanide based UV assay was also examined as a way of measuring the activity of
human brain QPRTase. In previous studies, the two spectrophotometric assays were
found to give very similar kinetic results and the kinetic parameters determined were
comparable to literature values reported for QPRTase from other sources.10 Therefore
the continuous spectrophotometric assay was selected as the assay of choice for all
kinetic studies due to its simplicity and convenience.
A
26
6
Time (minutes)
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2.4.1.2 Summary of the initial kinetic characterisation of human brain QPRTase
Previously in our laboratory,10 the kinetic parameters Km and Vmax for quinolinic acid
were determined at 0.1 mM PRPP and were found to be 21.6  3.0 M
and 1.19  0.05 M min-1, respectively. The specific activity was found to be
0.09 mol min-1 mg-1, which is of the same order of magnitude as data reported for
other QPRTases.21-23 The kinetic data for quinolinic acid were re-measured at
different PRPP concentrations and a small decrease in Km and a large increase in Vmax
were observed with increasing PRPP concentration up to 0.1 mM. The double
reciprocal plots for these data were observed to intersect to the left of the y-axis,
which indicated that the affinity of QPRTase for quinolinic acid is independent of the
PRPP concentration (Figure 2.17). This suggested that quinolinic acid binds to
QPRTase before PRPP.
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Figure 2.17: Lineweaver-Burk plot for quinolinic acid as the variable substrate.
Kinetic studies with PRPP as the variable substrate, with quinolinic acid fixed at
0.3 mM, showed pronounced substrate inhibition above 0.3 mM. However, taking
measurements in the range 0.01 to 0.3 mM, PRPP gave a Km of 23.2  3.6 M and
Vmax of 0.93  0.03 M min-1. When the kinetic data for PRPP were re-measured at
different quinolinic acid concentrations, Km for PRPP was found to decrease as the
quinolinic acid concentration was increased while Vmax was unchanged (Figure 2.18).
 0.1 mM PRPP
 0.05 mM PRPP
 0.025 mM PRPP
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Figure 2.18: Lineweaver-Burk plot for PRPP as the variable substrate.
Thus, it would appear that the quinolinic acid concentration affects the distribution of
enzyme species which can bind PRPP. Ultimately increased quinolinic acid
concentrations lead to increased levels of the QPRTase:quinolinic acid complex. The
increased affinity for PRPP observed at high quinolinic acid concentrations suggests
increased affinity for PRPP for the QPRTase:quinolinic acid complex, thus implying
that for human brain QPRTase the catalytic mechanism requires quinolinic acid to
bind to the enzyme before PRPP. Overall, the kinetic data were clearly characteristic
of an equilibrium ordered binding mechanism, which is similar to that observed for
the Salmonella typhimurium enzyme.21
The substrate inhibition observed with PRPP was then investigated in more detail by
determining the Km and Vmax for quinolinic acid at high levels of PRPP. It was found
that as the PRPP concentration was increased from 0.3 mM to 5 mM, the Km with
respect to quinolinic acid increased while the Vmax decreased. Thus, above 0.3 mM
PRPP mixed inhibition was observed. Substrate inhibition by PRPP was also
observed for the Salmonella typhimurium enzyme by Grubmeyer et al. and this was
explained by the formation of a dead-end QPRTase:PRPP complex (section 1.5).21
The formation of a dead-end QPRTase:PRPP complex would result in competitive
inhibition, as was observed for the bacterial enzyme. However, for human QPRTase
mixed inhibition was observed. The occurrence of mixed inhibition suggests that
 0.3 mM QA
 0.1 mM QA
 0.075 mM QA
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PRPP not only binds to an active site (competitive) but also to a second site which
perturbs and inhibits the active site (noncompetitive).
Thus the observed kinetics of the human enzyme10 appear to be more complex than
the kinetics of the bacterial enzymes. The hexameric structure recently established in
both the solid state and in solution for human brain QPRTase offers a possible
explanation for the complex kinetics this enzyme exhibits. The human QPRTase
hexamer is a very intimate structure in which every subunit makes contact with four
other monomers. Within the dimer, the active sites are separated by 35 Å. However,
the hexameric arrangement means the active sites from different dimers are much
closer to each other. The extensive contacts in the human brain QPRTase hexamer
provide a structural route for information from one dimer to be transmitted to another.
Changes in the active site structure in response to PRPP binding in one dimer (AB)
could be transmitted across this interface to another dimer (CD). Thus when PRPP
binds to the monomer A active site as well as blocking the quinolinic acid binding
site in monomer A (competitive inhibition) it could additionally inhibit catalysis in
monomer C (noncompetitive inhibition). This phenomenon may be the result of a
regulatory mechanism for human brain QPRTase.
Although the crystal structure of the Mycobacterium tuberculosis enzyme reported a
hexamer in the asymmetric unit, the bacterial enzymes are known to be dimeric in
solution.7 The hexamer seen in human brain QPRTase is unrelated to that seen in the
crystal of Mycobacterium tuberculosis QPRTase. Examination of the Mycobacterium
tuberculosis QPRTase hexamer suggested it was simply an artefact of crystal packing.
The bacterial enzymes show only competitive inhibition by PRPP and show no
cooperativity.21 This reinforces the idea that the complex kinetics observed for human
QPRTase are a consequence of the hexameric structure this enzyme adopts.
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2.4.2 Kinetic characterisation of QPRTase and HISTEV-QPRTase
For QPRTase, the kinetic parameters Km and Vmax for substrate quinolinic acid were
determined by employing the continuous spectrophotometric assay to measure the rate
of the enzymatic reaction at a range of different quinolinic acid concentrations at a
fixed concentration of PRPP (0.1 mM). The initial rate data were fitted to the
Michaelis-Menten equation using non-linear regression with GraphPad Prism 3
software (Figure 2.19). Km and Vmax for quinolinic acid were determined as
13.4  1.0 M and 0.92  0.01 M min-1, respectively, which are comparable to the
values determined previously in our laboratory. The value determined for Km is
within the range of Km values reported by Calvo et al. for QPRTase isolated from
various sources (6 – 19 M)24 and in particular is comparable to the value of 12 M
reported for rat liver and rat brain.15
Figure 2.19: Non-linear regression plot of QPRTase for quinolinic acid as the
variable substrate.
To determine whether the presence of the histidine tag affects the function of the
protein, the kinetic parameters Km and Vmax for substrate quinolinic acid were also
determined for pure HISTEV-QPRTase under the same conditions. The initial rate
data were fitted to the Michaelis-Menten equation using non-linear regression with
GraphPad Prism 3 software (Figure 2.20). Km and Vmax for quinolinic acid were
determined as 13.1 ± 1.9 μM and 0.93 ± 0.03 μM min-1, respectively.
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Figure 2.20: Non-linear regression plot of HISTEV-QPRTase for quinolinic acid as
the variable substrate.
By comparing the kinetic parameters determined for QPRTase and HISTEV-
QPRTase for the substrate quinolinic acid it can be concluded that the presence of the
histidine tag does not affect the substrate binding or the catalytic efficiency of the
enzyme (Table 2.3). It appears that the histidine tag is far enough removed from the
active site such that it does not interfere with substrate binding and the subsequent
reaction. Furthermore, the gel filtration and circular dichroism experiments showed
the solution structure of QPRTase is unaffected by the presence of the histidine tag.
Protein Km (μM) Vmax (μM min-1)
QPRTase 13.4 ± 1.0 0.92 ± 0.01
HISTEV-QPRTase 13.1 ± 1.9 0.93 ± 0.03
Table 2.3: Comparison of the kinetic parameters determined for QPRTase and
HISTEV-QPRTase with respect to quinolinic acid as the variable substrate.
The observation that the presence of the histidine tag has no effect on the enzyme
kinetics means that the histidine tag does not have to be cleaved from the enzyme
used in kinetic studies. This will increase the amount of protein available for kinetic
studies and also reduce the time required to obtain the protein since the need for the
troublesome TEV digestion step and the second nickel column will be eliminated.
HISTEV-QPRTase was used in the nucleotide inhibition study described in Chapter 3.
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2.4.3 Examination of cooperativity in quinolinic acid binding
Human brain QPRTase has a hexameric structure composed of six identical subunits
and containing six identical active sites. As can be seen in Figure 2.21, the saturation
curve for QPRTase with respect to quinolinic acid as the variable substrate is
hyperbolic. This suggests that quinolinic acid does not bind cooperatively to
QPRTase since, generally, if there is cooperative binding then the saturation curve
will be sigmoidal rather than hyperbolic.
Figure 2.21: Non-linear regression plot of QPRTase for quinolinic acid as the
variable substrate.
Construction of a Hill plot allows quantitative analysis of cooperativity.25 The Hill
plot is a logarithmic form of the Hill equation, the simplified rate equation for
allosteric enzymes.
log V
Vmax - V
nlog[S] - logK'=
The Hill coefficient, n, is a central parameter in the study of ligand-protein
interactions which measures the degree of cooperativity between subunits that bind
the ligand in multi-subunit enzymes. A coefficient of 1 indicates completely
independent binding, regardless of how many additional ligands are already bound. A
coefficient of greater than 1 indicates a positively cooperative reaction. The number
of n increases with the degree of cooperativity; the maximum number of n is equal to
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the number of binding sites. A coefficient of less than 1 indicates a negatively
cooperative reaction. The Hill constant K’ comprises the intrinsic dissociation
constant Ks and interaction factors and provides an estimate of the affinity of the
enzyme for a particular substrate.
Hill plots can be constructed by plotting log (V/(Vmax-V)) versus log [S]. The plot
gives a straight line with a slope of n. Thus, the Hill coefficient, n, can be read
directly from the plot. The Hill plot for QPRTase with respect to quinolinic acid as
the variable substrate is shown in Figure 2.22. The plot is linear with a slope of
approximately 1, which again suggests quinolinic acid does not bind cooperatively to
the subunits of QPRTase.
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Figure 2.22: Hill plot for QPRTase with respect to quinolinic acid as the variable
substrate.
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2.4.4 pH dependency of human brain QPRTase
The pH rate profile for human brain QPRTase was determined by measuring the rate
of the enzymatic reaction in a series of 50 mM K2HPO4/KH2PO4 buffers of varying
pH. The pH dependency of human brain QPRTase can be seen in graphical form in
Figure 2.23.
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Figure 2.23: pH dependency of purified human brain QPRTase
From Figure 2.23, it can be seen that the activity of human brain QPRTase increases
with increasing pH from pH 4.5 to a maximum activity of 1.93 M min-1 at
approximately pH 6. Above pH 6 the rate of the enzymatic reaction decreases fairly
rapidly, and then above pH 8 the rate decrease is much slower. It is interesting that
the optimum pH for enzyme activity is lower than physiological pH. However, this is
consistent with human liver QPRTase which showed a maximum activity at
approximately pH 6.5.26 Similarly, the pH optimum of hog liver QPRTase was found
to be pH 6.1.27
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2.4.5 Solvent isotope effect studies
Isotope effects are caused by the substitution of a light atom for a heavier one. A
kinetic isotope effect is the ratio of the reaction rates for molecules containing the
light and heavy atoms, i.e. kH/kD. Over the last 20 years, the measurement of isotope
effects has emerged as one of the most powerful techniques available for the
elucidation of the chemical mechanisms of enzyme catalysed reactions.28 The
measurement of isotope effects can provide useful information regarding the identity
of the rate-limiting step for a reaction. Also, it is possible to distinguish stepwise
from concerted reactions, and, for stepwise reactions, the order of the steps and the
nature of the intermediate can be determined. In addition, isotope effects can be used
to deduce the nature of the active site catalytic residues. Furthermore, the
determination of the intrinsic isotope effects gives a means of deducing the transition
state structure.
In the case of QPRTase, kinetic isotope effects can be used to assess the relative
kinetic importance of the two chemical steps, phosphoribosyl transfer and
decarboxylation. Since reprotonation of the putative ylide intermediate 18, that is
formed immediately following decarboxylation of QAMN 16, may be kinetically
important (Scheme 2.3), solvent deuterium isotope effects were measured in order to
determine if the proton transfer is rate limiting.
NO
OHOH
PiO
CO2H
NO
OHOH
PiO
CO2H
NO
OHOH
PiO
CO2H
CO2H
16
+-CO2 ++
-
H+
1118
Scheme 2.3: Decarboxylation of quinolinic acid mononucleotide.
An important part of solvent isotope effect studies is the accurate preparation of
buffers. It is essential to use equivalent buffers in H2O and D2O. This was achieved
by keeping the concentrations of all the solutes constant, including the acid-base pair
acting as the buffer and all the electrolytes. During the preparation of buffers, the
D2O solutions should not be exposed to atmospheric moisture. To avoid this, the
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buffer solutions were prepared under a nitrogen atmosphere. In addition, to prevent
the lowering of the % D content of the final solution the buffer solutes were
lyophilised from D2O twice to allow proton-deuterium exchange of all exchangeable
protons. Measurement of the pL (L = H or D) of the solution was carried out using a
normal glass pH electrode. Again, to prevent dilution of the % D in the buffer the
electrode was washed in a small amount of D2O prior to measuring the pD of the D2O
buffer solutions. As there is an actual solvent isotope effect on the electrode
response,29 the pD was then calculated using the following equation:
pD = meter reading + 0.4
In addition, the substrates, quinolinic acid and PRPP, were lyophilised from D2O to
allow the exchange of all the acidic protons for deuterium prior to preparation of the
stock solutions in the freshly prepared D2O buffer.
The isotope effects were measured at a high concentration of quinolinic acid
(0.3 mM), so essentially under saturating conditions. Therefore, it is the isotope
effect on Vmax that is measured. The solvent isotope effects were determined by
measuring the rate of the enzymatic reaction in equivalent 50 mM potassium
phosphate buffers in H2O and D2O at three points on the pL rate profile (L = H or D).
The rates were measured in triplicate. The results obtained at pL 7.2 indicate a small
normal isotope effect (kH/kD = 1.16) whereas small inverse isotope effects were
observed at pL 6.3 (kH/kD = 0.85) and pL 5.3 (kH/kD = 0.90). In order to confirm the
small inverse isotope effects at pL 6.3 and pL 5.3, fresh buffers were prepared and the
measurement of the isotope effects were repeated. As before, small inverse isotope
effects were observed.
It is unclear why a normal isotope effect (kH/kD  1) was observed at pL 7.2 while
inverse isotope effects (kH/kD  1) were measured closer to the optimum pL for
enzymatic activity. However, what can be concluded from the results obtained is that
the proton transfer is not rate limiting. If the reprotonation of the ylide 18 was clearly
rate limiting then the magnitude of the isotope effect may be as high as 8, and even if
the proton transfer was only partially rate limiting then an isotope effect of 3-4 would
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be expected.28 The results therefore suggest that the ylide intermediate 18 is unstable
and is rapidly protonated to form the product, nicotinic acid mononucleotide 11.
The observed isotope effects are small enough to be a result of small, non-specific
effects on enzyme structure. Therefore, it is not possible to make any useful
mechanistic conclusions from this set of data, apart from the implication the proton
transfer is not rate limiting.
2.4.6 Measurement of QPRTase activity
The continuous spectrophotometric assay used in this study to measure the activity of
QPRTase was found to be very reliable and provided reproducible data. However, as
can be seen from the typical UV trace for the conversion of quinolinic acid to
nicotinic acid mononucleotide by QPRTase (Figure 2.24), the absorbance at 266 nm
does not increase linearly during the entire 30 minute period over which the assay is
run. A curving of the graph is observed over the first few minutes of reaction before
A266 increases linearly over the remainder of the time. This has always been observed
in the UV trace resulting from this assay but the cause is unknown.
Figure 2.24: Typical UV trace for the conversion of quinolinic acid to NAMN by
QPRTase.
A
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6
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To investigate the effect of enzyme concentration on the extent of the curving, the UV
assay was performed at a range of different QPRTase concentrations. It was found
that the extent of the curving decreased slightly as the enzyme concentration increased
but was not eradicated.
In the standard UV assay, the reaction is initiated by addition of QPRTase. It was
found that reversing the order of addition i.e. adding the enzyme before the substrates,
had no significant effect on the resulting UV trace.
QPRTase appears to catalyse two distinct chemical reactions and one hypothetical
explanation for the appearance of the UV trace was that the initial decrease in
absorbance may occur as quinolinic acid undergoes rapid phosphoribosyl transfer to
form the intermediate quinolinic acid mononucleotide. The linear increase in
absorbance that follows could then be due to the slow decarboxylation of this
intermediate to form the nicotinic acid mononucleotide. However, the initial curving
of the UV trace was observed when QPRTase was incubated with the inhibitor
phthalic acid in the absence of quinolinic acid, which rules out this possibility since
phthalic acid 25 has no heterocyclic nitrogen atom for reaction (Figure 2.25).
Figure 2.25: UV trace for the incubation of phthalic acid with QPRTase.
The cause of the initial curving of the UV trace remains unknown. It is possible that
it is caused by a mixing effect or perhaps by protein reorganisation. However, the
assay provides reliable and reproducible data and the kinetic parameters determined
using this assay were comparable to literature values for QPRTase from other sources.
Time (minutes)
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2.5 Summary
Human brain QPRTase was successfully expressed in E. coli BL21 (DE3) from the
pEHISTEV-QPRTase construct and the protein was efficiently purified by nickel
affinity chromatography. The purified protein was isolated in a yield of 8 mg per litre
culture.
In the crystal structure, human brain QPRTase was found to adopt an energetically
stable hexameric arrangement in which each subunit makes extensive contacts with
four other monomers. The enzyme was also found to exist as a hexamer during gel
filtration under physiological conditions.
The structural studies enabled identification of the active site residues. The active site
is a deep pocket with a highly positive electrostatic surface composed of three
arginine residues, two lysine residues and one histidine residue. The quinolinic acid
binding site was occupied by a molecule of tartrate, which was present in the
precipitant used to crystallise the protein.
Kinetic studies allowed the measurement of the kinetic parameters for quinolinic acid.
The data gave a Km of 13.4  1.0 M and a Vmax of 0.92  0.01 M min-1. There was
no evidence for cooperative binding of quinolinic acid to the six subunits of the
QPRTase hexamer. Previous kinetic studies on human brain QPRTase showed
pronounced substrate inhibition by PRPP at high concentrations. The mixed
inhibition observed suggested that PRPP not only binds to an active site (competitive)
but also to a second site which perturbs and inhibits the active site (noncompetitive).
The hexameric structure observed for human brain QPRTase offers a possible
explanation for the complex kinetics this enzyme exhibits. However, no apparent
cooperativity was observed between sites for quinolinic acid binding.
It was found that the presence of the histidine tag does not affect the protein folding,
the oligomeric state of the protein or the enzymatic activity. The observation that the
presence of the histidine tag has no effect on the enzyme kinetics means that it does
not have to be cleaved from the enzyme used in kinetic studies.
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2.6 Further work
Crystallisation of the QPRTase-quinolinic acid complex would provide valuable
information about the active site as well as any structural changes which occur during
substrate binding. Firstly, due to the presence of tartrate in the active site,
crystallisation of QPRTase should be carried out using an alternative precipitant, such
as acetate, propionate or possibly quinolinic acid itself. The use of quinolinic acid as
the precipitant would allow direct access to the QPRTase-quinolinic acid complex.
Acetate or propionate should not bind as tightly in the active site as tartrate since they
lack the 1,2-dicarboxylic acid functionality. If crystals were generated under these
conditions then soaking experiments could be undertaken to access the complexes of
QPRTase with the substrates, products and inhibitors. If acetate or propionate
molecules did bind to the active site, displacement by substrate or inhibitor should be
easier due to the lower affinity for the enzyme. The availability of the crystal
structures of QPRTase with and without its substrates and products would provide
a detailed perspective for the active site interactions in pre-catalytic, catalytic and
post-catalytic stages of the enzyme.
Further kinetic isotope effect studies should be undertaken to examine the 13C isotope
effect for the decarboxylation step. This would not require the synthesis of labelled
substrates and could be measured using natural abundance material.30 From
measurements of the variation in the 13C/12C ratio of the carbon dioxide produced as
the reaction proceeds, using dual-isotope ratio mass spectrometry, the 13C isotope
effect can be measured with a high degree of accuracy. In addition, measurement of
the 13C isotope effect in D2O could be used to investigate the relative timing of O-H
and C-C bond cleavage during decarboxylation.
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3.1 Introduction
Investigation into the inhibition of an enzyme system is an extremely important part
of understanding the enzyme. The use of inhibitors is vital, not just to prevent the
enzyme from functioning, but also to examine possible mechanisms for the catalysed
reaction.
As discussed in section 1.6, inhibitors of QPRTase may have many important roles.
They may be useful mechanistic tools for identifying important interactions in the
active site and therefore assisting in the elucidation of the chemical mechanism of the
QPRTase catalysed reaction. They may also be useful biological tools for the
evaluation of QPRTase and its importance in vivo. Inhibitors of QPRTase may allow
the neurological effects of quinolinic acid to be investigated by blocking the active
site of the enzyme, inhibiting its action and therefore artificially raising quinolinic
acid levels. The biological effect of this increase could be investigated and compared
with neurological disorders. In addition, inhibitors of QPRTase may possess
anti-mycobacterial and anti-fungal activity.
Several inhibition studies on QPRTase have been reported, mostly using analogues of
quinolinic acid although some analogues of PRPP have also been examined as
inhibitors of QPRTase. Phthalic acid 25 and picolinic acid 26 are both potent
inhibitors of QPRTase from most sources.1-4 However, the methyl esters of these
compounds do not inhibit QPRTase, implying that the free acid is required at the
2-position for binding in the active site.5
Inhibition studies on QPRTase from ATCC strain 23269 carried out by Calvo et al.
also highlighted the importance of an acidic group at the 2-position for binding in the
active site.6 In this study it was found that analogues of nicotinic acid with a hydroxyl
28 or thiol 29 group at the 2-position were good competitive inhibitors of QPRTase,
while the corresponding 3-nitro derivatives 30 and 31 were even more effective. The
results therefore suggested that the effectiveness of an inhibitor correlates with the
degree of ionisation of the acidic group at the 2-position, implying that negative
charge on the 2-substituent is an important contributor to tight binding to the enzyme.
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N OH
CO2H
N SH
CO2H
N OH
NO2
N SH
NO2
28 29 30 31
Previously in our laboratory, two of these compounds were tested as inhibitors of
human brain QPRTase.7 A preliminary inhibition screen showed 2-mercaptonicotinic
acid 29 and 2-hydroxy-3-nitropyridine 30 were very good inhibitors, even when
present at a concentration of 1 M. Detailed inhibition studies then showed
2-mercaptonicotinic acid 29 was a very effective competitive inhibitor (Ki 3.55 M).
In addition, two new compounds were synthesised and tested as inhibitors of human
brain QPRTase. 2-Sulfonicotinic acid 36 was found to be a reasonable competitive
inhibitor (Ki 146 M) although was not as effective as 2-mercaptonicotinic acid 29.
This suggests that the presence of the larger sulfonate group at the 2-position leads to
weaker binding in the active site. The size effect was further highlighted by the poor
inhibitory properties of 2-phosphonomethylnicotinic acid 37 (Ki 1.32 mM), which has
an additional carbon between the ring and the acidic group at the 2-position.
Furthermore, the results suggest that the closer the anion at the 2-position is to the
pyridine ring, the more effective the inhibitor.
N SO3H
CO2H
N
CO2H
PO3H
36 37
Previous work on the synthesis of quinolinic acid analogues has therefore focused
mainly on replacing the carboxylic acid group at the 2-position with an alternative
acidic group. The aim now was to begin investigating the effect of substituents at
different positions of the ring with a view to probing binding interactions in the active
site of human brain QPRTase.
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3.2 Synthesis of potential inhibitors of human brain QPRTase
3.2.1 Synthesis of N-substituted compounds
3.2.1.1 Synthesis of N-methyl and N-ethylquinolinic acid
The first position of quinolinic acid selected for functionalisation was the ring
nitrogen. The rationale behind introducing substituents at this position was that the
resulting compounds would bear some resemblance to the putative reaction
intermediate, quinolinic acid mononucleotide 16, and might therefore prove to be
effective inhibitors of QPRTase. In addition, compounds of this type might be useful
as substrates for enzymatic decarboxylation studies (Chapter 4).
N
R
CO2H
CO2H NO
OHOH
PiO
CO2H
CO2H+ +
16
The first two synthetic targets were simple N-alkylquinolinic acid derivatives. The
synthetic route to N-methyl and N-ethylquinolinic acid is outlined in Scheme 3.1.
N
CO2H
CO2H N
CO2Me
CO2Me
N
CO2H
CO2
R
N
CO2Me
CO2Me
R
+
+
MeOH
conc. H2SO4
conc. HCl
reflux
3h
41 R = Me, 81%
42 R = Et, 79%
(R=Me or Et)
(RO)2SO2
70 oC
.H2O
ROSO3
-
-
reflux
24 h, 54%
10 38 39 R = Me
40 R = Et
Scheme 3.1: Synthetic route to N-alkylquinolinic acids.
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Firstly, dimethyl quinolinate 38 was prepared by acid catalysed esterification of
quinolinic acid 10 in boiling methanol (Scheme 3.1). The product was obtained as a
white solid in reasonable yield (54%). The 1H NMR spectrum was consistent with the
expected product. Two singlets were observed at 3.94 and 4.01 ppm corresponding to
the protons of the two methyl groups. The aromatic protons were observed between
7.50 and 8.77 ppm. The identity of the product was also confirmed by electrospray
mass spectrometry (ES+) which showed a signal corresponding to the (M+H)+
molecular ion at m/z 196.
The next step was to introduce the N-substituent (Scheme 3.1). The N-alkylation
reaction was achieved by treating dimethyl quinolinate 38 with one equivalent of the
appropriate dialkyl sulfate and heating the resulting mixture at 70 C.
In the case of the N-methylation reaction, 1H and 13C NMR spectroscopy showed the
reaction had reached completion after 2 hours. The signal corresponding to the
protons of the N-methyl group was observed as a singlet at 4.50 ppm in the 1H NMR
spectrum. In the 13C NMR spectrum, the signal for the N-methyl group was
observed at 58.0 ppm. The NMR spectra suggest the counterion for the positively
charged dimethyl N-methylquinolinate 39 is the methyl sulfate anion (CH3OSO3-).
The signal for the methyl protons of the counterion was observed as a singlet at
3.60 ppm in the 1H NMR spectrum. The corresponding signal was observed in the
13C NMR spectrum at 50.2 ppm.
It was found that the reaction of dimethyl quinolinate 38 with diethyl sulfate was
slower, reaching completion after 12 hours. 1H and 13C NMR spectroscopy confirmed
the desired product 40 had been formed exclusively. The signals corresponding to the
protons of the N-ethyl group were observed as a triplet at 1.71 ppm (CH3) and a
quartet at 4.78 ppm (CH2) in the 1H NMR spectrum. In the 13C NMR spectrum, the
signals for N-ethyl group were observed at 17.6 ppm (CH3) and 65.6 ppm (CH2). The
NMR spectra suggest the counterion is the ethyl sulfate anion (CH3CH2OSO3-). The
signals corresponding to the protons of the counterion were observed as a triplet at
1.26 ppm (CH3) and a quartet at 4.10 ppm (CH2) in the 1H NMR spectrum.
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In the final step, acid catalysed hydrolysis of the diester produced the desired
N-alkylquinolinic acid (Scheme 3.1). Following recrystallisation from water, both
N-methyl and N-ethylquinolinic acid were obtained as white crystalline solids in high
yields of 81% and 79%, respectively. The N-alkylquinolinic acids were fully
characterised. In the 1H NMR spectrum of N-methylquinolinic acid 41, the signal for
the protons of the N-methyl group was observed as a singlet at 4.36 ppm. The identity
of the product was also confirmed by electrospray mass spectrometry (ES+) which
showed a signal corresponding to the molecular ion at m/z 182. Similarly for
N-ethylquinolinic acid 42, a signal corresponding to the molecular ion was observed
at m/z 196. In the 1H NMR spectrum of N-ethylquinolinic acid, the signals
corresponding to the protons of the N-ethyl group were observed as a triplet at
1.50 ppm (CH3) and a quartet at 4.53 ppm (CH2). CHN microanalysis showed that
both N-methyl and N-ethylquinolinic acid exist in the zwitterionic monohydrate form
shown in Scheme 3.1. CHN microanalysis showed both compounds were pure and
are therefore suitable for biological testing.
3.2.1.2 Synthesis of 5-ethyl–N-methylquinolinic acid
5-Ethylquinolinic acid 43 is commercially available and it was decided to synthesise
the N-methyl derivative and test both compounds as inhibitors of human brain
QPRTase to further investigate the effect of the N-substituent on the inhibitory
properties. This inhibition study would also enable the effect of the substituent at the
5-position on the binding in the active site to be examined. The synthetic route to
5-ethyl-N-methylquinolinic acid 46 is outlined in Scheme 3.2.
N
CO2H
CO2H
Et
N
CO2Me
CO2Me
Et
N
CO2H
CO2
Me
Et
N
CO2Me
CO2Me
Me
Et
+
+
MeOH
conc. H2SO4
conc. HCl
reflux, 3h
89%
(MeO)2SO2
70 oC
.H2O
MeOSO3
-
-
reflux
24 h, 48%
43 44 45
46
Scheme 3.2: Synthesis of 5-ethyl-N-methylquinolinic acid.
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The synthetic route was successfully followed and after recrystallisation from water,
5-ethyl-N-methylquinolinic acid 46 was obtained as a white solid in high yield (89%).
The 1H NMR spectrum of the final product was consistent with the desired product.
The signal for the protons of the N-methyl group was observed as a singlet at
4.14 ppm. The identity of the product was also confirmed by electrospray mass
spectrometry (ES+) which showed a signal corresponding to the molecular ion at
m/z 210. CHN microanalysis showed 5-ethyl-N-methylquinolinic acid was pure and
exists in the zwitterionic monohydrate form shown in Scheme 3.2.
3.2.1.3 Synthesis of N-alkylpicolinic acids
To investigate the relative importance of the carboxylic acid group at the 3-position
and the presence of the N-substituent on binding in the active site of QPRTase, it was
decided to synthesise N-methyl and N-ethylpicolinic acid and test these compounds,
as well as picolinic acid 26, as inhibitors of QPRTase (Scheme 3.3).
N CO2H N CO2Me
N
R
CO2H
N CO2Me
R
+
+
MeOH
conc. H2SO4
conc. HCl
reflux
2h
50 R = Me, 92%
51 R = Et, 67%
(R=Me or Et)
(RO)2SO2
70 oC
.HSO4
ROSO3
-
reflux
24 h, 69%
-
26 47 48 R = Me
49 R = Et
Scheme 3.3: Synthetic route to N-alkylpicolinic acids.
By following this route N-methyl and N-ethylpicolinic acid were obtained as white
crystalline solids in good yields of 92% and 67%, respectively. The N-alkylpicolinic
acids were fully characterised. In the 1H NMR spectrum of N-methylpicolinic acid
50, the signal for the protons of the N-methyl group was observed as a singlet at
4.24 ppm. The identity of the product was also confirmed by electrospray mass
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spectrometry (ES+) which showed a signal corresponding to the molecular ion at
m/z 138. Similarly for N-ethylpicolinic acid 51, a signal corresponding to the
molecular ion was observed at m/z 152. In the 1H NMR spectrum of N-ethylpicolinic
acid, the signals corresponding to the protons of the N-ethyl group were observed as a
triplet at 1.42 ppm (CH3) and a quartet at 4.58 ppm (CH2). CHN microanalysis
showed that both N-methyl and N-ethylpicolinic acid were pure and exist as the
hydrogen sulfate salts shown in Scheme 3.3.
3.2.1.4 Synthesis of N-methylquinoline-2-carboxylic acid
Quinoline-2-carboxylic acid 52 is commercially available and it was decided to
synthesise the N-methyl derivative and test both compounds as inhibitors of human
brain QPRTase to further investigate the effect of the N-substituent on the inhibitory
properties. This inhibition study would also enable the effect of the larger bicyclic
structure on the binding in the active site to be examined. The synthetic route to
N-methylquinoline-2-carboxylic acid 55 is outlined in Scheme 3.4.
N CO2Me
MeOSO3
N CO2Me
Me
N
Me
CO2H
N CO2H
MeOH
conc. H2SO4
conc. HCl
reflux, 3h
62%
(MeO)2SO2
70 oC
reflux
24 h, 83%
+
-
+
.HSO4
-
52 53
5455
Scheme 3.4: Synthesis of N-methylquinoline-2-carboxylic acid.
The synthetic route was successfully followed and after recrystallisation from
methanol, N-methylquinoline-2-carboxylic acid 55 was obtained as a white solid in
good yield (62%). The 1H NMR spectrum of the final product was consistent with the
desired product. The signal for the protons of the N-methyl group was observed as a
singlet at 4.35 ppm. The identity of the product was also confirmed by electrospray
Chapter Three Inhibitor Synthesis and Inhibition Studies
101
mass spectrometry (ES+) which showed a signal corresponding to the molecular ion at
m/z 188. CHN microanalysis showed N-methylquinoline-2-carboxylic acid was pure
and exists as the hydrogen sulfate salt shown in Scheme 3.4.
3.2.1.5 Synthesis of N-alkylnicotinic acids
To investigate the relative importance of the carboxylic acid group at the 2-position
and the presence of the N-substituent on binding in the active site of QPRTase, it was
decided to synthesise N-methyl and N-ethylnicotinic acid and test these compounds,
as well as nicotinic acid 27, as inhibitors of QPRTase (Scheme 3.5).
N
CO2H
N
CO2Me
N
R
CO2H
N
R
CO2Me
+
+
MeOH
conc. H2SO4
conc. HCl
reflux
2h
59 R = Me, 90%
60 R = Et, 72%
(R=Me or Et)
(RO)2SO2
70 oC
.HSO4
ROSO3
-
reflux
24 h, 76%
-
27 56 57 R = Me
58 R = Et
Scheme 3.5: Synthetic route to N-alkylnicotinic acids.
N-Methyl and N-ethylnicotinic acid were obtained as white crystalline solids in good
yields of 90% and 72%, respectively. The N-alkylnicotinic acids were fully
characterised. In the 1H NMR spectrum of N-methylnicotinic acid 59, the signal for
the protons of the N-methyl group was observed as a singlet at 4.32 ppm. The identity
of the product was also confirmed by electrospray mass spectrometry (ES+) which
showed a signal corresponding to the molecular ion at m/z 138. Similarly for
N-ethylnicotinic acid 60, a signal corresponding to the molecular ion was observed at
m/z 152. In the 1H NMR spectrum of N-ethylnicotinic acid, the signals corresponding
to the protons of the N-ethyl group were observed as a triplet at 1.49 ppm (CH3) and a
quartet at 4.54 ppm (CH2). CHN microanalysis showed that both N-methyl and
N-ethylnicotinic acid exist as the hydrogen sulfate salts shown in Scheme 3.5.
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3.2.1.6 Synthesis of quinolinic acid N-oxide
Having prepared a series of N-alkyl compounds, it was decided to change the nature
of the N-substituent and examine the effect this has on the binding in the active site of
QPRTase. The initial synthetic route to quinolinic acid N-oxide 62 is outlined in
Scheme 3.6.
N
CO2Me
CO2Me
O
N
CO2Me
CO2Me N
O
CO2H
CO2H+
-
+
-
peracetic acid
acetic acid
DCM
Conc. HCl
reflux
reflux
38 61 62
Scheme 3.6: Proposed synthetic route to quinolinic acid N-oxide.
Firstly, formation of the N-oxide was achieved by treating dimethyl quinolinate 38
with excess peracetic acid in dichloromethane and heating under reflux for 6 hours
(Scheme 3.6). Analysis of the crude product by TLC and 1H NMR spectroscopy
showed there was still a small amount of unreacted dimethyl quinolinate remaining.
Recrystallisation from methanol gave the desired product 61 as a white solid in 24%
yield. In the 1H NMR spectrum of the product, the signals for the aromatic protons
were shifted upfield compared to the corresponding signals of the starting material
and were observed at 7.35 ppm (H-5), 7.82 ppm (H-4) and 8.30 ppm (H-6). The
identity of the product was confirmed by electrospray mass spectrometry (ES+) which
showed a signal corresponding to the (M+H)+ molecular ion at m/z 212.
In the next step, an attempt was made to hydrolyse the diester 61 under acidic
conditions to give the desired N-substituted quinolinic acid derivative 62 (Scheme
3.6). The 1H NMR spectrum of the crude product showed hydrolysis of the dimethyl
ester had been achieved. However, the desired product, quinolinic acid N-oxide 62,
has only 3 aromatic protons but 4 signals were observed in the 1H NMR spectrum at
7.62 ppm, 8.18 ppm, 8.42 ppm and 8.75 ppm. In addition, the 13C NMR spectrum
showed only one signal corresponding to a carbonyl carbon at 164.2 ppm. Therefore,
it would appear that under the conditions employed, decarboxylation at the 2-position
has occurred to form nicotinic acid N-oxide 63 (Scheme 3.7). This was confirmed by
electrospray mass spectrometry (ES+) which showed a signal corresponding to the
(M+H)+ molecular ion at m/z 140.
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Scheme 3.7: Formation of nicotinic acid N-oxide from dimethyl quinolinate N-oxide.
The initial route to quinolinic acid N-oxide 62, starting from dimethyl quinolinate 38,
was selected due to the poor solubility of quinolinic acid 10 in dichloromethane and
also because the diester moiety would make the product less polar and would
therefore aid purification. However, with the observation that decarboxylation occurs
at the 2-position when heated under reflux in concentrated hydrochloric acid, it was
decided to avoid the hydrolysis step and try to obtain quinolinic acid N-oxide 62 by
direct oxidation of quinolinic acid 10 with excess peracetic acid (Scheme 3.8).
N
O
CO2H
CO2HN
CO2H
CO2H +
-
peracetic acid
acetic acid
60 oC
10 62
Scheme 3.8: Synthesis of quinolinic acid N-oxide.
The reaction was heated gently until solution of quinolinic acid 10 was complete and
then heating was maintained at 60 C. After 4 hours, a white solid began to
precipitate. Heating at 60 C was continued for a further 2 hours then the product was
collected by suction filtration. Recrystallisation from water gave quinolinic acid
N-oxide 62 as a white solid in 30% yield. The identity of the product was confirmed
by electrospray mass spectrometry (ES+) which showed a signal corresponding to the
(M+H)+ molecular ion at m/z 184 (relative intensity 100%). The 1H and 13C NMR
spectra were also consistent with the desired product.
In the 1H NMR spectrum of the filtrate, there was evidence for a small amount of
nicotinic acid N-oxide 63 in addition to quinolinic acid N-oxide 62 and unreacted
quinolinic acid 10, which explains the low yield. A series of pyridine dicarboxylic
acid N-oxides have previously been prepared by treatment with aqueous acetic acid
and 30% hydrogen peroxide and the N-oxides were separated from unreacted starting
material as Pb2+ complexes which were subsequently decomposed with H2S.8 The
yield of quinolinic acid N-oxide (21%) was considerably lower than the other pyridine
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dicarboxylic acid N-oxides. In this reaction, decarboxylation was also observed and
some nicotinic acid N-oxide was isolated.
3.2.1.7 Attempted synthesis of N-(2-hydroxyethyl)quinolinic acid
Increasing the similarity of the N-substituent to that in the putative reaction
intermediate, quinolinic acid mononucleotide 16, might provide additional binding
interactions in the active site of human brain QPRTase and might therefore lead to
increased inhibition of the enzyme. Therefore, it was decided to attempt the synthesis
of N-(2-hydroxyethyl)quinolinic acid 64.
N
CO2H
CO2H
OH
NO
OHOH
PiO
CO2H
CO2H
64
+
16
+
The proposed synthetic route to N-(2-hydroxyethyl)quinolinic acid 64 is outlined in
Scheme 3.9.
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CO2H
CO2H
OH
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CO2Me N
OH
CO2Me
CO2Me
O
+
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+
THF, -78 oC
BF3.Et2O
38 65 64
Scheme 3.9: Proposed route to N-(2-hydroxyethyl)quinolinic acid.
The key reaction to introduce the N-substituent was achieved by reacting dimethyl
quinolinate 38 with excess ethylene oxide in the presence of boron trifluoride diethyl
etherate (BF3.Et2O). In the absence of boron trifluoride no reaction occurred
indicating that the Lewis acid is required to activate the ethylene oxide towards
nucleophilic attack by dimethyl quinolinate. It was found that the best results were
achieved when 3 equivalents of the Lewis acid catalyst were used. Under these
conditions, TLC and 1H NMR analysis of the crude product showed there was no
unreacted dimethyl quinolinate remaining. The 1H NMR spectrum of the crude
product was consistent with the desired product 65 and showed two triplets at
3.38 ppm and 4.05 ppm corresponding to the protons of the methylene groups of the
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N-substituent. However, an additional large signal was observed at 3.65 ppm. It was
thought that this might be due to polyethylene glycol, formed by the polymerisation of
ethylene oxide under the reaction conditions. This would also explain the high yield
and appearance of the crude product, which was a thick white semi-solid material.
Dimethyl N-(2-hydroxyethyl)quinolinate 65 was successfully extracted by washing
the crude material with water. The 1H NMR spectrum of the insoluble white solid
showed only a single signal at 3.45 ppm. The 1H NMR spectrum of the extracted
material however was consistent with the desired product 65 and the absence of the
large signal at 3.65 ppm showed the impurity had successfully been removed. The
identity of the product was also confirmed by electrospray mass spectrometry (ES+)
which showed a signal corresponding to the molecular ion at m/z 240 (relative
intensity 100%).
In the final step, an attempt was made to hydrolyse the diester 65 under acidic
conditions to give the desired N-substituted quinolinic acid derivative 64. The
1H NMR spectrum of the crude product showed hydrolysis of the dimethyl ester had
been achieved. However, analysis of the crude material by electrospray mass
spectrometry (ES+) indicated that the desired product had not been formed. A signal
was observed at m/z 194. Therefore, it would appear that under the acidic conditions,
the hydroxyl group of the N-substituent has reacted with the ester group at the
2-position resulting in the formation of a six membered ring (Scheme 3.10).
CO2H
N
O
O
N
OH
CO2Me
CO2Me +
conc. HCl
reflux, 6h
+
65 66
Scheme 3.10: Hydrolysis of dimethyl N-(2-hydroxyethyl)quinolinate.
While it was not the target compound, 66 would also be an interesting compound to
test as an inhibitor of QPRTase. Unfortunately, due to the polarity of the compound,
purification proved very difficult. All attempts at recrystallisation failed. However,
the compound appeared to be pure by NMR analysis so it was decided to perform a
preliminary inhibition screen to provide an indication of its inhibitory properties.
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3.2.2 Routes to 4-substituted quinolinic acid derivatives
The second group of synthetic target compounds were derivatives of quinolinic acid
substituted at the 4-position. These compounds were of interest as tools to probe
binding interactions in the active site of human brain QPRTase.
N
R
CO2H
CO2H
3.2.2.1 Route 1 - Directed ortho-metalation
The initial route to 4-substituted quinolinic acid derivatives was planned involving
directed ortho-metalation to guide the substitution of quinolinic acid.9 Directed
ortho-metalation involves the deprotonation of a site ortho to a heteroatom-containing
substituent (directed metalation group, DMG) by a strong base, normally an alkyl
lithium reagent, leading to an ortho-lithiated species. This species, upon treatment
with electrophilic reagents, yields 1,2-disubstituted products. This process can be
viewed, albeit rather simplistically, as a three step sequence: coordination of the
alkyllithium aggregate to the DMG heteroatom; deprotonation to give the coordinated
ortho-lithiated species; and reaction with an electrophile to yield the disubstituted
product (Scheme 3.11).
DMG DMG
H
DMG
Li
DMG
E
(RLi)n
(RLi)n
n
-(RH)n
n
E+
Scheme 3.11: The directed ortho-metalation process.
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An attempt was made to functionalise the 4-position of dimethyl quinolinate 38 by
employing an in situ trapping method of directed ortho-metalation.10 The hindered,
non-nucleophilic base lithium diisopropylamide (LDA) was generated in dry
tetrahydrofuran. The electrophilic trap, trimethylsilyl chloride, was then added just
prior to the addition of dimethyl quinolinate 38. The idea is that removal of the
pyridyllithium 67 by reaction with the electrophilic trap drives forward the otherwise
unfavourable equilibrium between dimethyl quinolinate 38 and the pyridyllithium 67
(Scheme 3.12). For the first attempts at the directed ortho-metalation reaction,
trimethylsilyl chloride was selected as the electrophilic trap simply because the
trimethylsilyl group is easily observed by 1H NMR spectroscopy and the low shift of
this signal means that it does not obscure any of the other signals making it easy to
establish whether or not the reaction was successful.
N
CO2Me
CO2Me
H
N
CO2Me
CO2Me
Li
Li N H N
N
CO2Me
CO2Me
SiMe3
+ +
Me3SiCl
38 67
68
Scheme 3.12: The in situ trapping method.
TLC analysis of the crude product showed there was no unreacted dimethyl
quinolinate 38 remaining. However, the 1H NMR spectrum of the crude material was
not very clean and showed no sign of the desired product, dimethyl
4-trimethylsilylquinolinate 68. While it can not be concluded from the spectral data,
it is possible that a self-condensation reaction is competing with the trapping with
trimethylsilyl chloride. In a study of the in situ trapping of ortho-lithiated alkyl
benzoates by Krizan et al, it was found that the reaction worked best with isopropyl
benzoate, while the less sterically hindered ethyl ester had a tendency to
self-condense.11
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Therefore it was decided to synthesise diisopropyl quinolinate 69 for use in the
directed ortho-metalation reaction. This involved a simple esterification of quinolinic
acid 10 with isopropanol in the presence of acid (Scheme 3.13). Purification of the
crude product by column chromatography on silica gave the desired product as a
colourless oil in 40% yield. The 1H NMR spectrum was consistent with the expected
product. Two doublets were observed at 1.36 and 1.39 ppm corresponding to the
methyl protons from the two isopropyl groups. The corresponding methine protons
were both observed in a complex multiplet that spanned 5.17 to 5.31 ppm. The
aromatic protons were observed between 7.63 and 8.72 ppm. The identity of the
product was also confirmed by electrospray mass spectrometry (ES+) which showed a
signal corresponding to the (M+H)+ molecular ion at m/z 252.
N
CO2H
CO2H N
CO2
CO2
iPr
iPr
iPrOH
conc. H2SO4
reflux
24 h
10 69
Scheme 3.13: Synthesis of diisopropyl quinolinate.
The next step was to attempt the directed ortho-metalation reaction with diisopropyl
quinolinate 69 as the substrate. As before, trimethylsilyl chloride was used as the
electrophilic trap, but lithium 2,2,6,6-tetramethylpiperidine (LiTMP), which is a very
sterically encumbered base, was used instead of LDA (Scheme 3.14). A 1:2:10 ratio
of substrate, base and electrophilic trap was used.
N
CO2
CO2 N
CO2
CO2
SiMe3
iPr
iPr
LiTMP / TMSCl
-78 oC 25 oC
2 h
THF
iPr
iPr
69 70
Scheme 3.14: Attempted synthesis of diisopropyl 4-trimethylsilylquinolinate.
TLC analysis of the crude material showed the reaction was not clean and a number
of products had been produced. An attempt was made to separate the different
components of the crude product by column chromatography on silica. The least
polar component was the major product and was isolated as a pure white solid in 15%
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yield. In the 1H NMR spectrum of this solid there were two singlets at 0.25 and
0.27 ppm and in the aromatic region there was only one singlet at 7.66 ppm. This
suggested that this compound contained two trimethylsilyl groups. This was
confirmed by electrospray mass spectrometry (ES+), which showed a signal
corresponding to a (M+H)+ molecular ion at m/z 396 (relative intensity 25%) and also
(M+Na)+ at m/z 418 (relative intensity 100%). The shift of the aromatic signal in the
1H NMR spectrum is consistent with H-5 and therefore the disubstituted product
appears to be diisopropyl 4,6-di(trimethylsilyl)quinolinate 71.
N
CO2
CO2
SiMe3
Me3Si
iPr
iPr
71
Isolation of the second least polar component of the crude product in pure form by
column chromatography proved difficult but it was isolated in a mixture with the
identified 4,6-disubstituted derivative. The 1H NMR spectrum of this mixture
showed, in addition to the signals for the disubstituted derivative, a pair of doublets in
the aromatic region at 7.42 ppm (J 5 Hz) and 8.48 ppm (J 5 Hz). This suggested the
possible presence of the desired diisopropyl 4-trimethylsilylquinolinate 70 in the
product mixture. However, the electrospray mass spectrum of the mixture was
identical to that for the pure disubstituted derivative and showed no sign of the desired
product. Due to the lack of material no further purification attempt was made to
separate the two components of this mixture.
In this directed ortho-metalation reaction, a second lithiation at the 6-position ortho to
the ring nitrogen occurred leading to a complex mixture of mono- and disubstituted
products that proved difficult to separate. This is often seen with pyridines.
However, in this reaction 2 equivalents of LiTMP were used and it was therefore
decided to try and optimise the reaction by using less base in the hope that this would
prevent the formation of the disubstituted derivative. The reaction was repeated using
the same substrate, base, electrophilic trap and reaction conditions but reducing the
amount of base added to just 1.1 equivalents. However, this reaction was
unsuccessful. The 1H NMR spectrum of the crude product showed only unreacted
starting material.
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Replacing trimethylsilyl chloride with different electrophiles gave similar negative
results. Firstly, diisopropyl quinolinate was treated with 1.1 equivalents of LiTMP in
the presence of 3 equivalents of benzyl bromide as the electrophilic trap. However,
the 1H NMR spectrum of the crude product showed only unreacted starting material.
It was therefore decided to increase the reactivity of the electrophile, but the reaction
with benzaldehyde under the same conditions was also unsuccessful. The attempted
reactions are summarised in Table 3.1.
Substrate Base Electrophilic
trap
Substrate:base:trap Outcome
Diisopropyl
quinolinate
LiTMP Trimethylsilyl
chloride
1:2:10 Complex
mixture of
products
Diisopropyl
quinolinate
LiTMP Trimethylsilyl
chloride
1:1.1:10 No reaction
Diisopropyl
quinolinate
LiTMP Benzyl
bromide
1:1.1:3 No reaction
Diisopropyl
quinolinate
LiTMP Benzaldehyde 1:1.1:3 No reaction
Table 3.1: Reaction summary.
It is possible that the latter reactions failed because the deprotonation of diisopropyl
quinolinate 69 was unsuccessful when only 1.1 equivalents of the base were used.
However, it was shown that using a larger excess of the base leads to the formation of
a complex mixture of products including mono- and disubstituted derivatives that are
difficult to separate. With the failure of the directed ortho-metalation reaction, an
alternative route to 4-substituted quinolinic acid derivatives was sought.
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3.2.2.2 Route 2 - Addition of organometallic reagents to 1-acylpyridinium salts
Many investigations have been reported on the reaction of organometallic reagents
with pyridines to introduce substituents directly to the pyridine ring. The synthesis of
substituted pyridines by the reaction of Grignard reagents and pyridine is not a
practical method due to the strenuous conditions required for addition, the low yields
obtained and frequent lack of regioselectivity. Therefore to obtain high yields of
addition with Grignard reagents, activation of the pyridine ring is necessary.
Fraenkel et al. reported that the pyridine ring could be readily attacked by Grignard
reagents in the presence of ethyl chloroformate to produce 2-substituted
1-(ethoxycarbonyl)-1,2-dihydropyridines 73 (Scheme 3.15).12 Lyle et al. elaborated
on this method by demonstrating that acid chlorides are also effective in activating the
pyridine ring towards nucleophilic attack by Grignard reagents.13 It was shown that
the intermediate 1,2-dihydropyridines 73 could then be readily oxidised by heating
with sulfur to produce the 2-substituted pyridines 74 in good yield (Scheme 3.15).14
N
R
N
OR'O
H
R''
R
NR''
R
1. R'OCOCl
2. R''MgBr S,
72 73 74
Scheme 3.15: Grignard addition to 1-acylpyridinium salts followed by
rearomatisation.
However, the degree of regioselectivity of the addition (1,2- versus 1,4-addition) of
the Grignard reagents to the 1-acylpyridinium salts was unclear from this study since
in most of the reactions examined, 4-alkylpyridines 72, in which the 4-position is
blocked, were used as the starting material and hence nucleophilic attack occurred
preferentially at the 2-position (Scheme 3.15).
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In a study by Comins et al., the regioselectivity of this reaction with regard to how the
structures of the acyl halide and Grignard reagent influence the degree of 1,2- versus
1,4-addition to unsubstituted pyridine was investigated.15 It was found that the
amount of attack at the 4-position is dependent upon the degree of steric hindrance at
the 2-position. The larger the N-substituent and the Grignard reagent, the more
1,4-addition occurs. The nitrogen substituent must sterically shield the 2-position
while activating the 4-position to nucleophilic attack.
In the same study, the effect of adding a catalytic amount of cuprous iodide on the
regioselectivity of the Grignard addition step was investigated. The Grignard reagent
was added dropwise to the preformed acylpyridinium salt and CuI in tetrahydrofuran,
allowing the organocopper intermediate to react with the substrate as soon as it was
formed. This procedure gave good yields and the added catalytic amount of CuI had a
major effect on the regioselectivity, causing nearly exclusive attack at the 4-position
(Scheme 3.16). Similarly, Piers et al. reported that lithium dialkylcuprates react with
pyridine in the presence of methyl chloroformate to give mainly 1,4-dihydropyridines,
which were readily oxidised to the corresponding 4-alkylpyridines.16
N N
H R'
ORO
N
R'1. 5% CuI
2. ROCOCl
3. R'MgBr S,
75 76 77
Scheme 3.16: Regioselective synthesis of 4-substituted pyridines.
The previous studies have therefore demonstrated a highly efficient and practical
synthesis of 4-substituted pyridines. In addition, it has been shown that the pyridine
ring is so activated that addition to the ring will occur in the presence of other reactive
functional groups such as ketones and esters.13 It was therefore decided to attempt the
synthesis of 4-substituted quinolinic acid derivatives utilising this methodology.
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The previous studies had shown that nucleophilic attack occurs preferentially at the
4-position of 1-acylpyridinium salts when soft, bulky nucleophiles and large
N-substituents are used. An attempt was therefore made to synthesise
5-phenylquinolinic acid by first reacting diisopropyl quinolinate 69 with phenyl
magnesium bromide in presence of ethyl chloroformate and catalytic CuI, following
the procedure reported by Comins et al. (Scheme 3.17).15
N
CO2
CO2 N
CO2
CO2
H
O OEt
Ph1. 5% CuI
2. EtOCOCl
3. PhMgBr
iPr
iPriPr
iPr
69 78
Scheme 3.17: Attempted functionalisation of diisopropyl quinolinate.
However, analysis of the crude product by TLC and 1H NMR spectroscopy showed
the reaction had been unsuccessful. If the desired product had been formed it was
expected that, in the 1H NMR spectrum, the signals corresponding to the three protons
in the ring would be shifted upfield relative to the starting material. However, the
signals for the ring protons were observed at 7.60 (H-5), 8.20 (H-4) and 8.75 (H-6),
which are almost identical to the shifts observed for diisopropyl quinolinate 69.
Signals corresponding to the protons of the two isopropyl groups were observed
showing the diester moiety was still intact and no side reactions had occurred. In
addition, signals corresponding to unreacted ethyl chloroformate (1.20 ppm and
4.25 ppm) and the quenched organometallic reagent (7.05-7.40 ppm) were observed
in the 1H NMR spectrum of the crude product. Therefore it would appear that no
reaction occurred.
It is possible that this reaction failed due to steric factors. The combination of using a
large organometallic reagent (phenyl magnesium bromide (5% CuI)) and the bulky
diisopropyl ester of quinolinic acid may make nucleophilic attack at the 4-position
very difficult. It was therefore decided to repeat the reaction using a smaller
nucleophile, methyl magnesium bromide in the presence of 5% CuI. However, this
reaction was also unsuccessful. The reaction was then carried out using the less bulky
dimethyl ester of quinolinic acid, the idea being that reducing the size of the ester
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group might make the 4-position more accessible for nucleophilic attack. However,
the reaction between dimethyl quinolinate 38 and phenyl magnesium bromide in the
presence of 5% CuI and ethyl chloroformate was also unsuccessful. The attempted
reactions are summarised in Table 3.2.
Starting material Organometallic
reagent
Alkyl
chloroformate
Outcome
Diisopropyl
quinolinate
PhMgBr (5% CuI) Ethyl
chloroformate
No reaction
Diisopropyl
quinolinate
MeMgBr (5% CuI) Ethyl
chloroformate
No reaction
Dimethyl
quinolinate
PhMgBr (5% CuI) Ethyl
chloroformate
No reaction
Table 3.2: Reaction summary.
It is possible that, rather than steric factors preventing nucleophilic attack on the
N-acylpyridinium salt 80, the failure of these reactions could be due to a combination
of steric and electronic factors preventing the formation of the N-acylpyridinium salt
80 in the first place. Firstly, the steric bulk of the ester group at the 2-position may
prevent the reaction between the dialkyl quinolinate 79 and ethyl chloroformate
taking place, as this would leave the nitrogen very congested. Furthermore, the two
ester groups will have an electron withdrawing effect on the pyridine ring and as a
result the ring nitrogen might be a reasonably poor nucleophile, which could prevent
the reaction with ethyl chloroformate taking place. N-Acylation is required to activate
the ring towards nucleophilic attack and hence if the N-acylpyridinium salt 80 does
not form, the subsequent reaction with the organometallic reagent will not occur
(Scheme 3.18).
N
CO2R
CO2R N
CO2R
CO2R
H
O OEt
Nu
N
CO2R
CO2R
O OEt
+
Cl-
EtOCOCl Nu -
79 80 81
Scheme 3.18: Formation of the N-acylpyridinium salt followed by nucleophilic attack.
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3.2.2.3 Route 3 - Oxidation of substituted quinolines
Due to the problems with the initial synthetic strategy, an alternative route to
4-substituted quinolinic acid derivatives was sought. A literature search revealed that
oxidation of 4-substituted quinolines 82 could be an attractive route to the
corresponding substituted quinolinic acids 83 (Scheme 3.19). There are several
reports of different methods for the oxidation of quinolines to the corresponding
quinolinic acids, with varying degrees of success. These include potassium
permanganate oxidation,17-20 oxidation with hydrogen peroxide in the presence of
cupric acetate,21 ruthenium tetroxide catalysed oxidation using sodium periodate,
periodic acid or sodium hypochlorite as the oxidant,22-25 ozone oxidation22,26 and
electrolytic oxidation.27,28
N
R
N
R
HO2C
HO2C
[Ox]
82 83
Scheme 3.19: Preparation of 4-substituted quinolinic acids by oxidation of the
corresponding quinolines.
Access to a series of quinolinic acid analogues substituted at the 4-position would
require the availability of the corresponding series of substituted quinolines. Starting
from 4-methylquinoline 84, it is possible to modify and extend the side chain at the
4-position to access a range of substituted quinolines. Methyl groups at the C-2 and
C-4 positions of quinoline are easily deprotonated. This is because the resultant
carbanion 85 is resonance stabilised and the negative charge can be delocalised onto
the electronegative nitrogen atom (Scheme 3.20). The stabilised anion can then be
alkylated, acylated or condensed with aldehydes to extend the quinoline side chain.
Oxidation of the substituted quinolines 86 will lead to the corresponding quinolinic
acid derivatives.
N
CH3
N
CH2
N
CH2
R X
N
R-
-
B -
84 85 86
Scheme 3.20: Deprotonation and alkylation of 4-methylquinoline.
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An initial attempt was made to prepare 4-isobutylquinoline 87 from
4-methylquinoline 84, n-butyllithium and isopropyl bromide following the procedure
reported by Osuch et al. (Scheme 3.21).29 A 2:2:1 molar ratio of substrate,
organolithium compound and alkyl halide was used.
N
CH3
N
n-BuLi
isopropyl bromide
dry ether
reflux
84 87
Scheme 3.21: Attempted synthesis of 4-isobutylquinoline.
TLC analysis showed there was no starting material remaining and indicated the
presence of two new, less polar compounds. The 1H NMR spectrum of the crude
product was not consistent with the desired product but did confirm the presence of
two new compounds. The minor product was identified as 2-butyl-4-methylquinoline
89. This conclusion was reached because in the aromatic region of the 1H NMR
spectrum (Figure 3.1), the signal corresponding to H-2 was absent and the signal
corresponding to H-3 was observed as a singlet at 7.06 ppm. The signals
corresponding to the protons of the butyl group were observed at 0.88 ppm (CH3),
1.13 ppm, 1.35 ppm and 1.69 ppm (3  CH2). In addition, the presence of the singlet
at 2.59 ppm indicated the methyl group at the 4-position was still intact. Similarly,
the major product was identified as 2-butyl-4-methyl-1,2-dihydroquinoline 88. The
key evidence for this product from the 1H NMR spectrum (Figure 3.1) was the
presence of only 4 signals in the aromatic region and a signal corresponding to an
alkene proton (H-3) at 5.31 ppm. Also, a signal corresponding to the remaining H-2
was observed at 4.07 ppm and a broad signal was observed at 3.56-3.80 ppm due to
the presence of the NH. Again, the signals for the protons of the butyl group were
present and the singlet at 1.90 ppm confirmed the methyl group at the 4-position was
still intact. The identity of the two products was confirmed by mass spectrometry
which showed a signal corresponding to the (M+H)+ molecular ion for
2-butyl-4-methylquinoline 89 at m/z 200 (relative intensity 100%) and also the
(M+H)+ molecular ion for 2-butyl-4-methyl-1,2-dihydroquinoline 88 at m/z 202
(relative intensity 10%).
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Figure 3.1: 1H NMR spectrum of the crude product mixture from the attempted
alkylation reaction.
The spectral data are therefore consistent with nucleophilic addition of n-butyllithium
to form the major product, 2-butyl-4-methyl-1,2-dihydroquinoline 88, followed by
some adventitious oxidation to give the minor product, 2-butyl-4-methylquinoline 89
(Scheme 3.22).
N
CH3
N
CH3
N
CH3
Li
N
H
CH3
Oxn
Li84 88
89
Scheme 3.22: Formation of 2-butyl-4-methyl-1,2-dihydroquinoline and 2-butyl-4-
methylquinoline by reaction of 4-methylquinoline with n-butyllithium.
Therefore, apparently n-butyllithium is not an effective reagent for the deprotonation
of the methyl group of 4-methylquinoline 84 under the conditions employed. It has
been reported that phenyllithium also adds to the azomethine linkage of
4-methylquinoline to give a mixture of 2-phenyl-4-methylquinoline and 2,2-diphenyl-
4-methyl-1,2-dihydroquinoline.30 However, it has been claimed that the desired
alkylated product was produced when methyllithium was used as the base. 29
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An attempt was therefore made to prepare 4-isobutylquinoline 87 from
4-methylquinoline 84 and isopropyl bromide using methyllithium in place of
n-butyllithium. As before, a 2:2:1 molar ratio of substrate, organolithium compound
and alkyl halide was used. However, this reaction was also unsuccessful. Both the
1H NMR data and the mass spectrometry data showed addition of methyllithium at the
2-position had occurred to give 2,4-dimethyl-1,2-dihydroquinoline 90 (Scheme 3.23).
N
CH3
N
H
CH3
CH3
MeLi
isopropyl bromide
dry ether
reflux
84 90
Scheme 3.23: Nucleophilic addition of methyllithium to 4-methylquinoline.
An attempt was then made to prepare 4-isobutylquinoline 87 by treating
4-methylquinoline 84 with the sterically hindered, non-nucleophilic base, lithium
diisopropylamide and then reacting the resulting anion with isopropyl bromide
(Scheme 3.24). However, both TLC and 1H NMR analysis of the crude product
showed only the two intact starting materials were present, indicating no reaction had
occurred.
N
CH3
N
lithium diisopropylamide
isopropyl bromide
dry tetrahydrofuran
84 87
Scheme 3.24: Attempted synthesis of 4-isobutylquinoline.
Attention therefore turned to the alkylation of 4-methylquinoline using sodium amide
as the base, a method that has greater literature precedent.31-36 An initial attempt was
made to prepare 4-isobutylquinoline 87 by treating 4-methylquinoline 84 with 1.1
equivalents of sodium amide, generated in situ from metallic sodium, liquid ammonia
and iron (III) nitrate, and then reacting the resulting anion with 1.1 equivalents of the
alkylating agent, isopropyl bromide (Scheme 3.25).31,32
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CH3
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NaNH2, NH3(l)
isopropyl bromide
84 87
Scheme 3.25: Synthesis of 4-isobutylquinoline.
TLC analysis indicated the presence of a new less polar compound in addition to
unreacted 4-methylquinoline 84. The product was successfully purified by column
chromatography on silica. The 1H NMR spectrum of the pure product was consistent
with the desired product, 4-isobutylquinoline 87. The signal corresponding to the new
CH2 group was observed as a doublet at 2.84 ppm. The identity of the product was
confirmed by electrospray mass spectrometry (ES+) which showed a signal
corresponding to the (M+H)+ molecular ion at m/z 186 (relative intensity 100%).
However, the yield of 4-isobutylquinoline was low (20%). Since a lot of unreacted
starting material was recovered, it was decided to try and push the reaction closer to
completion by using 1.5 equivalents of base and alkylating agent and increasing the
reaction time. An improved yield of pure 4-isobutylquinoline 87 (43%) was achieved,
but there was still unreacted starting material present in the crude product.
Using the same method, two further 4-substituted quinolines were successfully
synthesised. 4-Benzylquinoline 91 was prepared by treating 4-methylquinoline 84
with 1.5 equivalents of sodium amide and then reacting the resulting anion with 1.5
equivalents of bromobenzene (Scheme 3.26).31,32
N
CH3
N
NaNH2, NH3(l)
bromobenzene
84 91
22%
Scheme 3.26: Synthesis of 4-benzylquinoline.
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TLC analysis showed there was unreacted 4-methylquinoline 84 present. Purification
of the crude product by column chromatography on silica gave the desired product in
22% yield. The 1H NMR spectrum was consistent with the expected product,
4-benzylquinoline 91. The signal for the CH2 group that links the two aromatic rings
was observed as a singlet at 4.44 ppm. The identity of the product was confirmed by
electrospray mass spectrometry (ES+), which showed a signal corresponding to the
(M+H)+ molecular ion at m/z 220 (relative intensity 100%).
It is thought that this reaction proceeds via an elimination-addition mechanism
(Scheme 3.27). This would involve removal of a proton ortho to the bromo
substituent of bromobenzene 92 by sodium amide, followed by loss of the bromide
ion in an elimination reaction to form benzyne 93. The next step would then involve
addition of the nucleophilic anion 85, formed by deprotonation of 4-methylquinoline
84 by sodium amide, to the triple bond of benzyne. Finally, protonation of the
benzene ring would give the product.
Br
H
Br
N
CH2
H
N
CH2
N
CH2
NN
H NH2
-
-
-
NH2
-
NH2
-
-
92 93
84 85
91
Scheme 3.27: Possible mechanism for the formation of 4-benzylquinoline.
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Finally, 4-phenethylquinoline 94 was prepared by treating 4-methylquinoline 84 with
1.5 equivalents of sodium amide and then reacting the resulting anion with 1.5
equivalents of benzyl bromide (Scheme 3.28).31,32
N
CH3
N
NaNH2, NH3(l)
benzyl bromide
84 94
24%
Scheme 3.28: Synthesis of 4-phenethylquinoline.
TLC analysis showed there was unreacted 4-methylquinoline 84 present. Purification
of the crude product by column chromatography on silica gave the desired product in
24% yield. The 1H NMR spectrum was consistent with the expected product,
4-phenethylquinoline 94. The signals for the two CH2 groups that link the two
aromatic rings were observed as a pair of triplets at 3.01 ppm and 3.32 ppm. The
identity of the product was confirmed by mass spectrometry, which showed a signal
corresponding to the (M+H)+ molecular ion at m/z 234 (relative intensity 100%).
Although 4-isobutylquinoline 87, 4-benzylquinoline 91 and 4-phenethylquinoline 94
were successfully prepared by the sodium amide mediated alkylation of
4-methylquinoline 84, the yield of pure product in each case was rather low. A lot of
unreacted starting material was recovered indicating incomplete conversion. In
addition, the low crude yield of each product suggested material was being lost during
the work-up procedure. However, sufficient product had been obtained in each case
to attempt the oxidation reaction to produce the corresponding quinolinic acid
derivatives.
Chapter Three Inhibitor Synthesis and Inhibition Studies
122
There are several reports of different methods for the oxidation of quinolines to the
corresponding quinolinic acid derivatives.17-28 An initial attempt was made to oxidise
4-methylquinoline 84 using potassium permanganate as the oxidising agent (Scheme
3.29).19 This involved heating a mixture of 4-methylquinoline 84 and water under
reflux while slowly adding an aqueous solution of potassium permanganate. Upon
addition, the potassium permanganate decolourised and a brown precipitate formed.
The addition of the potassium permanganate solution was continued until the
decolourisation became much slower. After six hours, approximately 6.5 equivalents
of potassium permanganate had been added. The brown precipitate of manganese
dioxide was removed by filtration and the filtrate was concentrated. The product did
not precipitate upon addition of acid, so the remainder of the water was removed
under reduced pressure to give a yellow solid.
N
CH3
N
CH3
CO2H
CO2H
KMnO4, H2O
reflux
84 95
Scheme 3.29: Attempted potassium permanganate oxidation of 4-methylquinoline.
The 1H NMR spectrum of the desired product, 4-methylquinolinic acid 95, would be
expected to show a pair of doublets corresponding to the two aromatic protons and a
singlet upfield corresponding to the methyl group protons. Interestingly, the 1H NMR
spectrum of the crude product showed a pair of doublets in the aromatic region at 7.76
and 8.37 ppm with a corresponding singlet for a methyl group at 2.45 ppm, but also a
lower intensity pair of doublets at 7.51 and 8.45 ppm, also with a corresponding
singlet for a methyl group at 2.25 ppm. Also observed were small signals
corresponding to unreacted 4-methylquinoline 84. TLC analysis confirmed the
presence of the unreacted starting material and also showed a spot on the baseline.
The mechanism of the oxidation reaction may provide a clue as to the identity of the
two products from the initial oxidation attempt. The reaction proceeds in two stages;
oxidative cleavage of the aromatic ring to form a dialdehyde 96 followed by oxidation
of the intermediate dialdehyde to give the desired diacid 95 (Scheme 3.30). It is
possible that the desired reaction has not reached completion and an intermediate
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from incomplete oxidation may be present in addition to the desired diacid. The
absence of a signal in the 1H NMR spectrum in the region 9-10 ppm corresponding to
an aldehyde proton suggests that the dialdehyde 96 is not present. It is possible that
the product is a cyclised adduct 99, 100 formed from an intermediate containing one
aldehyde group and one carboxylic acid group 97, 98 (Scheme 3.30).
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Scheme 3.30: Oxidation of 4-methylquinoline.
In an attempt to push the oxidation reaction closer to completion, the oxidation of
4-methylquinoline 84 was repeated using a greater excess of potassium permanganate
and a longer reaction time. Over a period of six hours, approximately 8 equivalents of
the oxidising agent were added and then heating under reflux was continued
overnight. The 1H NMR spectrum of the crude material showed 4 products had been
produced. The same two pairs of doublets in the aromatic region and corresponding
singlets upfield were observed. However, two new pairs of doublets were also
observed in the aromatic region. This would suggest that further reaction has
occurred, probably oxidation of the methyl group to the carboxylic acid. The crude
mixture was analysed by electrospray mass spectrometry (ES+), which showed a
signal corresponding to a (M+H)+ molecular ion at m/z 182 (relative intensity 100%)
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and also (M+K)+ at m/z 220 (relative intensity 20%) corresponding to the desired
product, 4-methylquinolinic acid 95. Also observed was a signal at m/z 250
(relative intensity 25%), which is consistent with an (M+K)+ ion for the fully oxidised
pyridine-2,3,4-tricarboxylic acid 101. The identity of the remaining two products is
still unknown.
N
CH3
CO2H
CO2H N
CO2H
CO2H
CO2H
95 101
Since the separation of the desired product from the mixture of oxidation products is
very difficult, a more efficient oxidation method was sought. Attention turned to the
ruthenium tetroxide (RuO4) catalysed oxidation of quinolines using sodium
hypochlorite as the stoichiometric co-oxidant, a method of interest because of its
simplicity and convenience.22 Such reactions are carried out in an aqueous / organic
biphasic solvent system. Scheme 3.31 represents the processes that occur within the
biphasic system. Initially, ruthenium tetroxide (RuO4) is generated in situ by the
oxidation of the ruthenium (IV) oxide by the hypochlorite in the aqueous phase. The
RuO4 then partitions between the two phases, strongly favouring the organic phase
where it oxidises the water-insoluble organic substrate. In doing so, the RuO4 is
reduced to an insoluble Ru (IV) species and when this species is transferred into the
aqueous phase it is reoxidised to RuO4 by the excess hypochlorite present. The RuO4
then partitions into the organic phase and the catalytic cycle involving RuO4
mediating the oxidation of the organic substrate by the strong oxidising agent
continues. It is crucial to have the maximum degree of mixing of the two phases in
order that there should be rapid transfer of RuO4 from the aqueous phase into the
organic phase and, upon reduction, return of RuO2 back into the aqueous phase. This
will aid the fast and efficient oxidation of the organic substrate.
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Scheme 3.31: Schematic diagram illustrating the processes which occur in the
biphasic system during the oxidation of a water-insoluble organic substrate using an
oxidising agent (OCl-) mediated by RuO4, generated in situ.
The oxidation of 4-methylquinoline 84 was attempted using this ruthenium tetroxide
catalysed method (Scheme 3.32).22
N
CH3
N
CH3
CO2H
CO2H
RuO2(cat), NaOCl
CH2Cl2, H2O
84 95
Scheme 3.32: Ruthenium tetroxide catalysed oxidation of 4-methylquinoline.
The progress of the reaction was monitored by TLC using samples taken from both
the aqueous phase and the organic phase at regular intervals. The reaction was
continued until TLC analysis showed there was no 4-methylquinoline 84 remaining in
the organic phase. TLC analysis showed the product was present in the aqueous
phase. The two phases were separated and the aqueous phase was acidified and
evaporated to dryness to give the crude product. The 1H NMR spectrum of the crude
product was consistent with the expected product, 4-methylquinolinic acid 95,
showing a pair of doublets at 7.91 ppm and 8.49 ppm for the two aromatic protons
and a corresponding singlet at 2.52 ppm for the protons of the methyl group.
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While the 1H NMR spectrum showed there were no organic impurities present, it was
evident from the high crude yield that there were some inorganic impurities present.
Also, the crude product smelled strongly of bleach. The crude product was obtained
from the aqueous phase and since the reaction uses a large excess of sodium
hypochlorite as the co-oxidant, evaporation to dryness gives the product mixed with
the excess solid sodium hypochlorite salt. Hence the product required desalinisation.
However, the product was too polar for purification by column chromatography on
silica or alumina. The product also proved to be too polar for chromatography on a
C-18 reverse phase column and passed through unhindered. Attention therefore
turned to ion exchange chromatography, a technique commonly used to purify amino
acids. This technique achieves separation based on the charges carried by a molecule.
At pH 1, 4-methylquinolinic acid 95 will exist in the fully protonated cationic form
102 (Scheme 3.33) and an attempt was made to purify the product by cation exchange
chromatography using an aliphatic sulfonic acid resin. However, this was
unsuccessful. At pH 10, 4-methylquinolinic acid 95 will exist in the fully
deprotonated anionic form 103 (Scheme 3.33). However, an attempt to purify the
product by anion exchange chromatography using a quaternary amine resin was also
unsuccessful.
N
CH3
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CH3
CO2
CO2
H
N
CH3
CO2
CO2+
-
-
102 103
-
-
+
Scheme 3.33: Different protonated forms of 4-methylquinolinic acid.
It was therefore decided to try and separate the product from the excess sodium
hypochlorite by utilising their different chemical properties, in particular solubility.
N,N-Dimethylformamide was added to dissolve the product and the insoluble sodium
hypochlorite salt was removed by filtration. The filtrate was evaporated to dryness
and the resulting orange solid was washed repeatedly with toluene followed
by chloroform and the product was recrystallised from ethanol. Spectroscopic
characterisation of the product confirmed its identity as the desired
4-methylquinolinic acid 95. Analysis of the product by electrospray mass
spectrometry (ES+) showed a signal corresponding to the (M+H)+ molecular ion at
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m/z 182 (relative intensity 100%). The 1H NMR spectrum showed signals
corresponding to the two aromatic protons at 7.91 ppm and 8.49 ppm, with a
corresponding singlet at 2.52 ppm for the protons of the methyl group. The 13C NMR
spectrum showed two quaternary carbon signals at 167.5 ppm and 171.4 ppm,
confirming the presence of the two carboxylic acid groups. This was also confirmed
by infrared spectroscopy. However, the slightly low melting point and the UV data
(max 276 nm log  1.96, cf. lit.37 max 276 log  3.69) suggested the product was not
entirely pure. Also, the product still smelled slightly of bleach. Therefore, while this
appears to be a simpler and more efficient oxidation method than the potassium
permanganate oxidation, there are still problems with purification.
Using this ruthenium tetroxide catalysed method, attempts were also made to oxidise
the other 4-substituted quinoline derivatives that had been prepared. In all the
attempts to oxidise 4-isobutylquinoline 87 two products were produced. In the
1H NMR spectrum of the crude product, two doublets were observed at 8.09 and
8.67 ppm and two lower intensity doublets were observed at 7.97 and 8.75 ppm. For
each pair of doublets there were signals corresponding to the protons of an isobutyl
group, indicating the side chain was intact in both products. It is possible that the
desired product was present in addition to an intermediate from incomplete oxidation.
Since the polarity of the two products would make separation by column
chromatography impossible, it was decided to try to esterify the desired
4-isobutylquinolinic acid in the crude material to make it less polar and therefore
separable from the crude mixture. The crude mixture was thus heated in refluxing
methanol in the presence of acid overnight. However, the 1H NMR spectrum of the
crude material showed no sign of the desired product, showing the reaction had been
unsuccessful.
Similarly for 4-benzylquinoline 91 and 4-phenethylquinoline 94 the oxidation
reaction produced a mixture of products that proved difficult to separate. Therefore,
this route also failed to produce pure 4-substituted quinolinic acid derivatives that
could be tested as inhibitors of QPRTase.
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3.3 Inhibition studies on human brain QPRTase
3.3.1 Introduction
In 1913, Michaelis and Menten described a simple model for a single substrate
enzyme that accounts for the kinetic properties of enzyme catalysed reactions.38
Although the QPRTase catalysed reaction is bimolecular, if kinetic studies are carried
out under pseudo-first order conditions then the Michaelis-Menten model can be
employed. The Michaelis-Menten model describes an enzymatic reaction as a
two-step process (Scheme 3.34). Firstly, an enzyme E combines with substrate S to
form an enzyme-substrate complex (ES). The ES complex has two possible fates; it
can dissociate to E and S or can proceed to form product P. It is assumed that product
formation is irreversible. A further assumption implicit in this model is that there is
only one kinetically significant step between the ES complex and product formation.
The product formation step is first order, with the rate constant kcat. The kinetic
constant kcat represents the number of substrate molecules turned over by one
molecule of enzyme per second and therefore provides an indication of how quickly
an enzyme is operating.
E + S ES P
Km kcat
Scheme 3.34: General reaction described by the Michaelis-Menten equation.
The Michaelis-Menten equation quantitatively describes the rate of an enzyme
catalysed reaction. Vmax is the maximum rate of an enzyme catalysed reaction and is
attained when the catalytic sites on the enzyme are saturated with substrate. The
Michaelis constant, Km, is equal to the substrate concentration at which the reaction
rate is half its maximal value and reflects the affinity of an enzyme for its substrate.
The lower the value of Km the greater the affinity of the enzyme for its substrate. The
kinetic parameters Km and Vmax can be readily derived from rates of catalysis
measured at different substrate concentrations:
Vmax [S]
Km + [S]
V =
Chapter Three Inhibitor Synthesis and Inhibition Studies
129
Addition of an inhibitor to this system makes the reaction slightly more complicated.
The enzyme can now exist as four possible species; the free enzyme E, the
enzyme-substrate complex (ES), the enzyme-inhibitor complex (EI) or the
enzyme-substrate-inhibitor complex (ESI) depending on the type of inhibition
observed.
In reversible competitive inhibition, an inhibitor I binds at the same site as the
substrate S and therefore competes with the enzyme’s substrate for binding to the
active site (Scheme 3.35).
E + S ES P
I
EI + S
+
Km kcat
Ki
Scheme 3.35: Competitive inhibition.
This results in an apparent increase in Km (i.e. an apparent decrease in the affinity of
the enzyme for its substrate). Vmax is unaffected by competitive inhibition since at
high substrate concentrations the substrate can competitively displace the inhibitor.
The rate equation for an enzymatic reaction in the presence of a competitive inhibitor
then becomes:
Vmax [S]
Km(app) + [S]
V = where Km(app) = Km (1 + [I] / Ki)
Ki is the dissociation constant for the enzyme-inhibitor complex. The lower the value
of Ki, the greater the affinity of the enzyme for the inhibitor i.e. the better the
compound is at inhibiting the enzyme.
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In reversible noncompetitive inhibition, the substrate and inhibitor can bind
simultaneously to the enzyme. They are not competing for the same binding site and
therefore the inhibitor can interact with both the free enzyme and the
enzyme-substrate complex (Scheme 3.36).
Km kcat
Ki
E + S ES P
I
EI + S
I
ESI
++
Ki
Km
Scheme 3.36: Noncompetitive inhibition.
A noncompetitive inhibitor acts by decreasing the turnover number rather than by
diminishing the proportion of enzyme molecules that are bound to substrate.
Noncompetitive inhibition cannot be overcome by increasing the substrate
concentration. Therefore in noncompetitive inhibition an apparent decrease in Vmax is
observed, while Km remains unaffected. The rate equation for an enzymatic reaction
in the presence of a noncompetitive inhibitor then becomes:
Vmax(app) [S]
Km + [S]
V = where Vmax(app) = Vmax / (1 + [I] / Ki)
In reversible uncompetitive inhibition, the inhibitor interacts with the
enzyme-substrate complex at a site other than the active site (Scheme 3.37).
Km kcat
+
Ki
E + S ES P
I
ESI
Scheme 3.37: Uncompetitive inhibition.
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This results in an apparent decrease in both Vmax and Km. The apparent increase in
affinity of the enzyme for substrate is due to unproductive substrate binding, resulting
in a decrease in free enzyme concentration. Half-maximum rate, or half-maximal
saturation, will therefore be attained at a relatively lower substrate concentration. The
rate equation for an enzymatic reaction in the presence of an uncompetitive inhibitor
then becomes:
Vmax(app) [S]
Km(app) + [S]
V =
where Vmax(app) = Vmax / (1 + [I] / Ki)
Km(app) = Km / (1 + [I] / Ki)
The different types of reversible inhibition are therefore kinetically distinguishable. A
summary of the effects of reversible inhibitors on the kinetic parameters Km and Vmax
is presented in Table 3.3.
Type of inhibition Km(app) Vmax(app)
Competitive Increase
Km (1+ [I]/Ki)
No effect
Vmax
Noncompetitive No effect
Km
Decrease
Vmax/(1+ [I]/Ki)
Uncompetitive Decrease
Km/(1+ [I]/Ki)
Decrease
Vmax/(1+ [I]/Ki)
Table 3.3: Summary of the effects of reversible inhibitors on the kinetic parameters
Km and Vmax.
A useful way to illustrate the type of inhibition observed is to display the kinetic data
as a Lineweaver-Burk plot. The Lineweaver-Burk plot is a linear transform obtained
by inverting the Michaelis-Menten equation:
1 1Km 1
V VmaxVmax [S]
= +.
A plot of 1/V versus 1/[S] is linear with a slope equal to Km/Vmax. The y-intercept
represents 1/Vmax and the x-intercept represents -1/Km. Therefore this plot can be used
to illustrate the effect of an inhibitor on the kinetic parameters Km and Vmax.
Although linear regression is effective for illustrative purposes, it is a poor model for
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calculating kinetic parameters accurately. Since it is a double reciprocal plot, errors at
low concentration are overemphasised while errors at high concentration are
underemphasised. Therefore the best way to analyse enzyme kinetic data is to fit the
data directly to the Michaelis-Menten equation using nonlinear regression. A
Lineweaver-Burk plot can then be employed to illustrate the results.
3.3.2 Inhibition studies using quinolinic acid analogues
The following quinolinic acid analogues, which were either commercially available or
were prepared in the laboratory, were all tested as inhibitors of human brain
QPRTase.
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26 50 51 105
52 55 7
27 59 60 63 106
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Firstly, a preliminary inhibition screen of the compounds was carried out by assessing
the percentage inhibition of QPRTase activity at a fixed concentration of quinolinic
acid (0.1 mM) and PRPP (0.1 mM). Detailed inhibition studies were then carried out
on the compounds that were found to inhibit QPRTase. In order to determine the
inhibitory properties of the compounds, the Km and Vmax values for the QPRTase
reaction with respect to quinolinic acid as the variable substrate were determined at
various fixed inhibitor concentrations. The effect on the kinetic parameters gave a
measure of inhibition and also identified the type of inhibition observed.
Lineweaver-Burk plots were constructed to illustrate the type of inhibition exhibited
by each inhibitor, although these were used for illustrative purposes only and not for
calculating kinetic parameters. Note that in all the Lineweaver-Burk plots, the line
was constructed to fit the Km(app) and Vmax(app) values determined from non-linear
regression. Ki values were determined using linear regression plots of Km(app) versus
inhibitor concentration.
3.3.2.1 2,3-Dicarboxylic acid derivatives
The results of the preliminary inhibition screen of the 2,3-dicarboxylic acid
derivatives are summarised in Table 3.4 and displayed in Figure 3.2.
% Inhibition withInhibitor
0.01 mM
inhibitor
0.1 mM
inhibitor
1 mM
inhibitor
10 mM
inhibitor
N-Methylquinolinic acid 41 0 28 93 100
N-Ethylquinolinic acid 42 0 24 96 100
5-Ethylquinolinic acid 43 0 5 43 95
5-Ethyl-N-methylquinolinic acid
46
0 0 30 90
Quinolinic acid N-oxide 62 0 40 100 100
Phthalic acid 25 6 45 100 100
2,3-Naphthalene dicarboxylic acid
104
0 11 59 100
NMDA 14 0 0 0 18
Table 3.4: Percentage inhibition at varied inhibitor concentrations.
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Figure 3.2: Preliminary inhibition screen of the 2,3-dicarboxylic acid derivatives.
Phthalic acid 25 was the only compound tested that inhibited QPRTase when present
at a concentration of 0.01 mM. N-Methylquinolinic acid 41, N-ethylquinolinic acid
42, quinolinic acid N-oxide 62 and 2,3-naphthalene dicarboxylic acid 104 showed
good levels of inhibition when present at concentrations above 0.1 mM.
5-Ethylquinolinic acid 43 and 5-ethyl-N-methylquinolinic acid 46 were effective
inhibitors of QPRTase at higher concentrations.
NMDA 14, however, showed only a low level of inhibition at high concentrations
(18%, 10 mM). Quinolinic acid exerts its neurotoxic activity by overstimulating
NMDA receptors.39 Quinolinic acid is able to interact with the NMDA receptor since
quinolinic acid and NMDA possess a similar backbone consisting of a
1,2-dicarboxylic acid functionality. The apparent lack of binding of NMDA to the
active site of QPRTase at low concentrations may therefore be due to the absence of
aromaticity. Structural studies on QPRTase have highlighted residues that are within
Van der Waals distance of the substrate and in human brain QPRTase the sidechain of
His160 could form an important interaction with the aromatic ring of quinolinic acid.
However, in the structural studies on human brain QPRTase, tartaric acid was found
bound in the active site (section 2.3.1). Tartaric acid was present at a concentration of
0.6 M in the precipitant used to crystallise the protein. The 1,2-dicarboxylic acid
functionality present in quinolinic acid is also present in tartaric acid and hence
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tartaric acid is able to bind in the active site of QPRTase. Therefore, it seems that
despite the lack of aromaticity, simple dicarboxylic acids are able to bind to QPRTase
when present at high concentrations. Similarly, previous inhibition studies have
found that maleic acid, malic acid, oxaloacetic acid, citric acid and succinic acid show
low levels of inhibition of QPRTase when present at concentrations above 10 mM.40,41
Due to the low level of inhibition observed, it was decided not to carry out any further
inhibition studies on NMDA. The inhibitory properties of all the other
2,3-dicarboxylic acid derivatives were examined in detail by performing careful
kinetic analysis of the QPRTase catalysed reaction in the presence of different
concentrations of the inhibitors.
3.3.2.1.1 N-Methylquinolinic acid
N-Methylquinolinic acid 41 was found to be a competitive inhibitor of QPRTase with
respect to quinolinic acid. This was observed by an increase in Km with increasing
inhibitor concentration, while Vmax remained relatively unchanged within the
experimental error (Table 3.5). The competitive inhibition pattern is illustrated with a
Lineweaver-Burk plot, which shows a series of straight lines intersecting on the y-axis
(Figure 3.3).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.6  1.2 0.94  0.02
100 42.4  4.1 0.93  0.03
200 74.1  6.7 0.99  0.04
300 106.8  8.6 1.02  0.04
Table 3.5: Effect of N-methylquinolinic acid on kinetic parameters.
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Figure 3.3: Lineweaver-Burk plot for inhibition with N-methylquinolinic acid.
In the presence of a competitive inhibitor, Km increases by a factor of (1 + [I]/Ki).
The inhibition constant Ki can therefore be determined from a plot of Km(app) versus
inhibitor concentration. This plot is linear and the slope is equal to Km/Ki.
[I] +.
Km(app) = Km (1 + [I] / Ki)
Km(app) = Km
Ki
Km
By performing this analysis, the Ki value for N-methylquinolinic acid was determined
as 40  2 M with respect to quinolinic acid as the variable substrate (Figure 3.4).
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Figure 3.4: Plot of Km(app) versus [N-methylquinolinic acid].
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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3.3.2.1.2 N-Ethylquinolinic acid
Similarly, N-ethylquinolinic acid 42 was found to be a competitive inhibitor of
QPRTase with respect to quinolinic acid (Table 3.6). The competitive inhibition
pattern is illustrated with a Lineweaver-Burk plot (Figure 3.5).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.6  2.3 0.89  0.05
100 32.1  3.2 0.87  0.03
200 70.5  6.9 0.91  0.04
300 98.0  9.8 0.83  0.08
Table 3.6: Effect of N-ethylquinolinic acid on kinetic parameters.
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Figure 3.5: Lineweaver-Burk plot for inhibition with N-ethylquinolinic acid.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
N-ethylquinolinic acid 42 was determined as 34  4 M with respect to quinolinic
acid as the variable substrate (Figure 3.6). This is very similar to the value of 40 M
determined for N-methylquinolinic acid 41 which suggests that increasing the size of
the N-substituent from a methyl group to an ethyl group does not significantly affect
the binding in the QPRTase active site.
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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Figure 3.6: Plot of Km(app) versus [N-ethylquinolinic acid].
The effectiveness of N-methyl and N-ethylquinolinic acid as inhibitors of QPRTase
could be explained by their resemblance to the putative reaction intermediate, QAMN
16. These compounds could be viewed as simple mimics of QAMN.
N
Me
CO2H
CO2H N
Et
CO2H
CO2H NO
OHOH
PiO
CO2H
CO2H+ + +
1641 42
3.3.2.1.3 5-Ethylquinolinic acid
5-Ethylquinolinic acid 43 was found to be a competitive inhibitor of QPRTase with
respect to quinolinic acid. This was observed by an increase in Km with increasing
inhibitor concentration, while Vmax remained relatively unchanged within the
experimental error (Table 3.7). The competitive inhibition pattern is illustrated with a
Lineweaver-Burk plot (Figure 3.7).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.4  1.0 0.92  0.01
600 33.2  2.9 0.98  0.04
800 44.9  5.9 0.90  0.06
1000 74.1  12.1 0.86  0.07
Table 3.7: Effect of 5-ethylquinolinic acid on kinetic parameters.
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Figure 3.7: Lineweaver-Burk plot for inhibition with 5-ethylquinolinic acid.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
5-ethylquinolinic acid 43 was determined as 158  21 M with respect to quinolinic
acid as the variable substrate (Figure 3.8). 5-Ethylquinolinic acid is therefore an
effective inhibitor of QPRTase.
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Figure 3.8: Plot of Km(app) versus [5-ethylquinolinic acid].
 No inhibitor
 0.6 mM inhibitor
 0.8 mM inhibitor
 1.0 mM inhibitor
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3.3.2.1.4 5-Ethyl-N-methylquinolinic acid
Similarly, 5-ethyl-N-methylquinolinic acid 46 was found to be a competitive inhibitor
of QPRTase with respect to quinolinic acid (Table 3.8). The competitive inhibition
pattern is illustrated with a Lineweaver-Burk plot (Figure 3.9).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.4  1.0 0.92  0.01
600 26.8  2.5 0.97  0.02
800 37.5  3.3 0.93  0.02
1000 54.6  8.4 0.88  0.04
Table 3.8: Effect of 5-ethyl-N-methylquinolinic acid on kinetic parameters.
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Figure 3.9: Lineweaver-Burk plot for inhibition with 5-ethyl-N-methylquinolinic acid.
The Ki value for 5-ethyl-N-methylquinolinic acid 46 was determined as 270  29 M
with respect to quinolinic acid as the variable substrate (Figure 3.10).
5-Ethyl-N-methylquinolinic acid 46 is therefore a weaker inhibitor than the
non-methylated derivative 43. It would appear therefore that the presence of the
N-substituent causes unfavourable interactions in the active site, leading to
weaker binding. Furthermore, by comparing the Ki values determined
for 5-ethyl-N-methylquinolinic acid 46 (270  29 M) and N-methylquinolinic acid
 No inhibitor
 0.6 mM inhibitor
 0.8 mM inhibitor
 1.0 mM inhibitor
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41 (40  2 M), it can be seen that 5-ethyl-N-methylquinolinic acid is a less effective
inhibitor of QPRTase. Thus it would appear that, rather than providing additional
binding interactions, the increased steric bulk resulting from the presence of the ethyl
group at the 5-position of the pyridine ring leads to weaker binding in the active site.
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Figure 3.10: Plot of Km(app) versus [5-ethyl-N-methylquinolinic acid].
3.3.2.1.5 Quinolinic acid N-oxide
Quinolinic acid N-oxide 62 was found to be a competitive inhibitor of QPRTase with
respect to quinolinic acid (Table 3.9). The competitive inhibition pattern is illustrated
with a Lineweaver-Burk plot (Figure 3.11).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.6 0.94  0.02
50 35.7  3.5 0.94  0.03
100 60.7  5.1 1.00  0.03
200 111.0  10.0 1.07  0.04
Table 3.9: Effect of quinolinic acid N-oxide on kinetic parameters.
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Figure 3.11: Lineweaver-Burk plot for inhibition with quinolinic acid N-oxide.
The Ki value for quinolinic acid N-oxide was determined as 25  2 M with respect to
quinolinic acid as the variable substrate (Figure 3.12). Quinolinic acid N-oxide is
therefore a potent competitive inhibitor of human brain QPRTase and appears to bind
more tightly in the active site than the N-alkyl quinolinic acid derivatives. This could
be due to electrostatic interactions between the negatively charged oxygen of the
N-oxide and the highly positive electrostatic surface of the QPRTase active site.
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Figure 3.12: Plot of Km(app) versus [quinolinic acid N-oxide].
 No inhibitor
 0.05 mM inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
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3.3.2.1.6 Phthalic acid
Phthalic acid 25 was found to be a competitive inhibitor of QPRTase with respect to
quinolinic acid. This was observed by an increase in Km with increasing inhibitor
concentration, while Vmax remained relatively unchanged within the experimental
error (Table 3.10). The competitive inhibition pattern is illustrated with a
Lineweaver-Burk plot (Figure 3.13).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
50 74.0  7.4 1.03  0.04
100 109.7  11.2 1.06  0.06
200 203.0  28.9 1.17  0.09
Table 3.10: Effect of phthalic acid on kinetic parameters.
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Figure 3.13: Lineweaver-Burk plot for inhibition with phthalic acid.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
phthalic acid was determined as 21  3 M with respect to quinolinic acid as the
variable substrate (Figure 3.14).
 No inhibitor
 0.05 mM inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
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Figure 3.14: Plot of Km(app) versus [phthalic acid].
Phthalic acid 25 is therefore a potent competitive inhibitor of human brain QPRTase.
This suggests that the ring nitrogen is not essential for binding. Consistent with this
observation, previous structural studies on bacterial QPRTase did not highlight any
binding interactions between the ring nitrogen of quinolinic acid and the active site
residues.42
3.3.2.1.7 2,3-Naphthalene dicarboxylic acid
2,3-Naphthalene dicarboxylic acid 104 was found to be a competitive inhibitor of
QPRTase with respect to quinolinic acid (Table 3.11). The competitive inhibition
pattern is illustrated with a Lineweaver-Burk plot (Figure 3.15).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 25.4  2.0 0.95  0.02
200 37.8  3.2 0.94  0.02
300 55.1  4.3 0.98  0.03
Table 3.11: Effect of 2,3-naphthalene dicarboxylic acid on kinetic parameters.
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Figure 3.15: Lineweaver-Burk plot for inhibition with 2,3-naphthalene dicarboxylic
acid.
The Ki value for 2,3-naphthalene dicarboxylic acid 104 was determined as 90  4 M
with respect to quinolinic acid as the variable substrate (Figure 3.16).
2,3-Naphthalene dicarboxylic acid is therefore an effective inhibitor of QPRTase.
This again suggests that the ring nitrogen is not essential for binding. However, this
compound does not bind as tightly as phthalic acid 25. This may be due to steric
interference as a result of the larger bicyclic structure of 2,3-naphthalene dicarboxylic
acid.
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Figure 3.16: Plot of Km(app) versus [2,3-naphthalene dicarboxylic acid].
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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3.3.2.2 2-Carboxylic acid derivatives
The results of the preliminary inhibition screen of the 2-carboxylic acid derivatives
are summarised in Table 3.12 and displayed in Figure 3.17.
% Inhibition withInhibitor
0.01 mM
inhibitor
0.1 mM
inhibitor
1 mM
inhibitor
10 mM
inhibitor
Picolinic acid 26 0 14 75 100
N-Methylpicolinic acid 50 0 8 60 100
N-Ethylpicolinic acid 51 0 10 63 100
Picolinic acid N-oxide 105 0 10 68 100
Quinoline-2-carboxylic acid 52 0 5 47 95
N-Methylquinoline-2-caboxylic
acid 55
0 0 32 85
Kynurenic acid 7 0 0 5 26
Table 3.12: Percentage inhibition at varied inhibitor concentrations.
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Figure 3.17: Preliminary inhibition screen of the 2-carboxylic acid derivatives.
Picolinic acid, the N-methyl and N-ethyl derivatives and picolinic acid N-oxide
showed good levels of inhibition of QPRTase when present at concentrations
above 0.1 mM, inhibiting the enzyme completely at 10 mM. Similarly,
quinoline-2-carboxylic acid and the N-methyl derivative were effective inhibitors of
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the enzymatic reaction at concentrations above 1 mM. Kynurenic acid, however,
showed only a low level of inhibition at high concentrations (26%, 10 mM).
The rationale behind testing kynurenic acid as an inhibitor of QPRTase was that
quinolinic acid and kynurenic acid are neurologically important co-metabolites, both
acting on the NMDA receptor. Kynurenic acid is an NMDA receptor antagonist and
is therefore able to block neuronal damage induced by quinolinic acid, which is an
agonist.43
The structure of kynurenic acid 7 differs from the structure of quinoline-2-carboxylic
acid 52 only by the presence of an hydroxyl group at the 4-position. This suggests
there might be a certain degree of steric interference at the 4-position preventing
kynurenic acid from binding tightly in the active site. Due to the low level of
inhibition observed, it was decided not to carry out any further inhibition studies on
this compound.
The inhibitory properties of all the other 2-carboxylic acid derivatives were examined
in detail by performing careful kinetic analysis of the QPRTase catalysed reaction in
the presence of different concentrations of the inhibitors.
3.3.2.2.1 Picolinic acid
Picolinic acid 26 was found to be a competitive inhibitor of QPRTase with respect to
quinolinic acid. This was observed by an increase in Km with increasing inhibitor
concentration, while Vmax remained unchanged within the experimental error (Table
3.13). The competitive inhibition pattern is illustrated with a Lineweaver-Burk plot,
which shows a series of straight lines intersecting on the y-axis (Figure 3.18).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.1 0.94  0.02
100 30.6  2.5 0.96  0.02
200 51.4  6.1 0.99  0.04
300 69.8  8.9 0.99  0.05
Table 3.13: Effect of picolinic acid on kinetic parameters.
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Figure 3.18: Lineweaver-Burk plot for inhibition with picolinic acid.
From a plot of Km(app) versus inhibitor concentration, the Ki value for picolinic acid
was determined as 68  2 M with respect to quinolinic acid as the variable substrate
(Figure 3.19). The observation that picolinic acid is an effective competitive inhibitor
of QPRTase suggests that the carboxylic acid group at the 3-position is not essential
for binding.
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Figure 3.19: Plot of Km(app) versus [picolinic acid].
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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3.3.2.2.2 N-Methylpicolinic acid
N-Methylpicolinic acid 50 was found to be a competitive inhibitor of QPRTase with
respect to quinolinic acid (Table 3.14). The competitive inhibition pattern is
illustrated with a Lineweaver-Burk plot (Figure 3.20).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.1 0.94  0.02
100 22.4  1.3 0.96  0.01
200 30.6  2.5 0.95  0.02
300 43.4  4.4 0.98  0.04
Table 3.14: Effect of N-methylpicolinic acid on kinetic parameters.
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Figure 3.20: Lineweaver-Burk plot for inhibition with N-methylpicolinic acid.
The Ki value for N-methylpicolinic acid was determined as 131  4 M with respect
to quinolinic acid as the variable substrate (Figure 3.21). N-Methylpicolinic acid 50 is
therefore a weaker inhibitor than the non-methylated derivative 26. It would appear
therefore that the presence of the N-substituent causes unfavourable interactions in the
active site, leading to weaker binding. Furthermore, by comparing the Ki values
determined for N-methylpicolinic acid 50 (131 M) and N-methylquinolinic acid 41
(40 M), it can be seen that affinity is lost when the carboxylic acid group is absent at
the 3-position. This suggests that the carboxylic acid group at the 3-position is
important, but not essential, for binding.
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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Figure 3.21: Plot of Km(app) versus [N-methylpicolinic acid].
3.3.2.2.3 N-Ethylpicolinic acid
N-Ethylpicolinic acid 51 was found to be a competitive inhibitor of QPRTase with
respect to quinolinic acid (Table 3.15). The competitive inhibition pattern is
illustrated with a Lineweaver-Burk plot (Figure 3.22).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.1 0.94  0.02
100 22.5  1.5 0.94  0.02
200 29.7  2.2 0.95  0.03
300 44.6  3.8 0.99  0.03
Table 3.15: Effect of N-ethylpicolinic acid on kinetic parameters.
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Figure 3.22: Lineweaver-Burk plot for inhibition with N-ethylpicolinic acid.
From a plot of Km(app) versus inhibitor concentration, the Ki value for N-ethylpicolinic
acid 51 was determined as 124  6 M with respect to quinolinic acid as the variable
substrate (Figure 3.23). This is very similar to the value of 131 M obtained for
N-methylpicolinic acid 50 which again suggests that increasing the size of the
N-substituent from a methyl group to an ethyl group does not significantly affect the
binding in the QPRTase active site.
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Figure 3.23: Plot of Km(app) versus [N-ethylpicolinic acid].
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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3.3.2.2.4 Picolinic acid N-oxide
Picolinic acid N-oxide 105 was found to be a competitive inhibitor of QPRTase with
respect to quinolinic acid (Table 3.16). The competitive inhibition pattern is
illustrated with a Lineweaver-Burk plot (Figure 3.24).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.6 0.94  0.02
100 22.6  2.1 0.95  0.02
200 35.6  2.4 0.91  0.02
300 47.0  4.6 0.89  0.03
Table 3.16: Effect of picolinic acid N-oxide on kinetic parameters.
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Figure 3.24: Lineweaver-Burk plot for inhibition with picolinic acid N-oxide.
The Ki value for picolinic acid N-oxide was determined as 111  4 M with respect to
quinolinic acid as the variable substrate (Figure 3.25). Picolinic acid N-oxide is
therefore a good competitive inhibitor of human brain QPRTase and appears to bind
more tightly in the active site than the N-alkyl picolinic acid derivatives. Again, this
could be due to electrostatic interactions between the negatively charged oxygen of
the N-oxide and the highly positive electrostatic surface of the QPRTase active site.
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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Figure 3.25: Plot of Km(app) versus [picolinic acid N-oxide].
3.3.2.2.5 Quinoline-2-carboxylic acid
Quinoline-2-carboxylic acid 52 was found to be a competitive inhibitor of QPRTase
with respect to quinolinic acid. This was observed by an increase in Km with
increasing inhibitor concentration, while Vmax remained relatively unchanged within
the experimental error (Table 3.17). The competitive inhibition pattern is illustrated
with a Lineweaver-Burk plot (Figure 3.26).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
300 35.2  2.6 1.04  0.02
500 56.3  5.6 1.09  0.05
700 76.4  6.8 1.10  0.08
Table 3.17: Effect of quinoline-2-carboxylic acid on kinetic parameters.
Chapter Three Inhibitor Synthesis and Inhibition Studies
154
0
1
2
3
4
5
6
7
8
9
-100 -50 0 50 100 150
1/[Quinolinic acid] (mM-1)
1/
R
at
e
(
M
-1
m
in
)
Figure 3.26: Lineweaver-Burk plot for inhibition with quinoline-2-carboxylic acid.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
quinoline-2-carboxylic acid 52 was determined as 127  4 M with respect to
quinolinic acid as the variable substrate (Figure 3.27). Quinoline-2-carboxylic acid is
therefore a good competitive inhibitor of QPRTase. However, this compound does
not bind as tightly as picolinic acid 26. This may be due to steric interference as a
result of the larger bicyclic structure of quinoline-2-carboxylic acid.
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Figure 3.27: Plot of Km(app) versus [quinoline-2-carboxylic acid].
 No inhibitor
 0.3 mM inhibitor
 0.5 mM inhibitor
 0.7 mM inhibitor
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3.3.2.2.6 N-Methylquinoline-2-carboxylic acid
N-Methylquinoline-2-carboxylic acid 55 was found to be a competitive inhibitor of
QPRTase with respect to quinolinic acid (Table 3.18). The competitive inhibition
pattern is illustrated with a Lineweaver-Burk plot (Figure 3.28).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
300 25.5  1.7 1.00  0.02
500 35.5  2.7 1.01  0.03
700 49.0  4.0 1.02  0.03
Table 3.18: Effect of N-methylquinoline-2-carboxylic acid on kinetic parameters.
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Figure 3.28: Lineweaver-Burk plot for inhibition with N-methylquinoline-2-carboxylic
acid.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
N-methylquinoline-2-carboxylic acid 55 was determined as 242  7 M
with respect to quinolinic acid as the variable substrate (Figure 3.29).
N-Methylquinoline-2-carboxylic acid 55 is therefore a less effective inhibitor than the
non-methylated derivative 52. Again, it would appear that the presence of the
N-substituent causes unfavourable interactions in the active site, leading to weaker
binding.
 No inhibitor
 0.3 mM inhibitor
 0.5 mM inhibitor
 0.7 mM inhibitor
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Figure 3.29: Plot of Km(app) versus [N-methylquinoline-2-carboxylic acid].
3.3.2.3 3-Carboxylic acid derivatives
A preliminary inhibition screen of nicotinic acid 27, N-methylnicotinic acid 59,
N-ethylnicotinic acid 60, nicotinic acid N-oxide 63 and quinoline-3-carboxylic acid
106 showed that these compounds do not inhibit the QPRTase catalysed reaction
when present at a concentration of 0.01 mM, 0.1 mM, 1 mM or 10 mM. This
suggests that the carboxylic acid group at the 2-position is essential for binding. This
is consistent with previous inhibition studies carried out on QPRTase from other
sources.5 In addition, it would appear that the presence of a small, hydrophobic
N-substituent, the N-oxide functionality or an additional aromatic ring does not
compensate for the interactions lost when the carboxylic acid group at the 2-position
is absent, suggesting the carboxylic acid group at the 2-position is most important for
binding to the enzyme.
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3.3.2.4 Summary of the quinolinic acid analogues inhibition study
The results of this study on the inhibition of human brain QPRTase by quinolinic acid
analogues are summarised in Table 3.19.
Inhibitor Variable Substrate Type of Inhibition Ki (M)
N-Methylquinolinic
acid 41
Quinolinic acid Competitive 40  2
N-Ethylquinolinic acid
42
Quinolinic acid Competitive 34  4
5-Ethylquinolinic acid
43
Quinolinic acid Competitive 158  21
5-Ethyl-N-methyl
quinolinic acid 46
Quinolinic acid Competitive 270  29
Quinolinic acid
N-oxide 62
Quinolinic acid Competitive 25  2
Phthalic acid 25 Quinolinic acid Competitive 21  3
2,3-Napthalene
dicarboxylic acid 104
Quinolinic acid Competitive 90  4
NMDA 14 Quinolinic acid Preliminary screen showed low
inhibition at high concentrations
Picolinic acid 26 Quinolinic acid Competitive 68  2
N-Methylpicolinic
acid 50
Quinolinic acid Competitive 131  4
N-Ethylpicolinic acid
51
Quinolinic acid Competitive 124  6
Picolinic acid
N-oxide 105
Quinolinic acid Competitive 111  4
Quinoline-2-
carboxylic acid 52
Quinolinic acid Competitive 127  4
N-Methylquinoline-2-
carboxylic acid 55
Quinolinic acid Competitive 242  7
Kynurenic acid 7 Quinolinic acid Preliminary screen showed low
inhibition at high concentrations
Nicotinic acid 27 Quinolinic acid Preliminary screen showed no
inhibition
N-Methylnicotinic
acid 59
Quinolinic acid Preliminary screen showed no
inhibition
N-Ethylnicotinic acid
66
Quinolinic acid Preliminary screen showed no
inhibition
Nicotinic acid
N-oxide 63
Quinolinic acid Preliminary screen showed no
inhibition
Quinoline-3-
carboxylic acid 106
Quinolinic acid Preliminary screen showed no
inhibition
Table 3.19: Summary of the quinolinic acid analogues inhibition study. The Km for
quinolinic acid under these conditions is 13.5 M.
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Some general conclusions can be drawn from the results of this inhibition study:-
 It would appear that the ring nitrogen is not essential for binding. Of the
compounds tested, phthalic acid 25 proved to be the most effective
competitive inhibitor.
 The 3-carboxylic acid group is somewhat important for substrate interaction
with the enzyme because when this group was absent, the compounds became
less effective as inhibitors.
 The carboxylic acid group at the 2-position appears to be essential for binding.
This conclusion was most clearly indicated by the fact that nicotinic acid 27
did not inhibit the enzymatic reaction, whereas picolinic acid 26 did.
 Small, hydrophobic N-substituents do not provide additional binding. Instead
it would appear that the presence of such subsituents leads to weaker binding.
It was found that the size of the N-alkyl group does not significantly affect the
binding. N-Ethylquinolinic acid 42 and N-ethylpicolinic acid 51 were found to
be slightly better inhibitors than the corresponding N-methyl derivatives,
although the difference between the Ki values determined for these compounds
was just within experimental error.
 The N-oxide compounds appear to bind more tightly than the corresponding
N-alkyl compounds. This could be due to electrostatic interactions between
the negatively charged oxygen of the N-oxide and the highly positive
electrostatic surface of the QPRTase active site.
 It would appear that aromaticity is important for tight binding. However,
increasing the size of the aromatic ring system to a bicyclic structure leads to
weaker binding. This is most likely due to steric interference in the active site.
 Similarly, there appears to be a certain degree of steric hindrance at the 4- and
5-positions of the pyridine ring. This was indicated by the observation that
5-ethylquinolinic acid 43 and especially kynurenic acid 7, which has a
hydroxyl group at the 4-position, were weaker inhibitors of QPRTase.
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3.3.3 Inhibition studies using nucleotides
Nucleotides of adenine, cytosine, guanine, thymine and uracil have all previously
been tested as inhibitors of QPRTase from hog liver.4,44 In the preliminary inhibition
screens, the purine and pyrimidine nucleotide mono-, di- and triphosphates were all
shown to inhibit QPRTase. However, detailed inhibition studies to determine the type
of inhibition and the inhibition constants (Ki) for these compounds were not carried
out.
In this study, a detailed investigation of the inhibitory properties of
adenosine 5’-monophosphate (AMP, 107), guanosine 5’-monophosphate (GMP, 108),
cytidine 5’-monophosphate (CMP, 109) and thymidine 5’-monophosphate (TMP,
110) was undertaken.
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Firstly, to determine a suitable inhibitor concentration range for the inhibition studies,
a preliminary inhibition screen of the nucleotides was carried out by assessing the
percentage inhibition of QPRTase activity at a fixed concentration of quinolinic acid
(0.1 mM) and PRPP (0.1 mM). When present at a concentration of 0.01 mM, the
nucleotides did not inhibit QPRTase. However, when present at higher
concentrations (0.1 mM and 1 mM) the four nucleotides were found to inhibit
QPRTase to a similar extent (Table 3.20 and Figure 3.30).
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% Inhibition withInhibitor
0.01 mM inhibitor 0.1 mM inhibitor 1 mM inhibitor
AMP 107 0 19 60
GMP 108 0 18 57
CMP 109 0 24 65
TMP 110 0 26 68
Table 3.20: Percentage inhibition at varied inhibitor concentrations.
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Figure 3.30: Preliminary inhibition screen.
In order to determine the inhibitory properties of the four nucleotides, the Km and
Vmax values for the QPRTase reaction, with respect to both quinolinic acid and PRPP,
were then determined at various fixed inhibitor concentrations. The effect on the
kinetic parameters gave a measure of inhibition and also identified the type of
inhibition observed. Lineweaver-Burk plots were constructed to illustrate the type of
inhibition exhibited by each inhibitor, although these were used for illustrative
purposes only and not for calculating kinetic parameters. Note that in all the
Lineweaver-Burk plots, the line was constructed to fit the Km(app) and Vmax(app) values
determined from non-linear regression. Ki values were determined using linear
regression plots of Km(app) versus inhibitor concentration (competitive inhibition) or
1/Vmax(app) versus inhibitor concentration (noncompetitive inhibition).
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3.3.3.1 Adenosine 5’-monophosphate (inhibition with respect to quinolinic acid)
Adenosine 5’-monophosphate 107 was found to be a noncompetitive inhibitor of
QPRTase with respect to quinolinic acid. This was observed by a decrease in Vmax
with increasing inhibitor concentration, while Km remained unchanged within the
experimental error (Table 3.21). The noncompetitive inhibition pattern is illustrated
with a Lineweaver-Burk plot, which shows a series of straight lines intersecting,
approximately, on the x-axis (Figure 3.31).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 13.7  1.8 0.80  0.02
200 13.9  1.4 0.71  0.02
300 15.3  3.3 0.62  0.03
Table 3.21: Effect of adenosine 5’-monophosphate on kinetic parameters.
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Figure 3.31: Lineweaver-Burk plot for inhibition with adenosine 5’-monophosphate.
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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In the presence of a noncompetitive inhibitor, Vmax decreases by a factor of
(1 + [I]/Ki). The inhibition constant Ki can therefore be determined from a plot of
1/Vmax(app) versus inhibitor concentration. This plot is linear and the slope is equal to
1/Vmax.Ki.
Vmax(app) = Vmax / (1 + [I] / Ki)
1
Vmax(app) VmaxVmax.Ki
11 [I] += .
By performing this analysis, the Ki value for adenosine 5’-monophosphate 107 was
determined as 551  5 M with respect to quinolinic acid as the variable substrate
(Figure 3.32).
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 50 100 150 200 250 300 350
[Inhibitor] (M)
1/
V
m
ax
(a
pp
)
(
M
-1
m
in
)
Figure 3.32: Plot of 1/Vmax(app) versus [adenosine 5’-monophosphate].
3.3.3.2 Adenosine 5’-monophosphate (inhibition with respect to PRPP)
Adenosine 5’-monophosphate 107 was found to be a competitive inhibitor of
QPRTase with respect to PRPP. This was observed by an increase in Km with
increasing inhibitor concentration, while Vmax remained unchanged within the
experimental error (Table 3.22). The competitive inhibition pattern is illustrated with
a Lineweaver-Burk plot, which shows a series of straight lines intersecting on the
y-axis (Figure 3.33).
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[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.03
300 44.9  4.0 0.98  0.04
500 58.2  5.9 0.97  0.04
700 73.7  7.6 0.92  0.04
Table 3.22: Effect of adenosine 5’-monophosphate on kinetic parameters.
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Figure 3.33: Lineweaver-Burk plot for inhibition with adenosine 5’-monophosphate.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
adenosine 5’-monophosphate 107 was determined as 304  4 M with respect to
PRPP as the variable substrate (Figure 3.34).
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Figure 3.34: Plot of Km(app) versus [adenosine 5’-monophosphate].
 No inhibitor
 0.3 mM inhibitor
 0.5 mM inhibitor
 0.7 mM inhibitor
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3.3.3.3 Guanosine 5’-monophosphate (inhibition with respect to quinolinic acid)
Guanosine 5’-monophosphate 108 was found to be a noncompetitive inhibitor of
QPRTase with respect to quinolinic acid (Table 3.23). The noncompetitive inhibition
pattern is illustrated with a Lineweaver-Burk plot (Figure 3.35).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 13.0  1.6 0.82  0.02
200 13.1  1.3 0.72  0.02
300 14.9  2.0 0.63  0.03
Table 3.23: Effect of guanosine 5’-monophosphate on kinetic parameters.
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Figure 3.35: Lineweaver-Burk plot for inhibition with guanosine 5’-monophosphate.
From a plot of 1/Vmax(app) versus inhibitor concentration, the Ki value for
guanosine 5’-monophosphate 108 was determined as 576  4 M with respect to
quinolinic acid as the variable substrate (Figure 3.36).
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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Figure 3.36: Plot of 1/Vmax(app) versus [guanosine 5’-monophosphate].
3.3.3.4 Guanosine 5’-monophosphate (inhibition with respect to PRPP)
Guanosine 5’-monophosphate 108 was found to be a competitive inhibitor of
QPRTase with respect to PRPP (Table 3.24). The competitive inhibition pattern is
illustrated with a Lineweaver-Burk plot (Figure 3.37).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.03
300 39.6  2.1 0.98  0.02
500 53.2  3.4 0.98  0.02
700 69.7  5.7 0.97  0.04
Table 3.24: Effect of guanosine 5’-monophosphate on kinetic parameters.
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Figure 3.37: Lineweaver-Burk plot for inhibition with guanosine 5’-monophosphate.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
guanosine 5’-monophosphate 108 was determined as 309  6 M with respect to
PRPP as the variable substrate (Figure 3.38).
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Figure 3.38: Plot of Km(app) versus [guanosine 5’-monophosphate].
 No inhibitor
 0.3 mM inhibitor
 0.5 mM inhibitor
 0.7 mM inhibitor
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3.3.3.5 Cytidine 5’-monophosphate (inhibition with respect to quinolinic acid)
Cytidine 5’-monophosphate 109 was found to be a noncompetitive inhibitor of
QPRTase with respect to quinolinic acid (Table 3.25). The noncompetitive inhibition
pattern is illustrated with a Lineweaver-Burk plot (Figure 3.39).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 13.9  2.6 0.76  0.03
200 12.3  2.1 0.63  0.02
300 13.4  2.6 0.56  0.02
Table 3.25: Effect of cytidine 5’-monophosphate on kinetic parameters.
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Figure 3.39: Lineweaver-Burk plot for inhibition with cytidine 5’-monophosphate.
The Ki value for cytidine 5’-monophosphate 109 was determined as 423  6 M with
respect to quinolinic acid as the variable substrate (Figure 3.40).
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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Figure 3.40: Plot of 1/Vmax(app) versus [cytidine 5’-monophosphate].
3.3.3.6 Cytidine 5’-monophosphate (inhibition with respect to PRPP)
Cytidine 5’-monophosphate 109 was found to be a competitive inhibitor of QPRTase
with respect to PRPP (Table 3.26). The competitive inhibition pattern is illustrated
with a Lineweaver-Burk plot (Figure 3.41).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.03
300 48.3  4.4 0.98  0.04
500 70.0  6.0 1.00  0.03
700 88.6  9.0 0.98  0.04
Table 3.26: Effect of cytidine 5’-monophosphate on kinetic parameters.
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Figure 3.41: Lineweaver-Burk plot for inhibition with cytidine 5’-monophosphate.
The Ki value for cytidine 5’-monophosphate 109 was determined as 222  4 M with
respect to PRPP as the variable substrate (Figure 3.42).
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Figure 3.42: Plot of Km(app) versus [cytidine 5’-monophosphate].
 No inhibitor
 0.3 mM inhibitor
 0.5 mM inhibitor
 0.7 mM inhibitor
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3.3.3.7 Thymidine 5’-monophosphate (inhibition with respect to quinolinic acid)
Thymidine 5’-monophosphate 110 was found to be a noncompetitive inhibitor of
QPRTase with respect to quinolinic acid (Table 3.27). The noncompetitive inhibition
pattern is illustrated with a Lineweaver-Burk plot (Figure 3.43).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 15.6  2.7 0.73  0.02
200 15.9  2.8 0.64  0.02
300 15.6  3.5 0.55  0.03
Table 3.27: Effect of thymidine 5’-monophosphate on kinetic parameters.
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Figure 3.43: Lineweaver-Burk plot for inhibition with thymidine 5’-monophosphate.
The Ki value for thymidine 5’-monophosphate 110 was determined as 427  8 M
with respect to quinolinic acid as the variable substrate (Figure 3.44).
 No inhibitor
 0.1 mM inhibitor
 0.2 mM inhibitor
 0.3 mM inhibitor
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Figure 3.44: Plot of 1/Vmax(app) versus [thymidine 5’-monophosphate].
3.3.3.8 Thymidine 5’-monophosphate (inhibition with respect to PRPP)
Thymidine 5’-monophosphate 110 was found to be a competitive inhibitor of
QPRTase with respect to PRPP (Table 3.28). The competitive inhibition pattern is
illustrated with a Lineweaver-Burk plot (Figure 3.45).
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.04
300 51.2  5.5 1.00  0.03
500 68.6  4.9 1.02  0.03
700 88.8  7.6 1.00  0.03
Table 3.28: Effect of thymidine 5’-monophosphate on kinetic parameters.
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Figure 3.45: Lineweaver-Burk plot for inhibition with thymidine 5’-monophosphate.
From a plot of Km(app) versus inhibitor concentration, the Ki value for
thymidine 5’-monophosphate 110 was determined as 235  4 M with respect to
PRPP as the variable substrate (Figure 3.46).
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Figure 3.46: Plot of Km(app) versus [thymidine 5’-monophosphate].
 No inhibitor
 0.3 mM inhibitor
 0.5 mM inhibitor
 0.7 mM inhibitor
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3.3.3.9 Summary of the nucleotide inhibition study
The four nucleotides investigated in this study were all found to be competitive
inhibitors of human brain QPRTase with respect to PRPP as the variable substrate and
noncompetitive inhibitors with respect to quinolinic acid as the variable substrate
(Table 3.29).
Variable Substrate Inhibitor Type of Inhibition Ki (M)
Quinolinic acid AMP 107 Noncompetitive 551  5
Quinolinic acid GMP 108 Noncompetitive 576  4
Quinolinic acid CMP 109 Noncompetitive 423  6
Quinolinic acid TMP 110 Noncompetitive 427  8
PRPP AMP 107 Competitive 304  4
PRPP GMP 108 Competitive 309  6
PRPP CMP 109 Competitive 222  4
PRPP TMP 110 Competitive 235  4
Table 3.29: Summary of the nucleotide inhibition study.
The results therefore demonstrate that the nucleotides bind to the PRPP binding site of
QPRTase. This result can be explained by the structural similarity between the
5-phosphoribosyl moiety of the nucleotides and the substrate PRPP 15, meaning the
nucleotides can form similar hydrogen bonding interactions in the PRPP binding site
of QPRTase. The results appear to suggest that the nucleotides do not mimic the
putative reaction intermediate, quinolinic acid mononucleotide 16 or the product,
nicotinic acid mononucleotide 11, since if this was the case then it might be expected
that quinolinic acid binding could also be affected by the presence of the inhibitors.
The purine and pyrimidine nucleotides therefore appear to be acting as PRPP mimics.
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It was found that, with respect to PRPP as the variable substrate, the pyrimidine
nucleotides, CMP 109 and TMP 110, were better competitive inhibitors of QPRTase
than the purine nucleotides, AMP 107 and GMP 108 (Table 3.29). It is possible that
as a result of the greater steric bulk of the purine ring, AMP 107 and GMP 108 cannot
adopt a position in the active site to enable the 5-phosphoribosyl moiety to form the
hydrogen bonding interactions with the PRPP binding site as effectively as CMP 109
and TMP 110, which have a relatively smaller pyrimidine ring. Hence, CMP and
TMP are able to bind more tightly to the PRPP binding site of QPRTase, as is
reflected in the lower Ki values for these inhibitors with respect to PRPP (Table 3.29).
The observation that the nucleotides bind to the PRPP binding site of QPRTase is
consistent with results from previous inhibition studies. Both Calvo et al. and
Grubmeyer et al. have shown that NAMN 11, the product of the QPRTase reaction, is
a competitive inhibitor with respect to PRPP as the variable substrate.2,3 Furthermore,
structural studies have shown that NAMN adopts a conformation in the active site
such that both the 5-phosphate group and the ribose hydroxyl group oxygen atoms of
NAMN form similar hydrogen bonding interactions with the active site residues as
PRPP.42
The inhibition pattern of NAMN with respect to quinolinic acid has not previously
been determined. However, Calvo et al. found that the PRPP analogue
fructose-1,6-bisphosphate 32 was a weak noncompetitive inhibitor versus quinolinic
acid (Ki 10.9 mM).2 The four nucleotides examined in this study were all found to be
more effective noncompetitive inhibitors of QPRTase with respect to quinolinic acid
as the variable substrate.
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3.3.4 Potential irreversible inhibitors
Irreversible inhibition occurs when an inhibitor first binds at the active site, then
reacts with an active site group to form a covalent bond (Scheme 3.38). The active
site is then irreversibly blocked by the inhibitor and is permanently inactivated.
Km kcat
Ki
E + S ES P
I
EI E-I
+
ki
Scheme 3.38: Irreversible inhibition.
The kinetic characteristic associated with irreversible inhibition is that it is time-
dependent. This is because as time goes by more and more enzyme will be blocked
irreversibly by conversion of the reversible EI complex to E-I. If enzyme activity is
plotted versus time, an exponential decrease of activity is observed (Figure 3.47a).
This is in contrast to reversible inhibition where the enzyme activity is reduced, but is
constant with time (Figure 3.47b).
Activity
Time
100%
Activity
Time
100% I = 0
I
(a) (b)
Figure 3.47: (a) Time-dependence of irreversible inhibition (b) Time-independence of
reversible inhibition.
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Irreversible inhibitors usually contain electrophilic functional groups, such as halogen
substituents or epoxides that are capable of reacting with nucleophilic residues in the
enzyme active site. It was decided to examine two compounds as potential
irreversible inhibitors of QPRTase, pyridine 2,3-dicarboxylic acid anhydride 111 and
the bicyclic compound 66, which had been prepared in the laboratory (section
3.2.1.7).
N
O
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O
CO2H
N
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O
+
66111
Firstly, a preliminary inhibition screen of the compounds was carried out by assessing
the percentage inhibition of QPRTase activity at a fixed concentration of quinolinic
acid (0.1 mM) and PRPP (0.1 mM). In this inhibition screen, the enzyme was not
preincubated with the compounds prior to addition of the substrates. It was found that
neither compound inhibited the QPRTase catalysed reaction when present at a
concentration of 0.01 mM, 0.1 mM, 1 mM or 10 mM. This observation is consistent
with previous studies which have shown that the free carboxylic acid group at the
2-position is required for binding.5 Therefore if these compounds are to inhibit
QPRTase, they must do so by reacting with an active site residue. Structural studies
on human brain QPRTase have identified a lysine residue (Lys171) in the active site
that might react with the electrophilic groups in these molecules, leading to
irreversible inhibition of the enzyme (Scheme 3.39).
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Scheme 3.39: Potential irreversible inhibition of QPRTase.
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In order to probe this possibility, it was decided to carry out time-dependent inhibition
studies. To this end, QPRTase was incubated with each compound (0.5 mM) at 37 C
for a fixed length of time prior to adding the substrates and measuring the enzyme
activity. For each compound and set of reaction conditions, the rates were measured
in triplicate. The results are summarised in Table 3.30.
Compound Length of incubation (h) Average rate (M min-1)
Pyridine-2,3-dicarboxylic
acid anhydride 111
0 0.84
Pyridine-2,3-dicarboxylic
acid anhydride 111
2 0.70
Pyridine-2,3-dicarboxylic
acid anhydride 111
4 0.60
66 0 0.81
66 2 0.68
66 4 0.61
None present 0 0.82
None present 2 0.73
None present 4 0.58
Table 3.30: Results from the time-dependent inhibition study.
The observed time dependence of the decrease in enzyme activity may be indicative
of irreversible inhibition. However, it was found that the decrease in rate following
enzyme incubation at 37 C in the presence of the compounds was approximately the
same as the decrease in rate observed when the enzyme was incubated at the same
temperature for the same length of time but in the absence of the compounds (Table
3.30). It would appear therefore that the observed reduction in enzyme activity is a
consequence of the effect the temperature has on the enzyme rather than the
compounds binding irreversibly in the active site.
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3.4 Overall summary and further work
The four nucleotides (AMP 107, GMP 108, CMP 109 and TMP 110) investigated in
this study were all found to be competitive inhibitors of human brain QPRTase with
respect to PRPP as the variable substrate and noncompetitive inhibitors with respect
to quinolinic acid as the variable substrate. The results therefore demonstrated that
the nucleotides act as PRPP mimics and bind to the PRPP binding site of QPRTase.
The study of the inhibition of human brain QPRTase by quinolinic acid analogues
highlighted some structural features that are required for potent competitive inhibition
and can thus be incorporated into future inhibitor design. Pyridine 2,3-dicarboxylic
acid anhydride 111 did not show any inhibition of QPRTase suggesting the free
carboxylic acid groups are required for binding. The carboxylic acid group at the
3-position is somewhat important for interaction with the enzyme because when this
group was absent, the compounds became less effective as inhibitors. The carboxylic
acid group at the 2-position appears to be essential for binding. This conclusion was
most clearly indicated by the fact that nicotinic acid 27 did not inhibit the enzymatic
reaction, whereas picolinic acid 26 did.
The studies showed that aromaticity is important for tight binding. However, the
aromatic ring does not have to be a pyridine ring as is present in the substrate
quinolinic acid. Of the compounds tested, phthalic acid 25 proved to be the most
effective competitive inhibitor and therefore it would appear that the ring nitrogen is
not essential for binding. It might therefore be interesting to examine the inhibitory
properties of 2-hydroxybenzoic acid 112 and 2-mercaptobenzoic acid 113 since the
corresponding pyridine derivatives have previously been shown to be potent inhibitors
of QPRTase.
OH
CO2H
SH
CO2H
112 113
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It was found that increasing the size of the aromatic ring system to a bicyclic structure
leads to weaker binding. This is most likely due to steric interference in the active
site. Similarly, there appears to be a certain degree of steric hindrance at the 4- and
5-positions of the pyridine ring. This was indicated by the observation that
5-ethylquinolinic acid 43 and especially kynurenic acid 7, which has a hydroxyl group
at the 4-position, were weaker inhibitors of QPRTase.
Unfortunately, the attempts to synthesise 4-substituted quinolinic acid derivatives,
which could be used to further probe interactions at this position, were unsuccessful.
Both the directed ortho-metalation route and the route involving addition of
organometallic reagents to N-acylpyridinium salts failed to produce the desired
product. While the route involving the oxidation of 4-substituted quinolines looked
more promising, there were separation and purification problems and therefore this
route also failed to produce pure 4-subtituted quinolinic acid derivatives that could be
tested as inhibitors of human brain QPRTase.
In order to further probe the structural requirements for potent inhibition, a future
strategy might be to examine the inhibitory properties of substituted phthalic acid
derivatives.
CO2H
CO2H
R
Finally, a series of N-substituted compounds were successfully synthesised and tested
as inhibitors of human brain QPRTase. This study showed that the presence of small,
hydrophobic N-substituents leads to weaker binding. It was found that the size of the
N-alkyl group does not significantly affect the binding. The N-oxide compounds
appeared to bind more tightly than the corresponding N-alkyl compounds. Quinolinic
acid N-oxide was found to be a potent competitive inhibitor of human brain QPRTase,
with a Ki comparable to phthalic acid.
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4.1 Introduction
QPRTase is an unusual PRTase enzyme in that it appears to catalyse a second
reaction, decarboxylation of the quinolinic acid mononucleotide 16 to form the
corresponding nicotinic acid mononucleotide 11. This decarboxylation reaction is
considered to have an analogous mechanism to that observed for the decarboxylation
of pyridine carboxylic acids in chemical studies. The mechanism proposed by
Hammick et al. involves loss of carbon dioxide to form a nitrogen ylide, which is then
protonated to give the product (Scheme 4.1).1
N
OH
O
N
O
O
H
N
H
N H+ +
-
-CO2 H+
Scheme 4.1: Mechanism for the decarboxylation of pyridine carboxylic acids.
An analogous mechanism can be envisaged for the decarboxylation of quinolinic acid
mononucleotide 16, proceeding via the nitrogen ylide 18 (Scheme 4.2).
NO
OHOH
PiO
CO2H
NO
OHOH
PiO
CO2H
NO
OHOH
PiO
CO2H
CO2H
16
+-CO2 ++
-
H+
1118
Scheme 4.2: Decarboxylation of quinolinic acid mononucleotide.
However, enzymatic involvement in the decarboxylation step is yet to be conclusively
proven. As similar reactions were observed to occur spontaneously, it was suggested
that QPRTase played no part in the decarboxylation step and it occurred after the
mononucleotide had been released from the active site. In order to test this theory,
experiments were conducted involving the non-enzymatic decarboxylation of pyridine
carboxylic acids.2-4 Quinolinic acid was the most rapidly decarboxylated of all the
pyridine carboxylic acids studied, but the reaction was still very slow and required
harsh conditions. Quinolinic acid was shown to decarboxylate in aqueous
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hydrochloric acid (pH 1) at 95 °C, with a half life of ca. 3 days.2 Clearly the harsh
conditions whereby decarboxylation was observed are quite remote from the
physiological conditions (pH 7.2 and 37 °C) under which the QPRTase catalysed
reaction takes place. Some enzymatic involvement would therefore seem to be
necessary. Ideally, examination of the non-enzymatic decarboxylation of quinolinic
acid mononucleotide 16 would solve this problem.
Previously in our laboratory, considerable effort was made towards the synthesis of
quinolinic acid mononucleotide 16 for use in decarboxylation studies.5 The initial
proposed synthetic route involved direct coupling to form the N-glycosidic bond
(Scheme 4.3).
NO
OHOH
PiO
CO2H
CO2H
O
OHOH
PiO
Br N
CO2H
CO2H
16
+ +
Scheme 4.3: Disconnection of quinolinic acid mononucleotide.
To investigate this route, a series of model reactions involving the coupling of
2,3-disubstituted pyridine derivatives to acetobromoglucose 114 were carried out
(Scheme 4.4). Similar coupling reactions involving acetobromoglucose are well
documented.6-8
OAcO
AcO
AcO
AcO Br
N R
R'
OAcO
AcO
AcO
AcO
N
R
R'+
+
Br -
MeCN
reflux
114
Scheme 4.4: Coupling of substituted pyridine derivatives to acetobromoglucose.
The coupling of dimethyl quinolinate (R=R’=CO2Me) and acetobromoglucose failed.
It is possible this was due to the steric bulk of the ester group at the 2-position of the
pyridine ring since coupling reactions between nicotinamide (R=H, R’=CONH2) and
either acetobromoglucose or 2,3,5-triacetylribofuranosyl bromide were successful.
Chapter Four Enzymatic Decarboxylation Studies
185
The coupling of pyridine 2,3-dicarboxylic acid anhydride and acetobromoglucose
was then attempted. The reason for using pyridine 2,3-dicarboxylic acid anhydride
was that in this molecule the acidic substituents at C-2 and C-3 are tied together to
form the anhydride and it was hoped this would reduce steric congestion around the
nitrogen atom, enabling the coupling reaction to occur. Subsequent hydrolysis would
generate the desired diacid functionality. However, the coupling reaction failed. It is
possible that the anhydride has a substantial electron withdrawing effect on the
pyridine ring. As a result the ring nitrogen is a very poor nucleophile, which prevents
the coupling reaction taking place.
The reaction of pyridine-2,3-dicarbinol (R=R’=CH2OH) with acetobromoglucose was
then attempted. It was hoped the use of pyridine-2,3-dicarbinol might eliminate the
steric and electronic problems, enabling the coupling reaction to occur. Subsequent
oxidation would generate the desired diacid functionality. However, this coupling
reaction was also unsuccessful.
Therefore, due to a combination of steric and electronic effects, direct coupling of
2,3-disubstituted pyridines to sugar groups is not an effective method for the synthesis
of quinolinic acid mononucleotide.
An alternative synthetic route to quinolinic acid mononucleotide 16, involving
reacting an amino sugar with a 1,5-diketo compound to construct the pyridine ring,
was then investigated (Scheme 4.5). However, this route was also unsuccessful.
NO
OHOH
PiO
CO2H
CO2H
O
OHOH
PiO
NH2 O
H O
CO2H
CO2H
CO2H
CO2H
16
+ +
Scheme 4.5: Alternative disconnection of quinolinic acid mononucleotide.
Thus previous studies have shown quinolinic acid mononucleotide is a very difficult
compound to synthesise.5 Therefore, it has not been possible to determine the role of
QPRTase in the decarboxylation reaction. However, simple mimics of quinolinic acid
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mononucleotide would be easier to synthesise and might be useful as substrates for
enzymatic and non-enzymatic decarboxylation studies. The decarboxylation studies
might provide some information that can be translated to the quinolinic acid
mononucleotide system.
4.2 Non-enzymatic decarboxylation studies
Previously in our laboratory, two simple mimics of quinolinic acid mononucleotide,
N-methyl and N-ethylquinolinic acid, were synthesised and non-enzymatic
decarboxylation studies were carried out on these compounds.9
N
CO2H
Me
CO2H N
CO2H
Et
CO2H+ +
41 42
Dunn et al. found that quinolinic acid decarboxylates in aqueous hydrochloric acid
(pH 1) at 95 °C, with a half life of ca. 3 days.2 The non-enzymatic decarboxylation
studies on the N-alkylquinolinic acid derivatives showed that N-substitution increases
the rate of decarboxylation and the bulkier the N-substituent the greater the observed
increase in rate (N-methylquinolinic acid 41, t1/2 6.7 hours and N-ethylquinolinic acid
42, t1/2 4.6 hours).9 However, the actual rate was still quite slow when compared to an
enzymatic reaction. Furthermore, the harsh conditions required for decarboxylation
(pH 1 and 95 °C) are quite remote from physiological conditions (pH 7.2 and 37 °C).
Presumably, the larger N-substituent increases steric congestion around the
2-carboxylic acid group which is released upon decarboxylation. This effect would
be even greater in the case of quinolinic acid mononucleotide 16. However, it cannot
yet be deduced whether there would be sufficient rate increase to make this reaction
as rapid as an enzymatic reaction under physiological temperature and pH. Therefore,
it is still likely that the decarboxylation reaction is catalysed by QPRTase. It is
possible that the enzyme is involved in reducing the effective pH at the active site,
therefore ensuring that the quinolinic acid mononucleotide is in a monoprotonated
form, allowing efficient decarboxylation.
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4.3 Enzymatic decarboxylation studies
Now that QPRTase is available in our laboratory, the aim was to undertake enzymatic
decarboxylation studies to determine whether QPRTase can catalyse the
decarboxylation of the simple N-alkylquinolinic acids under physiological conditions
(Scheme 4.6).
N
CO2H
R
CO2H N
CO2H
R
+ +
QPRTase
pH 7.2, 37 oC
41 R = Me
42 R = Et 60 R = Et
59 R = Me
Scheme 4.6: Possible decarboxylation of N-alkylquinolinic acids.
Firstly, the substrates for the decarboxylation studies, N-methyl and N-ethylquinolinic
acid 41 and 42, were synthesised as described in section 3.2.1. The authentic
decarboxylation products, N-methyl and N-ethylnicotinic acid 59 and 60, were also
synthesised in an identical manner.
A UV scan for each compound was then carried out which revealed it is possible to
monitor the decarboxylation reaction by measuring the decrease in absorbance at
280 nm over time as the substrate is converted to product. The UV absorbance
spectra for N-methylquinolinic acid 41 and N-methylnicotinic acid 59 are shown in
Figure 4.1.
Figure 4.1: UV absorbance spectra for N-methylquinolinic acid (turquoise) and
N-methylnicotinic acid (pink) at 37 C, pH 7.2.
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For the decarboxylation studies, the assay mixtures contained 0.3 mM
N-alkylquinolinic acid in 50 mM K2HPO4/KH2PO4 buffer (pH 7.2). Each assay was
initiated by the addition of QPRTase (14 g). The absorbance at 280 nm was then
measured continuously over a 30 minute period at 37 °C. For comparison, control
experiments in which the N-alkylquinolinic acids were incubated under the same
conditions but in the absence of QPRTase were also set up so that if decarboxylation
was observed, the role of the enzyme would be apparent. However, for both
the N-methyl and N-ethyl compounds, A280 remained constant with time suggesting
no decarboxylation occurred, either in the presence or absence of the enzyme. A
series of assays were then set up to monitor the reaction continuously over a longer
period of time (2 h, 5 h and 8 h) under the same conditions. However, no significant
change in absorbance was observed, again suggesting no decarboxylation occurred.
The initial decarboxylation studies were performed in the absence of the second
QPRTase substrate, PRPP. Since it is possible that binding of both substrates may
lead to structural changes in the active site causing the enzyme to adopt a reactive
conformation, it was decided to repeat the decarboxylation studies on the
N-alkylquinolinic acid derivatives in the presence of PRPP. However, as before no
change in absorbance at 280 nm was observed suggesting no decarboxylation
occurred.
It was therefore decided to set up a longer incubation of the N-alkylquinolinic acid
derivatives with QPRTase at 37 C and pH 7.2. Rather than monitor the reactions
continuously at 280 nm, the UV absorbance scan of the incubated reactions were
recorded after 48 hours and compared to the UV spectra of the pure starting material
(N-alkylquinolinic acid) and authentic decarboxylation product (N-alkylnicotinic
acid). For both the N-methyl and N-ethyl compounds, the UV spectra recorded after
48 hours were identical to the UV spectra of the N-alkylquinolinic acid derivatives
suggesting no decarboxylation occurred under the enzymatic conditions examined
(Figure 4.2).
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(a)
(b)
Figure 4.2: (a) UV absorbance spectra for N-methylquinolinic acid (turquoise),
N-methylnicotinic acid (pink) and the reaction incubated for 48 hours (dark blue) at
37 C, pH 7.2. (b) UV absorbance spectra for N-ethylquinolinic acid (turquoise),
N-ethylnicotinic acid (pink) and the reaction incubated for 48 hours (dark blue) at
37 C, pH 7.2.
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4.4 Summary and further work
Previous non-enzymatic decarboxylation studies showed N-methyl and
N-ethylquinolinic acid undergo spontaneous decarboxylation but the reactions were
slow and required harsh conditions.9 The model studies suggested some enzymatic
involvement in the decarboxylation of quinolinic acid mononucleotide would seem to
be necessary.
However, the enzymatic decarboxylation experiments undertaken in this study
suggested QPRTase is unable to catalyse the decarboxylation of N-methyl and
N-ethylquinolinic acid under physiological conditions. The inhibition studies had
shown that both N-methyl and N-ethylquinolinic acid are potent competitive inhibitors
of QPRTase with respect to quinolinic acid as the variable substrate, confirming they
do bind to the quinolinic acid binding site (section 3.3.2). However, the inhibition
studies also showed that the presence of the N-alkyl substituent leads to weaker
binding. It is therefore possible that the small hydrophobic N-substituent cannot
position the molecules correctly in the active site to allow catalysis of the
decarboxylation. Structural studies on QPRTase with the N-alkylquinolinic acid
derivatives bound in the active site are required to probe the interactions between
these compounds and the enzyme.
Thus the involvement of QPRTase in the decarboxylation of quinolinic acid
mononucleotide remains unclear from these studies. Increasing the similarity of the
N-substituent to that in quinolinic acid mononucleotide might lead to more useful
substrates for enzymatic decarboxylation studies. Quinolinic acid mononucleotide
itself remains a key synthetic target since access to this compound would enable the
unambiguous determination of the enzymatic involvement in the decarboxylation
reaction.
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5.1 Introduction
5.1.1 Chemical modifications of amino acids
Chemical reagents that react specifically with a given amino acid side chain can be
used to identify the presence of the amino acid in an unknown protein. In addition, by
examination of the effect that chemical modification of different classes of amino acid
side chains has on the activity of the enzyme, it is possible to determine which amino
acids are critical for the structure or function of the protein. For example, if a reagent
that covalently interacts with only lysine residues is found to inhibit the function of
the protein, a lysine might be considered to be important for the catalytic activity of
the protein. A list of some reagents used for the modification of specific amino acids
is shown in Table 5.1.
Amino acid Group
modified
Reagent Modification reaction
Cysteine SH Iodoacetate
Iodoacetamide
DTNB
p-Hydroxymercuribenzoate
Alkylation
Alkylation
Disulfide formation
Metal complexation
Histidine NH Diethyl pyrocarbonate Acylation
Lysine NH2 Succinic anhydride Acylation
Arginine Guanidine Phenylglyoxal Heterocycle formation
Aspartate
Glutamate
CO2H EDC + amine Amide formation
Tyrosine Phenol Tetranitromethane Nitration
Tryptophan Indole N-Bromosuccinimide Oxidation
Table 5.1: Group specific reagents used for amino acid modification.
(DTNB 5,5’-dithiobis-(2-nitrobenzoic acid); EDC 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide)
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The effects of various chemical modification agents on the activity of hog
liver QPRTase have been investigated.1 -Naphthoquinone-4-sulfonic acid and
2,4,6-trinitrobenzene sulfonic acid are known to react with lysine residues. Histidine
residues can be modified by reaction with diethylpyrocarbonate or p-diazobenzene
sulfonic acid. Arginine residues can be modified by reaction with glyoxal. All of
these reagents showed inhibitory effects at fairly low concentrations, which implied
that lysine, histidine and arginine residues may be involved in the active site of
QPRTase. Inhibition with -naphthoquinone-4-sulfonic acid and p-diazobenzene
sulfonic acid was suppressed by the presence of the substrate, although reaction with
glyoxal was not. Chemical modifications of hog liver QPRTase therefore
demonstrated that arginine, lysine and histidine residues are necessary for activity,
with lysine and histidine residues closely associated with the quinolinic acid binding
site.
Diisopropylfluorophosphate, 2-hydroxy-5-nitrobenzyl bromide and acetylimidazole
are chemical modification agents for serine, tryptophan and tyrosine residues
respectively. These reagents did not inhibit QPRTase to any degree, which suggested
that these residues are not present in the active site of hog liver QPRTase.
It was found that QPRTase from hog liver was strongly inhibited by reagents
that react specifically with thiol groups, such as p-chloromercuribenzoic acid,
N-ethylmaleimide, 5,5’-dithiobis-(2-nitrobenzoic acid) and monoiodoacetic acid.2
This suggested that thiol groups have an important role in determining the enzymatic
activity of the hog liver enzyme. This is in contrast to the shiitake mushroom
enzyme, the activity of which was unaffected by treatment with such reagents.3
The effects of various chemical modification agents on the activity of hog kidney
QPRTase have also been investigated.4 It was found that acetylimidazole, 2-hydroxy-
5-nitrobenzyl bromide and 1,2-cyclohexanedione did not affect the enzyme activity.
These results suggested that tryptophan, tyrosine and arginine residues are not present
in the active site of the enzyme. However, it was found that enzymatic activity was
significantly reduced when treated with thiol group modifying reagents
(p-chloromercuribenzoic acid and 5,5’-dithiobis-(2-nitrobenzoic acid)), amino group
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modifying reagents (trinitrobenzenesulfonate) and imidazole group modifying
reagents (diethyl pyrocarbonate). In addition, it was found that inhibition by these
chemical modification reagents was suppressed by preincubation with the substrates.
The results therefore suggested that thiol, amino and imidazole groups exist in the
binding sites of quinolinic acid and PRPP in hog kidney QPRTase.
In a recent study by Gaur et al., QPRTase from E. coli was examined for
susceptibility to different chemical modification reagents.5 Loss of enzyme activity
with trinitrobenzenesulfonate (TNBS) occurred when 1.1 lysines per subunit were
modified. Tryptic digestion of the modified enzyme followed by HPLC-MS analysis
of the peptides showed Lys70 reacts with TNBS. This lysine is not conserved in the
sequence of the enzyme from all sources, nor is the amino acid part of the active site
according to the X-ray structures of QPRTase from Salmonella typhimurium and
Mycobacterium tuberculosis. Based on X-ray studies, it was found that this amino
acid residue participates in a conformational change distant from the active site. The
Lys70 modified enzyme is no longer functional, which suggested that chemical
modification hinders a catalytically critical movement.
In the same study, the modification of cysteine residues was investigated with several
reagents; iodoacetic acid, iodoacetamide, 5,5’-dithiobis-(2-nitrobenzoic acid) and
N-ethylmaleimide. No significant loss of activity of QPRTase was observed with any
of these reagents. Similarly, arginine modifying reagents such as butanedione and
phenylglyoxal did not lead to loss of enzyme activity.
In summary, the chemical modification experiments performed on QPRTase from
various sources have demonstrated that lysine and histidine residues are present in the
active site and are essential for enzymatic activity. It would appear that arginine and
cysteine residues have an important role in determining the enzymatic activity of
QPRTase from some sources. Tryptophan, tyrosine and serine residues do not appear
to be present in the active site of any of the QPRTases investigated.
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5.1.2 Site-directed mutagenesis
A useful way to obtain information regarding the importance of specific active site
residues in binding and catalysis is to perform site-directed mutagenesis studies. The
genetic code programmed into DNA determines the number and sequence of amino
acids in a protein, and thus also the functional properties of the protein. Site-directed
mutagenesis, first reported by Smith et al. in 1982, makes it possible to reprogramme
the genetic code and in this way replace specific amino acids in proteins.6
This technique requires that the wild-type gene sequence is known. The key to the
mutation is the preparation of an oligonucleotide primer that is complementary to the
wild-type gene but contains a mismatched nucleotide (Figure 5.1). Oligonucleotide
primers are usually 20-30 bases in length and are synthesised chemically exactly
according to the designed sequence. Since a small number of mismatches (1-3 bp) are
tolerable for primer binding to the template wild-type DNA, mismatches can be
precisely incorporated as mutations in the newly synthesised DNA. In general,
mismatches are placed in the middle of a primer rather than at the 5’- or 3’-ends,
enabling the wild-type template to bind the primer by both stretches of sequence
surrounding the mismatch. By using a specific mutagenic primer, a specific mutant
with a predetermined site and type of mutation will be produced.
3' TGTCGAAGAGGGCCT 5'
Wild-type template strand
Mutagenic primer 5' ACAGCTT TCCCGGA-OH 3'
l l l l l l l l l l l l l l
G
Mismatched
nucleotide
Figure 5.1: Oligonucleotide-directed mutagenesis reported by Smith et al. A primer
containing a mismatched nucleotide is used to produce a desired point mutation.
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Following wild-type strand separation, the specifically designed mutagenic primer is
annealed to the complementary sequence on the wild-type template strand
(Figure 5.1). The primer is then elongated by DNA polymerase and the double
stranded circle is closed by adding DNA ligase. Other than the mismatches
introduced through the primer, the mutant DNA is reproduced exactly according to
the wild-type DNA template. The mutant DNA sequence is then replicated in a
suitable host organism.
Expression of the plasmid containing the specific codon change (e.g. TCT to TGT)
will produce a protein with the desired amino acid substitution (e.g. Ser to Cys) at a
unique position. The biological activity of the mutated protein can then be compared
to that of the wild-type protein. In this way, the functional and structural roles of
amino acid residues in a protein of interest can be studied. By making one amino acid
substitution at a time, it is possible to build up a picture of the importance of each
active site residue in binding and catalysis.
Since its invention, there have been continual improvements in the basic
methodologies and versatility of site-directed mutagenesis, in particular the
employment of the polymerase chain reaction (PCR) to amplify the mutant DNA
sequence.7 So central has this technique become to all of biochemistry and molecular
biology that Michael Smith, its pioneer, shared the Nobel Prize in Chemistry in 1993
with Kary B. Mullis who developed PCR.
To date, no site-directed mutagenesis studies on QPRTase have been reported.
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5.2 Site-directed mutagenesis studies on human brain QPRTase
5.2.1 Introduction
Structural studies carried out on human brain QPRTase have enabled the identity and
spatial positioning of the active site residues to be determined (Figure 5.2). The
active site of human brain QPRTase is located at the centre of the /-barrel and is a
deep pocket with a highly positive electrostatic surface. This surface is composed of
three arginine residues (Arg161, Arg138, Arg102’ (‘ denotes residues from the other
subunit of the dimer)), two lysine residues (Lys139 and Lys171) and one histidine
residue (His160). These residues are highly conserved among QPRTase enzymes
(section 2.3.1) and adopt similar conformations in the structures of Mycobacterium
tuberculosis QPRTase and Salmonella typhimurium QPRTase. These residues are
therefore ideal targets for site-directed mutagenesis studies to probe the mechanism of
QPRTase.
Figure 5.2: Active site of human brain QPRTase.
The role of these residues is unclear from the structural studies on human brain
QPRTase since currently only the structure of the apoenzyme has been determined.
However, detailed structural studies have been carried out on Mycobacterium
tuberculosis QPRTase and various complex structures with substrates, products and
inhibitors bound in the active site are available.8 The structure of Mycobacterium
tuberculosis QPRTase with the inhibitor phthalic acid bound in the active site is
Arg138
Arg161
Lys171
His160
Lys139
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shown in Figure 5.3. From this structure the possible interactions between the
enzyme and the substrate become clearer and hence more informed decisions can be
made regarding the choice of mutations. Sequence alignment has shown that the
target residues in human brain QPRTase, Arg161, Arg138, Arg102’, Lys171 and
Lys139, correspond to residues Arg162, Arg139, Arg105’, Lys172 and Lys140,
respectively, in Mycobacterium tuberculosis QPRTase (section 2.3.1).
Figure 5.3: Active site of Mycobacterium tuberculosis QPRTase with inhibitor
phthalic acid bound [Protein Data Bank 1QPQ].
The three arginine residues in the active site might be involved in electrostatic
interactions with the carboxylate groups of the substrate quinolinic acid. Therefore, to
probe binding interactions, it was decided to change the nature of the amino acid side
chain and examine the effect of replacing each individual arginine residue with
alanine and also with glutamine, since a glutamine residue would still be of
reasonable size and polarity but not positively charged like arginine.
The side chain of residue Lys172 (Mycobacterium tuberculosis QPRTase numbering)
appears to be close to the C-2 carboxylate group and might therefore play an
important role in binding and/or catalysis (Figure 5.3). It was decided to replace this
lysine residue in human brain QPRTase (Lys171) with alanine and also serine, which
is a bit bigger and more polar but still uncharged, and examine the effect this has on
the enzymatic reaction. Similarly, it was decided to replace residue Lys139 in human
brain QPRTase with alanine and serine. This residue looks important in the active
site of human brain QPRTase although its role was unclear from the structures of
Mycobacterium tuberculosis QPRTase.
His161
Arg162
Arg139
Lys172
Arg105’
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5.2.2 Generation of the mutant proteins
5.2.2.1 Cloning and amplification of the mutant QPRTase genes
Site-directed mutagenesis makes it possible to replace specific amino acids in proteins
by reprogramming the genetic code. The target mutations in human brain QPRTase
were:
Arg102Gln Arg102Ala Lys139Ala Lys139Ser
Arg161Gln Arg161Ala Lys171Ala Lys171Ser
Arg138Gln
Site-directed mutagenesis was performed on a pEHISTEV-QPRTase clone based on
the megaprimer PCR method9 by Dr Huanting Liu (The Centre for Biomolecular
Science, University of St Andrews).
The principle of the megaprimer method for PCR site-directed mutagenesis is
outlined in Figure 5.4. For this method two flanking primers (primers A and C), one
internal mutagenic primer (primer B) and wild-type templates are needed. The first
round of PCR uses one flanking primer (primer A) and the internal mutagenic primer
(primer B), containing the desired base substitution(s), to generate a double stranded
megaprimer containing the mutations introduced by the mutagenic primer. Both the
original template and the product become further templates for subsequent rounds of
DNA synthesis and the mutant DNA predominates over the original template after
several PCR cycles. The pure megaprimer is isolated by extraction from an agarose
gel. In the second round of PCR, the purified megaprimer is then used together with
the second flanking primer (primer C) to generate the complete mutant DNA
sequence for subsequent purification and cloning into the appropriate expression
vector.
Chapter Five Site-directed Mutagenesis Studies
201
PCR 1
3' 5'
3'5'
3'5'
3' 5'
5'
3' 5'
3'
3' 5'
3'5'
5' 3'
5'3'
PCR 2
5' 3'
5'3'
primer A
primer B
primer C
megaprimer
1st step PCR product
2nd step PCR product
(1st step PCR product)
template (wild-type DNA)
template (wild-type DNA)
Restriction enzyme digestion
and ligation to vector
(complete mutant DNA)
Figure 5.4: Schematic outline of the mutagenesis protocol used in this study.
In this study, the template DNA was a pEHISTEV-QPRTase clone, which contains a
full length DNA sequence encoding wild-type human brain QPRTase. All the
primers used were synthesised by Eurogentic. Specific internal mutagenic primers
(primer B) were designed to introduce the desired mutations at the correct position in
the QPRTase gene. The two flanking primers (primers A and C) were designed to
bind to the two ends of the target sequence (the wild-type QPRTase gene). To enable
the subsequent cloning of the mutant QPRTase gene into the pEHISTEV expression
vector, the 5’ primer (primer A) contained a BspHI recognition site and the 3’ primer
(primer C) contained a BamHI recognition site just after the QPRTase stop codon.
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The final DNA product from each mutagenesis reaction was digested with the
appropriate restriction enzymes. The expression vector pEHISTEV-QPRTase was
then constructed by ligating the BspHI/BamHI digested mutant QPRTase gene into
the compatible NcoI/BamHI digested pEHISTEV vector. The constructed expression
vector is shown in Figure 5.5.
pEHISTEV
BamHI
NcoI/
BspHIEcoRV
Figure 5.5: Construction of the pEHISTEV-QPRTase expression vector. The partial
circle represents the pEHISTEV plasmid. The transcription/expression region
encompasses the mutant QPRTase gene (red bar), a TEV protease recognition site
(green bar) and a 6 x histidine tag (blue bar).
The resulting ligation mixture was used to transform competent E. coli cells. Several
colonies from each mutagenesis reaction were selected and the plasmid DNA was
isolated. The pure plasmid DNA was isolated by firstly lysing the bacterial cells
under alkaline conditions. The lysate was then neutralised and adjusted to high-salt
binding conditions. The DNA was adsorbed onto a silica column, washed and then
the pure plasmid DNA was eluted. The purified plasmids from each mutagenesis
reaction were screened for the presence of the desired mutation by DNA sequencing.
All the mutations and the sequence integrity of the QPRTase gene were confirmed by
automated DNA sequencing (The Sequencing Service, School of Life Sciences,
University of Dundee). T7 promoter and terminator primers were employed to read
the DNA sequence from 5’ to 3’ and 3’ to 5’ respectively. The DNA sequences were
transformed to give the protein sequence using the program DNAMAN. Short
segments of the DNA and protein sequences showing the mutations present in the
nine QPRTase mutants are shown in Figure 5.6. No additional secondary mutations
were observed in any of the sequences.
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Figure 5.6: Partial DNA and amino acid sequences for the QPRTase mutants. The
mutations are highlighted in red.
Lys171Ala
L V M V K D N H V
C T G G T G A T G G T G A A G G A T A A C C A T G T G
                        
C T G G T G A T G G T G G C G G A T A A C C A T G T G
L V M V A D N H V
Lys171Ser
L V M V K D N H V
C T G G T G A T G G T G A A G G A T A A C C A T G T G
                        
C T G G T G A T G G T G T C G G A T A A C C A T G T G
L V M V S D N H V
Arg102Ala
L L G E R V A L N
C T G C T G G G G G A A C G G G T G G C C C T C A A C
                        
C T G C T G G G G G A A G C G G T G G C C C T C A A C
L L G E A V A L N
Arg102Gln
L L G E R V A L N
C T G C T G G G G G A A C G G G T G G C C C T C A A C
                         
C T G C T G G G G G A A C A G G T G G C C C T C A A C
L L G E Q V A L N
Lys139Ala
A G T R K T T P G
G C A G G C A C G A G G A A G A C C A C G C C A G G C
                        
G C A G G C A C G A G G G C G A C C A C G C C A G G C
A G T R A T T P G
Lys139Ser
A G T R K T T P G
G C A G G C A C G A G G A A G A C C A C G C C A G G C
                        
G C A G G C A C G A G G T C G A C C A C G C C A G G C
A G T R S T T P G
Arg161Ala
A A S H R Y D L G
G C C G C C T C G C A C C G C T A C G A C C T G G G A
                       
G C C G C C T C G C A C G C G T A C G A C C T G G G A
A A S H A Y D L G
Arg161Gln
A A S H R Y D L G
G C C G C C T C G C A C C G C T A C G A C C T G G G A
                       
G C C G C C T C G C A C C A G T A C G A C C T G G G A
A A S H Q Y D L G
Arg138Gln
V A G T R K T T P
G T G G C A G G C A C G A G G A A G A C C A C G C C A
                        
G T G G C A G G C A C G C A G A A G A C C A C G C C A
V A G T Q K T T P
Mutant
WILD-TYPE AMINO ACID SEQUENCE
WILD-TYPE DNA SEQUENCE (5’ to 3’)
MUTANT DNA SEQUENCE (5’ to 3’)
MUTANT AMINO ACID SEQUENCE
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5.2.2.2 Expression and purification of the mutant proteins (HISTEV-QPRTase*)
To express the QPRTase mutants, the purified plasmids containing the human brain
QPRTase gene with the designed mutations (pEHISTEV-QPRTase*) were
transformed into E. coli strain BL21 (DE3). Small scale expression trials showed all
the QPRTase mutants expressed well under the same conditions used for the
expression of the wild-type enzyme. Each QPRTase mutant was then expressed on a
large scale under these conditions. The transformed E. coli were grown in L-broth
medium (1 L) containing kanamycin to a cell density of OD600 0.4 at 37 C. The
temperature was then reduced to 20 C and the cells were grown to OD600 0.6 prior to
induction with IPTG. The cultures were then incubated at 20 C for 15 hours
post-induction.
Since it had been shown for wild-type QPRTase that the presence of the histidine tag
does not affect the protein folding, the oligomeric state of the protein or the enzymatic
activity (Chapter 2), it was decided to leave the histidine tag attached to all the mutant
QPRTase proteins. Therefore, the over-expressed mutant HISTEV-QPRTase proteins
were purified by a single nickel affinity column followed by gel filtration. The
purified proteins were dialysed then concentrated to 10 mg/mL. The purity of the
HISTEV-QPRTase mutants was confirmed by SDS-PAGE (Figure 5.7).
1 2 3 4 5 6 7 8 9 10 11
Figure 5.7: Coomassie stained SDS-PAGE gel of the purified HISTEV-QPRTase
proteins; Lane 1 wild-type QPRTase, lane 2 empty, lane 3 Lys139Ala QPRTase,
lane 4 Lys139Ser QPRTase, lane 5 Lys171Ala QPRTase, lane 6 Lys171Ser QPRTase,
lane 7 Arg138Gln QPRTase, lane 8 Arg102Ala QPRTase, lane 9 Arg102Gln
QPRTase, lane 10 Arg161Ala QPRTase and lane 11 Arg161Gln QPRTase.
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5.2.3 Characterisation of the mutant proteins
5.2.3.1 Analysis of the mutant proteins by mass spectrometry
The molecular weight of an intact protein is a key physiocochemical characteristic
because it reflects the amino acid composition and the modifications of a polypeptide.
Analysis of the intact QPRTase mutants by electrospray mass spectrometry suggested
the desired amino acid substitutions were present in the proteins (Table 5.2).
Molecular weight (Da)Protein
Expected Found
Arg102Ala QPRTase 33695.9 33696.6
Arg102Gln QPRTase 33752.9 33751.0
Arg161Ala QPRTase 33695.9 33678.8
Arg161Gln QPRTase 33752.9 33749.7
Arg138Gln QPRTase 33752.9 33750.0
Lys139Ala QPRTase 33723.9 33730.1
Lys139Ser QPRTase 33739.9 33743.7
Lys171Ala QPRTase 33723.9 33722.8
Lys171Ser QPRTase 33739.9 33746.0
Table 5.2: Molecular weights of the HISTEV-QPRTase mutants.
Furthermore, digestion of the modified proteins with trypsin, a proteolytic enzyme
which cleaves selectively at the carboxyl side of lysine and arginine residues,
followed by MALDI-MS or nanoLC ESI-MS/MS analysis of the resulting peptides
confirmed the desired amino acid substitutions in the QPRTase mutants.
The tryptic peptides aa92-102 (1165.6 Da) and aa87-102 (1719.9 Da) were observed
for the wild-type enzyme but not for Arg102Ala QPRTase and Arg102Gln QPRTase,
confirming residue Arg102 has been replaced in these proteins. Furthermore, for
Arg102Ala QPRTase, peptides corresponding to aa92-110 (1976.1 Da) and aa87-110
(2530.4 Da) were observed. The molecular weights of these peptides are consistent
with the replacement of Arg102 with alanine and therefore confirm the desired amino
acid substitution. Similarly, for Arg102Gln QPRTase, the desired amino acid
substitution was confirmed by the observation of peptides aa92-110 (2033.1 Da) and
aa87-110 (2582.4 Da).
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The tryptic peptide aa139-145 (806.5 Da) was observed for the wild-type enzyme but
not for Arg138Gln QPRTase, confirming residue Arg138 has been replaced in this
protein. The replacement of this arginine residue by glutamine was confirmed the
observation of the peptide aa127-139 (1269.6 Da).
The tryptic peptide aa127-139 (1297.7 Da) was observed for the wild-type enzyme
but not for Lys139Ala QPRTase and Lys139Ser QPRTase, confirming residue
Lys139 has been replaced in these proteins. Furthermore, for Lys139Ala QPRTase, a
peptide corresponding to aa139-145 (749.4 Da) was observed. The molecular weight
of this peptide is consistent with the replacement of Lys139 with alanine and therefore
confirms the desired amino acid substitution. Similarly, for Lys139Ser QPRTase, the
desired amino acid substitution was confirmed by the observation of the peptide
aa139-145 (765.4 Da).
The tryptic peptides aa150-161 (1200.7 Da) and aa146-161 (1669.9 Da) were
observed for the wild-type enzyme but not for Arg161Ala QPRTase and Arg161Gln
QPRTase, confirming residue Arg161 has been replaced in these proteins.
Furthermore, for Arg161Ala QPRTase, peptides corresponding to aa150-171
(2191.2 Da) and aa146-171 (2660.4 Da) were observed. The molecular weights of
these peptides are consistent with the replacement of Arg161 with alanine and
therefore confirm the desired amino acid substitution. Similarly, for Arg161Gln
QPRTase, the desired amino acid substitution was confirmed by the observation of
the peptide aa150-171 (2248.2 Da).
The tryptic peptide aa172-183 (1195.6 Da) was observed for the wild-type enzyme
but not for Lys171Ala QPRTase and Lys171Ser QPRTase, confirming residue
Lys171 has been replaced in these proteins. Furthermore, for Lys171Ala QPRTase, a
peptide corresponding to aa162-183 (2214.1 Da) was observed. The molecular
weight of this peptide is consistent with the replacement of Lys171 with alanine and
therefore confirms the desired amino acid substitution. Similarly, for Lys171Ser
QPRTase, the desired amino acid substitution was confirmed by the observation of
the peptide aa162-183 (2230.1 Da).
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5.2.3.2 Analysis of the mutant proteins by circular dichroism
As discussed in section 2.3.3, the near-UV CD spectrum of a protein represents a
highly sensitive criterion for the native state of a protein and can thus be used as a
fingerprint of the correctly folded conformation. Therefore this technique is useful
for comparing wild-type and mutant proteins to see if the mutation causes any
significant changes in protein conformation. The near-UV (260-320 nm) CD spectra
of wild-type QPRTase and the QPRTase mutants were measured using a Jasco J-8.10
spectropolarimeter (Figure 5.8).
Figure 5.8: Near-UV CD spectra of Wild-type QPRTase, Arg102Ala QPRTase,
Arg102Gln QPRTase, Arg138Gln QPRTase, Arg161Ala QPRTase, Arg161Gln
QPRTase, Lys139Ala QPRTase, Lys139Ser QPRTase, Lys171Ala QPRTase, and
Lys171Ser QPRTase measured using a Jasco J-8.10 spectropolarimeter (Band width,
1nm; Response, 1 s; Data pitch, 0.2 nm; Scanning speed, 20 nm/min; Accumulation,
4; Cell length, 0.5 cm; Solvent, 50 mM potassium phosphate buffer; Concentration,
1 mg/mL; Temperature, room temperature).
By comparing the CD spectra of wild-type QPRTase and the nine QPRTase mutants,
it can be concluded that all the proteins are folded correctly. If the proteins were not
folded then the aromatic CD would be virtually zero. Instead, CD bands of
comparable magnitude were observed at the same wavelengths in all the spectra. The
slight differences between the spectra are due to small differences in the concentration
of the protein samples.
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5.2.3.3 Kinetic analysis of the mutant proteins
The activity of each QPRTase mutant was determined using a continuous
spectrophotometric assay based on the difference in extinction coefficients between
quinolinic acid and nicotinic acid mononucleotide at 266 nm (Δ266 = 920 M-1cm-1).
This involved measuring the change in absorbance at this wavelength over a
30 minute period, at 37 ºC. The assay mixtures contained 0.3 mM quinolinic acid,
0.1 mM PRPP and 6 mM MgCl2 in 50 mM K2HPO4/KH2PO4 buffer (pH 7.2). Each
assay was initiated by the addition of the mutant QPRTase (14 g). The rates were
measured in triplicate for each QPRTase mutant and were compared to a standard
assay for wild-type QPRTase. The results are shown in Table 5.3 and are displayed in
graphical form in Figure 5.9.
QPRTase mutant Percentage activity
(compared to wild-type enzyme)
Arg161Ala 20%
Arg161Gln Inactive
Lys171Ala Inactive
Lys171Ser Inactive
Arg102Ala 11%
Arg102Gln 11%
Arg138Gln Inactive
Lys139Ala Inactive
Lys139Ser Inactive
Table 5.3: Activity of the QPRTase mutants.
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Figure 5.9: Activity of the QPRTase mutants.
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It was found that when Arg161 was replaced with alanine, the protein retained 20%
activity relative to the wild-type enzyme. However, when the same residue was
changed to glutamine, all activity was lost. The two Arg102 mutants (Arg102Ala and
Arg102Gln) were found to retain just over 10% of the activity of the wild-type
enzyme. All the other QPRTase mutants were found to be inactive.
The activities of Arg102Ala QPRTase and Arg102Gln QPRTase were too low to
accurately determine the kinetic parameters Km and Vmax for the substrates. However,
for Arg161Ala QPRTase, the kinetic parameters Km and Vmax with respect to
quinolinic acid were determined by measuring the rate of the enzymatic reaction at a
range of different quinolinic acid concentrations at a fixed concentration of PRPP
(0.1 mM). The initial rate data were fitted to the Michaelis-Menten equation using
non-linear regression with GraphPad Prism 3 software (Figure 5.10). Km and Vmax for
quinolinic acid were determined as 319 ± 60 M and 0.71 ± 0.06 M min-1,
respectively.
Figure 5.10: Non-linear regression plot of Arg161Ala QPRTase for quinolinic acid as
the variable substrate.
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5.2.4 Discussion
From the results of the kinetic studies on the QPRTase mutants, it would appear that
all the residues that were targeted in the site-directed mutagenesis studies are
important for binding and/or catalysis. The active site residues targeted in the
mutagenesis studies are all highly conserved among QPRTase enzymes (section 2.3.1)
and adopt similar conformations in the active sites of human brain QPRTase and
QPRTase from bacterial sources. Sequence alignment has shown that the target
residues in human brain QPRTase, Arg161, Arg138, Arg102’, Lys171 and Lys139,
correspond to residues Arg162, Arg139, Arg105’, Lys172 and Lys140, respectively,
in Mycobacterium tuberculosis QPRTase (section 2.3.1). From the schematic
diagram of the interactions of Mycobacterium tuberculosis QPRTase with quinolinic
acid 10 and PRPP 15, it can be seen that all the residues targeted in the mutagenesis
studies appear to form binding interactions with the substrates (Figure 5.11). By
mutating these residues and changing the nature of the amino acid side chain, key
interactions between the enzyme and substrates are lost, which explains the significant
reduction or complete loss of activity observed for the QPRTase mutants. A more
detailed discussion of the information gained from the individual mutations follows.
Figure 5.11: Schematic diagram of the interactions of Mycobacterium tuberculosis
QPRTase with quinolinic acid and PRPP (target residues are highlighted with *).8
*
*
*
* *
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5.2.4.1 Mutation of Arg161
Mutation of residue Arg161 to alanine was found to result in significant reduction in
the enzymatic activity. Careful kinetic analysis of the enzymatic reaction enabled
determination of the kinetic parameters Km and Vmax for quinolinic acid (Table 5.4).
Comparison with the kinetic parameters for the wild-type enzyme shows a significant
increase in Km for the mutant enzyme. This indicates loss of binding, suggesting
Arg161 must form an important binding interaction with quinolinic acid. The
observed decrease in Vmax indicates loss of catalytic efficiency.
Protein Km (M) Vmax (μM min-1)
Wild-type QPRTase 13.1 ± 1.9 0.93 ± 0.03
Arg161Ala QPRTase 319 ± 60 0.71 ± 0.06
Table 5.4: Comparison of the kinetic parameters for wild-type QPRTase and
Arg161Ala QPRTase.
Structural studies on Mycobacterium tuberculosis QPRTase suggested this arginine
residue binds to the C-3 carboxylate group of quinolinic acid (Figure 5.11).
Arg161Ala QPRTase does retain some enzymatic activity and shows some affinity for
quinolinic acid which indicates that this interaction is important but not essential for
binding in the active site. This is consistent with results from the inhibition of human
brain QPRTase by picolinic acid derivatives (Chapter 3). It was found that while the
compounds inhibited QPRTase, affinity was lost when the carboxylate group was
absent at the 3-position suggesting this carboxylate group is important, but not
essential, for binding in the active site of QPRTase.
When Arg161 was mutated to glutamine, however, the resulting protein was found to
be inactive. It is unlikely the differences between the two Arg161 mutants are due to
a size effect, since the glutamine side chain is still smaller than the arginine side
chain. It is possible that the glutamine residue introduced at this position makes new
interactions with the neighbouring arginine residue (Arg 138) and this disturbs the
normal interactions. Structural studies on this QPRTase mutant are required to probe
this further.
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5.2.4.2 Mutation of Arg138
It was found that mutation of residue Arg138 to glutamine results in complete loss of
enzymatic activity suggesting the positively charged arginine side chain is involved in
essential interactions between the enzyme and substrate. From structural studies on
Mycobacterium tuberculosis QPRTase, it would appear that this arginine residue
binds to both the C-2 and C-3 carboxylate groups of quinolinic acid (Figure 5.11).
5.2.4.3 Mutation of Lys139
The kinetic studies on the QPRTase mutants showed that when Lys139 was replaced
with the uncharged residues alanine or serine, all enzymatic activity was lost
suggesting this lysine residue is key to the catalytic activity of the enzyme. From
structural studies on Mycobacterium tuberculosis QPRTase, it would appear that this
lysine residue is involved in binding to the phosphate groups of PRPP (Figure 5.11).
It has been proposed that the QPRTase catalysed phosphoribosyl transfer reaction
proceeds via a two step SN1-type mechanism involving an oxocarbonium ion
intermediate 17 (Scheme 5.1).10 The active site residue Lys139 may participate in the
stabilisation of the excess negative charge on the leaving pyrophosphate group.
Subsequently, the nucleophilic N1 of quinolinic acid 10 combines with the
oxocarbonium ion 17 to form quinolinic acid mononucleotide 16. It is possible that a
large positive electrostatic potential due to the side chain of Lys139 guides the
movement of the oxocarbonium ion intermediate 17 towards quinolinic acid 10 by
repulsion of the positively charged C1-O4 bond.
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Scheme 5.1: SN1 mechanism for phosphoribosyl transfer step.
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5.2.4.4 Mutation of Arg102’
In the site-directed mutagenesis studies it was found that replacing residue Arg102’ in
human brain QPRTase with either alanine or glutamine resulted in significant
reduction in enzymatic activity. By examining the structure of Mycobacterium
tuberculosis QPRTase with just quinolinic acid bound in the active site, it can be seen
that the side chain of this arginine residue (Arg105’) is not very close to quinolinic
acid 10 and does not appear to bind to the C-2 carboxylate (Figure 5.12a). However,
in the structure of Mycobacterium tuberculosis QPRTase with bound phthalic acid 25
and PRPCP 33, stable substrate analogues of quinolinic acid 10 and PRPP 15
respectively, it can be seen that the side chain of this arginine residue appears to
swing round and bind to both the C-2 carboxylate of phthalic acid 25 and one of the
phosphate groups of PRPCP 33 (Figure 5.12b). This residue could therefore be
involved in holding the two substrates in the correct orientation for reaction. This
would explain the significant reduction in enzymatic activity observed when this
arginine residue was replaced with alanine or glutamine; neither residue is capable of
forming what are clearly important electrostatic interactions between the enzyme and
the substrates.
Figure 5.12: Active site of Mycobacterium tuberculosis QPRTase with (a) quinolinic
acid bound (pink) [Protein Data Bank 1QPQ] and (b) phthalic acid (pink) and
PRPCP (yellow) bound [Protein Data Bank 1QPR].
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5.2.4.5 Mutation of Lys171
The site-directed mutagenesis studies showed that residue Lys171 is critical for the
enzymatic activity of human brain QPRTase. Mutation of this residue to either
alanine or serine resulted in complete loss of enzymatic activity. Structural studies on
Mycobacterium tuberculosis QPRTase have also suggested this residue plays an
important role in the QPRTase catalysed reaction.
In the structure of the Mycobacterium tuberculosis QPRTase apoenzyme, the side
chain of this lysine residue (Lys172 in the Mycobacterium tuberculosis enzyme)
interacts with the side chains of residues Asn174 and Glu104’ (Figure of 5.13).
Binding of quinolinic acid 10 is accompanied by reorientation of the side chain of the
lysine residue towards the C-2 carboxylate of the substrate (Figure 5.13). This results
in a 5 Å movement of the lysine side chain N atom and a 2 Å displacement of its C
atom.8
Figure 5.13: Superimposition of the active sites in the Mycobacterium tuberculosis
QPRTase apoenzyme and QPRTase-quinolinic acid complex structures.8 Carbon
atoms are depicted in grey (apoenzyme), green (quinolinic acid bound enzyme) or
cyan (quinolinic acid); nitrogen atoms are shown in blue and oxygen atoms in red.
For the QPRTase-quinolinc acid complex, only residues that undergo substrate
induced conformational changes are shown.
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The site-directed mutagenesis studies on human brain QPRTase showed that replacing
this lysine residue with either alanine or serine results in complete loss of enzymatic
activity suggesting this is a key interaction between the enzyme and the substrate.
This is consistent with the results from the inhibition studies on human brain
QPRTase, which showed that the C-2 carboxylate group is essential for binding in the
active site (Chapter 3). Nicotinic acid 27 lacks the C-2 carboxylate and is therefore
not capable of forming this essential interaction with Lys171 in the QPRTase active
site.
Furthermore, by examining the active site of the Mycobacterium tuberculosis
QPRTase-NAMN complex, it can be seen that the overall conformation of the active
site appears to be more similar to that of the apoenzyme and the conformational
changes observed in the QPRTase-quinolinic acid complex are absent in the
QPRTase-NAMN complex (Figure 5.14). Again, this is consistent with the role of the
C-2 carboxylate group in inducing the conformational changes.
Figure 5.14: Stereoview of the active site of Mycobacterium tuberculosis QPRTase
with bound NAMN (green carbon atoms).8
It would appear, therefore, that QPRTase has two conformers: a relaxed conformer,
observed in the structures of the apoenzyme and its complex with the product NAMN,
and an active conformer, seen in its complex with substrate quinolinic acid. The
reorientation of the side chain of Lys171 has important implications for the
mechanism of the QPRTase catalysed reaction.
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5.2.4.6 Mechanistic information from the site-directed mutagenesis studies
QPRTase is an unusual phosphoribosyltransferase enzyme in that it appears to
catalyse a second reaction, decarboxylation of the quinolinic acid mononucleotide 16
to form the corresponding nicotinic acid mononucleotide 11. This decarboxylation
reaction is considered to have an analogous mechanism to that observed for the
decarboxylation of pyridine carboxylic acids in chemical studies. The mechanism
proposed by Hammick et al. involves loss of carbon dioxide to form a nitrogen ylide,
which is then protonated to give the product.11 However, enzymatic involvement in
the decarboxylation step has yet to be conclusively proven.
Based on the initial structural studies on human brain QPRTase, which identified the
active site residues, and the site-directed mutagenesis studies, which showed how
important these residues are for enzymatic activity, it is now possible to propose a
mechanism involving QPRTase in the decarboxylation step (Scheme 5.2). Key to this
mechanism is the active site residue Lys171, which the site-directed mutagenesis
studies showed is essential for enzymatic activity.
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Scheme 5.2: Proposed mechanism for QPRTase catalysed decarboxylation of QAMN.
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Firstly, interaction between Lys171 and the C-2 carboxylate may facilitate
decarboxylation of QAMN 16 to form the nitrogen ylide intermediate 18
(Scheme 5.2A). Residue Lys171 is then perfectly positioned to reprotonate the ylide
intermediate 18 to form the product, NAMN 11 (Scheme 5.2B). Finally, the lack of
any interaction at the C-2 position would lead to reorientation of the side chain of
Lys171 and a switch in conformation from active to relaxed thereby facilitating the
release of the product, NAMN 11, from the active site (Scheme 5.2C).
As discussed in section 1.5.3, orotidine 5’-monophosphate decarboxylase (OMP
decarboxylase, EC 4.1.1.23) carries out a very similar decarboxylation reaction to
QPRTase (Scheme 5.3). A mechanism involving a nitrogen ylide intermediate has
also been proposed for OMP decarboxylase.116 This ylide mechanism was supported
by inhibition studies,117 kinetic isotope effect studies119,120 and structural studies.121
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Scheme 5.3: Decarboxylation of orotidine 5’-monophosphate.
Furthermore, identification of the active site by structural studies enabled the
elucidation of the residues involved in the decarboxylation mechanism for this
enzyme.121 The proposed mechanism is similar in many respects to the enzymatic
mechanism proposed here for the decarboxylation of QAMN by QPRTase. In the
mechanism reported for OMP decarboxylase, the key residue responsible for
reprotonation of the ylide intermediate was also a lysine residue. The catalytic
importance of this lysine residue was confirmed by site-directed mutagenesis studies
carried out on yeast OMP decarboxylase.122
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5.2.5 Summary
By employing the megaprimer method for PCR site-directed mutagenesis, nine
QPRTase mutants were successfully generated. The desired mutations and the
sequence integrity of the QPRTase gene were confirmed by automated DNA
sequencing. No additional secondary mutations were observed in any of the
sequences.
The mutant QPRTase proteins were successfully over-expressed from the
pEHISTEV-QPRTase construct in E. coli strain BL21 (DE3). The proteins were
purified by nickel affinity chromatography followed by gel filtration. Digestion of the
proteins with trypsin followed by MALDI-MS analysis of the resulting peptides
confirmed the presence of the desired amino acid substitution in each QPRTase
mutant.
The kinetic studies showed the QPRTase mutants were either inactive or had very low
activity. The loss of activity resulting from mutagenesis of the target residues does
not appear to be a consequence of gross changes in enzyme structure, as indicated by
comparison of the CD spectra of the mutant and wild-type enzymes. Therefore, it
would appear that all the residues that were targeted in the mutagenesis studies are
important for binding and/or catalysis.
Based on the initial structural studies on human brain QPRTase, which identified the
active site residues, and the site-directed mutagenesis studies, which showed how
important these residues are for enzymatic activity, a possible mechanism involving
QPRTase in the decarboxylation of quinolinic acid mononucleotide was proposed.
The proposed mechanism is similar in many respects to the mechanism reported for
OMP decarboxylase.
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5.2.6 Further work
Isothermal titration calorimetry (ITC) is a thermodynamic technique that allows the
study of the interactions between two species. When two species interact, heat is
either generated or absorbed and by measuring the heat of interaction it is possible to
determine thermodynamic parameters of interactions such as binding affinity. This
technique has therefore been applied to measuring protein-substrate interactions. The
role of the QPRTase active site residues in substrate binding could be further
investigated by performing ITC studies on both the wild-type and the mutant
enzymes. For example, the complete loss of enzymatic activity observed for
Arg138Gln QPRTase was explained by the loss of essential binding interactions
between the enzyme and the C-2 and C-3 carboxylate groups of quinolinic acid. ITC
studies may be used to confirm that quinolinic acid does not bind in the active site of
this QPRTase mutant.
Having performed kinetic analysis of the mutant proteins, the next stage would be to
undertake structural studies. Detailed structural studies on both wild-type human
brain QPRTase and the mutant enzymes, with and without substrates and products,
are required to elucidate the proposed decarboxylation mechanism more thoroughly.
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Conclusions and further work
Human brain QPRTase was successfully expressed in E. coli BL21 (DE3) from the
pEHISTEV-QPRTase construct and the protein was efficiently purified by nickel
affinity chromatography.
The structure of the fully active enzyme was solved using multiwavelength methods
to a resolution of 1.9 Å. In the crystal structure, human brain QPRTase was found to
adopt an energetically stable hexameric arrangement in which each subunit makes
extensive contacts with four other monomers. The enzyme was also found to exist as
a hexamer during gel filtration under physiological conditions.
Kinetic studies allowed the measurement of the kinetic parameters for quinolinic acid.
The data gave a Km of 13.4  1.0 M and a Vmax of 0.92  0.01 M min-1. There was
no evidence for cooperative binding of quinolinic acid to the six subunits of the
QPRTase hexamer. Previous kinetic studies on human brain QPRTase showed
pronounced substrate inhibition by PRPP at high concentrations. The mixed
inhibition observed suggested that PRPP not only binds to an active site (competitive)
but also to a second site which perturbs and inhibits the active site (noncompetitive).
The hexameric structure observed for human brain QPRTase offers a possible
explanation for the complex kinetics this enzyme exhibits.
The structural studies enabled identification of the active site residues. The active site
is a deep pocket with a highly positive electrostatic surface composed of three
arginine residues (Arg161, Arg138 and Arg102’), two lysine residues (Lys139 and
Lys171) and one histidine residue (His160). These residues are highly conserved
among QPRTase enzymes.
A series of QPRTase mutants were successfully generated and characterised
(Arg102Gln, Arg102Ala, Arg138Gln, Arg161Ala, Arg161Gln, Lys139Ala,
Lys139Ser, Lys171Ala and Lys171Ser). The kinetic studies showed the QPRTase
mutants were either inactive or had very low activity. The loss of activity resulting
from mutagenesis of the target residues does not appear to be a consequence of gross
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changes in enzyme structure, as indicated by comparison of the CD spectra of the
mutant and wild-type enzymes. Therefore, it would appear that all the residues that
were targeted in the mutagenesis studies are important for binding and/or catalysis.
Based on the initial structural studies on human brain QPRTase, which identified the
active site residues, and the site-directed mutagenesis studies, which showed how
important these residues are for enzymatic activity, a possible mechanism involving
QPRTase in the decarboxylation of quinolinic acid mononucleotide was proposed.
Key to this mechanism is the active site residue Lys171, which the site-directed
mutagenesis studies showed is essential for enzymatic activity. The proposed
decarboxylation mechanism is similar in many respects to the mechanism reported for
OMP decarboxylase.
Detailed structural studies on both wild-type human brain QPRTase and the mutant
enzymes, with and without substrates and products, are required to elucidate the
proposed decarboxylation mechanism more thoroughly. The availability of the
crystal structures of QPRTase with and without its substrates and products would
provide a detailed perspective for the active site interactions in pre-catalytic, catalytic
and post-catalytic stages of the enzyme. Hence useful information could be obtained
concerning the mechanism of the QPRTase reaction.
The study of the inhibition of human brain QPRTase by quinolinic acid analogues
provided further insight into the interactions in the active site and highlighted some
structural features that are required for potent competitive inhibition and can thus be
incorporated into future inhibitor design. The free carboxylic acid groups are required
for binding. The 3-carboxylic acid group is somewhat important for substrate
interaction with the enzyme because when this group was absent, the compounds
became less effective as inhibitors. The carboxylic acid group at the 2-position
appears to be essential for binding. The studies showed that aromaticity is important
for tight binding. However, the aromatic ring does not have to be a pyridine ring as is
present in the substrate quinolinic acid. Of the compounds tested, phthalic acid 25
proved to be the most effective competitive inhibitor and therefore it would appear
that the ring nitrogen is not essential for binding.
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The inhibition studies have thus far shown that there appears to be a certain degree of
steric hindrance at the 4- and 5-positions of the pyridine ring. Furthermore, it was
found that introducing small hydrophobic N-substituents leads to weaker binding in
the active site. Increasing the similarity of the N-substituent to that in the putative
reaction intermediate, quinolinic acid mononucleotide, might lead to tighter binding in
the active site and thus increased inhibition. In addition, compounds of this type
might be useful substrates for further enzymatic decarboxylation studies. Quinolinic
acid mononucleotide itself remains a key synthetic target since access to this
compound would enable the unambiguous determination of the enzymatic
involvement in the decarboxylation reaction.
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7.1 Molecular Biology
7.1.1 Materials and instrumentation
The expression plasmid pEHISTEV and 6 x His-TEV protease were provided by
Dr Huanting Liu (The Centre for Biomolecular Science, University of St Andrews).
E. coli strains DH5 and BL21 (DE3) were supplied by Stratagene. All the primers
used in the site-directed mutagenesis studies were synthesised by Eurogentic. All
restriction endonucleases, deoxyribonucleotides, T4 DNA ligase and Vent DNA
polymerase were purchased from Promega, Amersham or New England BioLabs.
Bradford’s stain was purchased from Sigma.
Sonication was carried out using a Sanyo Soniprep 150.
Centrifugation was carried out using a Beckman L-60, Beckman J2-21, Beckman
J6-HC or a MSE Microcentaur.
7.1.2 General methods
7.1.2.1 DNA sequencing
To prepare the samples for DNA sequencing, 5 L of the pure mutant plasmid DNA
was mixed with 3.2 M T7 promoter primer or 3.2 M T7 terminator primer in 7 L
of sterile water. The sequences were determined by automated sequencing (The
Sequencing Service, School of Life Sciences, University of Dundee).
7.1.2.2 Preparation of competent cells
To prepare competent cells, an E. coli (DH5 or BL21 (DE3)) overnight culture
(1 mL) was inoculated into L-broth medium (100 mL). The culture was incubated at
37 C with a shaking speed of 120 rpm for 2 hours to a log growth stage. The culture
was then chilled on ice for 30 minutes before centrifugation at 2800 rpm for 5 minutes
at 4 C. The pellet was gently resuspended in 12.5 mL of 100 mM CaCl2 and
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12.5 mL of 40 mM MgSO4 which had been cooled on ice. The competent cells were
stored on ice for at least 2 hours prior to use.
7.1.2.3 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was carried
out using a 12% resolving gel and a 5% stacking gel. Samples (10 L) were mixed
with 2 x SDS-PAGE loading buffer (10 L) and boiled for 3 minutes at 100 °C prior
to loading on to the gel. Electrophoresis was carried out at room temperature with a
constant voltage of 180 V. Gels were stained with 0.25% Coomassie blue, destained
and photographed.
7.1.2.4 Bradford’s assay to measure protein concentration1
A series of standards of known protein concentration were prepared by adding
Bradford’s stain (1 mL) to 2 L, 5 L, 10L and 20 L of BSA (1 g/L). Similarly,
solutions of pure QPRTase were prepared by adding Bradford’s stain (1 mL) to 2 L
and 5 L of the concentrated protein. After mixing well, the samples were left to
stand for 30 minutes to allow the blue colour to develop. The absorbance of each
sample at 595 nm was then measured against the Bradford’s stain as a blank. A
calibration curve was then compiled by plotting A595 as a function of the amount of
protein in the assay mixture for the BSA standards. Using the A595 of the QPRTase
solutions, the amount of protein in the assay mixture, and hence the concentration of
the pure QPRTase, were determined.
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7.1.3 Expression and purification of wild-type human brain QPRTase
7.1.3.1 Expression of HISTEV-QPRTase in E. coli
A glycerol stock (stored at -80 °C) of E. coli strain BL21 (DE3) competent cells
containing the recombinant plasmid pEHISTEV-QPRTase was spread on to an L-agar
plate containing kanamycin. The plate was incubated at 37 °C overnight. A single
colony of E. coli containing pEHISTEV-QPRTase was picked and transferred into
L-broth medium (10 mL) containing kanamycin (50 g/mL medium). The culture
was grown at 37 °C with a shaking speed of 200 rpm overnight.
To express HISTEV-QPRTase, the E. coli overnight culture (10 mL) was inoculated
into L-broth medium (1 litre) containing kanamycin (50 g/mL medium). The cells
were grown at 37 °C with a shaking speed of 200 rpm to an optical density of 0.4.
The cell culture was cooled moderately to 20 °C and was grown with a shaking speed
of 200 rpm to an optical density of 0.6. Expression was then induced by the addition
of 0.4 mM isopropyl--D-thiogalactoside (IPTG). The culture was incubated at 20 °C
with a shaking speed of 200 rpm overnight.
The cells were harvested by centrifugation at 4000 rpm for 15 minutes at 4 °C. The
supernatant was discarded and the pellet was resuspended and washed in PBS (20 ml)
and centrifuged at 5000 rpm for 10 minutes at 4 °C. The supernatant was discarded
and the pellet was stored at -70 °C, for later purification. The expression of
HISTEV-QPRTase was analysed by SDS-PAGE.
7.1.3.2 Purification of HISTEV-QPRTase
The harvested cells from a 1 litre culture were resuspended in 10 mL of sample buffer
(1 x PBS, 0.3 M NaCl, 10 mM imidazole) which contained protease inhibitor (PIT)
(1 tablet/10 mL sample buffer) and 1 mM dithiothreitol (DTT). The cells were
sonicated on ice three times each for 30 seconds with 1 minute intervals. The
suspended cells were centrifuged at 5000 rpm for 10 minutes at 4 °C. The
supernatant was collected and the pellet was resuspended in standard sample buffer
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(no PIT or DTT). The cells were sonicated as before and then centrifuged at
5000 rpm for 10 minutes at 4 °C. The combined supernatants were then centrifuged
at 18000 rpm for 1 hour at 4 °C. The supernatant was then collected and passed
through a 0.2 m syringe filter and loaded on to a nickel column with a flow rate of
2 mL/min. After washing the column with wash buffer (1 x PBS, 0.3 M NaCl, 20 mM
imidazole, 1 mM PMSF, 100 mL), HISTEV-QPRTase was eluted from the column
using elution buffer (1 x PBS, 0.3 M NaCl, 100 mM imidazole, 1 mM PMSF,
100 mL). Protein elution was monitored using Bradford’s stain. The HISTEV-
QPRTase containing fractions were analysed by SDS-PAGE and pooled.
7.1.3.3 TEV protease digestion
The pooled HISTEV-QPRTase containing fractions were dialysed in dialysis buffer
(1 x sterile water, 0.3 M NaCl, 50 mM Tris pH 7.5, 1 mM DTT) overnight at 4 °C.
The buffer was then changed to fresh dialysis buffer and dialysis was carried out for a
further 2 hours. After dialysis, 1 mM DTT (1 L/mL sample) was added to the
HISTEV-QPRTase, followed by the addition of TEV protease (1 g/mg protein). The
digestion was carried out overnight at room temperature. The product was analysed
by SDS-PAGE.
7.1.3.4 Removal of the His-tag and TEV protease
Dialysis was then carried out in a final dialysis buffer (1 x sterile water, 50 mM Tris
pH 7.5, 200 mM NaCl) for 1 hour at room temperature. The buffer was then changed
to an imidazole containing buffer (1 x sterile water, 50 mM Tris pH 7.5, 200 mM
NaCl, 20 mM imidazole) and dialysis was carried out for a further 1 hour at room
temperature.
The sample was then loaded on to the nickel column and QPRTase was eluted with
wash buffer (1 x sterile water, 0.3 M NaCl, 20 mM imidazole, 1 mM PMSF, 100 mL).
The fractions containing QPRTase were pooled and concentrated. The purified
QPRTase was analysed by SDS-PAGE, and the concentration of the protein was
determined by a Bradford’s assay. The concentrated QPRTase was stored at -20 °C.
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7.1.4 Site-directed mutagenesis studies
7.1.4.1 Generation of the mutant QPRTase DNA
Site-directed mutagenesis was performed on a pEHISTEV-QPRTase clone based on
the megaprimer PCR method2 by Dr Huanting Liu (The Centre for Biomolecular
Science, University of St Andrews). The primers used for the generation of the
QPRTase mutants are shown in Table 7.1.
Primer Sequence Notes
Flanking primer Aa 5’CTAGTCATGAACGCTGAAGGCCTG3’ Forward
Arg102Ala 5’CGTGTTGAGGGCCACCGCTTCCCCCAGCAG3’ Reverse
Arg102Gln 5’CGTGTTGAGGGCCACCTGTTCCCCCAGCAG3’ Reverse
Arg138Gln 5’GCCTGGCGTGGTCTTCTGCGTGCCTGCCAC3’ Reverse
Lys139Ala 5’GAAGCCTGGCGTGGTCGCCCTCGTGCCTGC3’ Reverse
Lys139Ser 5’GAAGCCTGGCGTGGTCGACCTCGTGCCTGC3’ Reverse
Arg161Ala 5’TCCCAGGTCGTACGCGTGCGAGGCGGC3’ Reverse
Arg161Gln 5’TCCCAGGTCGTACTGGTGCGAGGCGGC3’ Reverse
Lys171Ala 5’CACCACATGGTTATCCGCCACCATCACCAG3’ Reverse
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Lys171Ser 5’CACCACATGGTTATCCGACACCATCACCAG3’ Reverse
Flanking primer Cc 5’ATGCGGATCCCTAGTGGATTTTGGGC 3’ Reverse
Table 7.1: Primers used for the generation of the QPRTase mutants. (a. BspHI site is
underlined, b. The mutated genetic codes are highlighted in bold, c. BamHI site is
underlined).
In the first round of PCR, the outside flanking primer (primer A) and the internal
mutagenic primer (primer B), containing the desired base substitution(s), were used to
generate a double stranded megaprimer containing the mutations introduced by the
mutagenic primer. The megaprimer was isolated by extraction from an agarose gel.
In the second round of PCR, the purified megaprimer was used together with the
second flanking primer (primer C) to generate the complete mutant QPRTase DNA
sequence.
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7.1.4.2 Restriction endonuclease digestion of the mutant QPRTase DNA and the
plasmid pEHISTEV
The megaprimer PCR generated mutant QPRTase DNA (1 g) was digested with the
restriction enzymes BspHI (1 unit) and BamHI (1 unit) in 1x NEBuffer 4 (total
volume 30 L) as described by the manufacturer (New England Biolabs). The
digestion mixture was incubated at 37 C for two hours.
The plasmid pEHISTEV was digested with the restriction endonucleases NcoI and
BamHI as described above.
7.1.4.3 Construction of the expression vector pEHISTEV-QPRTase*
The BspHI / BamHI digested mutant QPRTase gene fragment (30 ng) was ligated into
NcoI / BamHI digested pEHISTEV (10 ng) using T4 DNA ligase (1 L) in 1x ligation
buffer (total volume 20 L). Ligation was carried out at 14 C overnight.
7.1.4.4 Transformation in E. coli
DH5 competent cells (100 L) were mixed with the ligation mixture and chilled on
ice for 30 minutes. The competent cells were then heat shocked for 4 minutes at
42 C, then immediately returned to ice for 15 minutes. L-Broth medium (1 mL) was
added to the heat shocked competent cells which were then incubated at 37 C for
1 hour. The competent cells were centrifuged at 10000 rpm for 3 minutes. The pellet
was resuspended in L-broth medium (100 L) and spread on to an L-agar plate
containing kanamycin (50 g/mL). The plates were incubated at 37 C overnight.
The number of colonies on each agar plate was counted and a single colony was
picked and transferred into L-broth medium (10 mL) containing kanamycin
(50 g/mL medium). The culture was grown at 37 C with a shaking speed of
200 rpm overnight. The cells were then harvested by centrifugation at 4000 rpm for
10 minutes.
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7.1.4.5 Isolation of the pure mutant plasmid DNA (pEHISTEV-QPRTase*)
The pure mutant plasmid DNA was isolated using a QIAprep Miniprep Kit. The
pelleted bacterial cells were resuspended in buffer P1 (250 L) containing LyseBlue
reagent. The bacterial cells were lysed under alkaline conditions by adding buffer P2
and mixing gently until a homogeneously blue coloured suspension was obtained.
The lysate was then neutralised and adjusted to high-salt binding conditions by adding
buffer N3 (350 L). The suspension was mixed gently until all traces of blue were
removed and a homogeneously colourless suspension was obtained, indicating that
SDS from the lysis buffer had been effectively precipitated. The suspension was
centrifuged at 13000 rpm for 10 minutes. The supernatant was applied to a QIAprep
spin column and centrifuged at 13000 rpm for 1 minute. The flow-through was
discarded. The column was then washed sequentially with buffer PB (0.5 mL) to
remove any endonucleases followed by buffer PE (0.75 mL) to remove salts. After
centrifugation at 13000 rpm for 1 minute, the flow-through was discarded and the
column was centrifuged for a further 1 minute to remove any residual wash buffer.
The QIAprep column was then placed in a clean eppendorf. To elute the DNA, buffer
EB (50 L) was added to the centre of the QIAprep column. After 1 minute, the pure
plasmid DNA was eluted by centrifugation at 13000 rpm for one minute. All the
mutations and sequence integrity of the QPRTase gene were confirmed by automated
DNA sequencing.
7.1.4.6 Expression and purification of the mutant QPRTases
The purified plasmids containing the human brain QPRTase gene with the designed
mutations (pEHISTEV-QPRTase*) were transformed into E. coli strain BL21 (DE3)
competent cells. Preparations and transformations were carried out as described
previously. A single colony of E. coli containing pEHISTEV-QPRTase* was grown
in L-broth (10 mL) containing kanamycin (50 g/mL medium) at 37 °C with a
shaking speed of 200 rpm overnight.
Expression and purification of the mutant QPRTase proteins were then carried out as
described previously for wild-type QPRTase (sections 7.1.3.1 and 7.1.3.2).
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7.2 Kinetic studies on human brain QPRTase
7.2.1 Standard activity assay3
The activity of QPRTase was determined using a continuous spectrophotometric
assay based on the difference in extinction coefficients between quinolinic acid and
nicotinic acid mononucleotide at 266 nm (Δ266 = 920 M-1cm-1). Typical assay
mixtures contained 0.3 mM quinolinic acid, 0.1 mM PRPP and 6 mM MgCl2 in
50 mM K2HPO4/KH2PO4 buffer (pH 7.2). Each assay was initiated by the addition of
QPRTase (14 g). The absorbance at 266 nm was then measured over a 30 minute
period at 37 °C.
7.2.2 Determination of the kinetic parameters for wild-type QPRTase
The kinetic parameters Km and Vmax for quinolinic acid were determined by
measuring the rate of the enzymatic reaction at a range of different quinolinic acid
concentrations (10 – 300 M) at a fixed and saturating concentration of PRPP
(0.1 mM). The reaction was linear over the time course studied and the rates were
measured in triplicate.
[Quinolinic
acid]
(M)
ΔA266 Δ[NAMN] 
(M)
Rate of
formation of
NAMN
(M min-1)
Average rate
of formation of
NAMN
(M min-1)
10
0.0090
0.0097
0.0105
9.78
10.54
11.41
0.36
0.39
0.42
0.39
25
0.0137
0.0142
0.0156
14.89
15.43
16.95
0.55
0.57
0.63
0.58
50
0.0179
0.0185
0.0193
19.46
20.11
20.98
0.72
0.74
0.78
0.75
100
0.0197
0.0204
0.0209
21.41
22.17
22.72
0.79
0.82
0.84
0.82
200
0.0205
0.0209
0.0219
22.23
22.72
23.80
0.82
0.84
0.88
0.85
300
0.0211
0.0216
0.0223
22.93
23.48
24.24
0.85
0.87
0.90
0.87
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Kinetic parameters were then evaluated by fitting the initial rate data to the
Michaelis-Menten equation using non-linear regression with GraphPad Prism 3
software. Km and Vmax for quinolinic acid were determined as 13.4  1.0 M and
0.92  0.01 M min-1, respectively.
7.2.3 Determination of the kinetic parameters for wild-type HISTEV-QPRTase
The kinetic parameters Km and Vmax for quinolinic acid were determined by
measuring the rate of the enzymatic reaction at a range of different quinolinic acid
concentrations (10 – 300 M) at a fixed and saturating concentration of PRPP
(0.1 mM). The reaction was linear over the time course studied and the rates were
measured in triplicate.
[Quinolinic
acid]
(M)
ΔA266 Δ[NAMN] 
(M)
Rate of
formation of
NAMN
(M min-1)
Average rate
of formation of
NAMN
(M min-1)
10
0.0097
0.0102
0.0112
10.52
11.09
12.17
0.39
0.41
0.45
0.42
25
0.0126
0.0132
0.0141
13.71
14.35
15.32
0.51
0.53
0.57
0.54
50
0.0194
0.0199
0.0202
21.09
21.63
21.96
0.78
0.80
0.81
0.80
100
0.0205
0.0206
0.0211
22.28
22.39
22.93
0.83
0.83
0.85
0.84
200
0.0213
0.0218
0.0219
23.15
23.70
23.83
0.86
0.88
0.88
0.87
300
0.0208
0.0209
0.0214
22.60
22.72
23.26
0.84
0.84
0.86
0.85
Kinetic parameters were then evaluated by fitting the initial rate data to the
Michaelis-Menten equation using non-linear regression with GraphPad Prism 3
software. Km and Vmax for quinolinic acid were determined as 13.1 ± 1.9 μM and
0.93 ± 0.03 μM min-1, respectively.
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7.2.4 pH rate profile for QPRTase
The pH rate profile for human brain QPRTase was determined by utilising the
standard UV activity assay to measure the rate of the enzymatic reaction in a series of
50 mM K2HPO4/KH2PO4 buffers of varying pH (pH 4.5 – 9) at fixed concentrations
of quinolinic acid (0.3 mM) and PRPP (0.1 mM). Each reaction was initiated by the
addition of QPRTase (14 g). The reaction was linear over the time course studied
and the rates were measured in triplicate. The table represents the overall data for the
profile, which can be seen in graphical form in section 2.4.4.
pH ΔA266 Δ[NAMN] 
(M)
Rate of
formation of
NAMN
(M min-1)
Average rate
of formation of
NAMN
(M min-1)
4.50
0.0328
0.0345
0.0360
35.67
37.48
39.09
1.32
1.39
1.45
1.39
5.03
0.0392
0.0393
0.0395
42.61
42.70
42.93
1.58
1.58
1.59
1.58
5.50
0.0468
0.0472
0.0475
50.81
51.33
51.64
1.88
1.90
1.91
1.90
6.00
0.0473
0.0479
0.0487
51.41
52.08
52.97
1.90
1.93
1.96
1.93
6.51
0.0358
0.0385
0.0393
38.92
41.80
42.70
1.44
1.55
1.58
1.52
7.02
0.0236
0.0272
0.0283
25.69
29.51
30.73
0.95
1.09
1.14
1.06
7.51
0.0178
0.0199
0.0252
19.36
21.64
27.35
0.72
0.80
1.01
0.84
8.00
0.0122
0.0132
0.0148
13.17
14.36
16.11
0.49
0.53
0.60
0.54
8.50
0.0115
0.0135
0.0137
12.49
14.60
14.85
0.46
0.54
0.55
0.52
8.98
0.0107
0.0123
0.0135
11.67
13.29
14.64
0.43
0.49
0.54
0.49
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7.2.5 Solvent isotope effect studies on QPRTase
The solvent isotope effects were determined by measuring the rate of the enzymatic
reaction in equivalent 50 mM potassium phosphate buffers in H2O and D2O at a fixed
concentration of quinolinic acid (0.3 mM) and PRPP (0.1 mM). Each reaction was
initiated by the addition of QPRTase (14 g). The reaction was linear over the time
course studied and the rates were measured in triplicate. The solvent isotope effects
were determined at pL 7.2, pL 6.3 and pL 5.3 (L = H or D).
pL ΔA266 Δ[NAMN] (M)
Rate of
formation of
NAMN
(M min-1)
Average rate
of formation
of NAMN
(M min-1)
Solvent
isotope
effect
(kH/kD)
pH 7.2
0.0213
0.0216
0.0223
23.15
23.48
24.24
0.86
0.87
0.90
0.88
pD 7.2
0.0186
0.0190
0.0194
20.22
20.65
21.09
0.75
0.76
0.78
0.76
1.16
pH 6.3
0.0425
0.0437
0.0447
46.20
47.50
48.59
1.71
1.76
1.80
1.75
pD 6.3
0.0482
0.0514
0.0529
52.39
55.87
57.50
1.94
2.07
2.13
2.05
0.85
pH 5.3
0.0427
0.0430
0.0437
46.41
46.74
47.50
1.72
1.73
1.76
1.74
pD 5.3
0.0472
0.0485
0.0488
51.33
52.72
53.04
1.90
1.95
1.96
1.94
0.90
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7.2.6 Determination of the kinetic parameters for Arg161Ala HISTEV-QPRTase
The kinetic parameters Km and Vmax for quinolinic acid were determined by
measuring the rate of the enzymatic reaction at a range of different quinolinic acid
concentrations (50 – 1000 M) at a fixed concentration of PRPP (0.1 mM). The
reaction was linear over the time course studied and the rates were measured in
triplicate.
[Quinolinic
acid]
(M)
ΔA266 Δ[NAMN] 
(M)
Rate of
formation of
NAMN
(M min-1)
Average rate
of formation of
NAMN
(M min-1)
50
0.0023
0.0041
0.0045
2.50
4.34
4.81
0.09
0.16
0.18
0.14
100
0.0044
0.0051
0.0060
4.73
5.49
6.48
0.18
0.20
0.24
0.21
200
0.0050
0.0051
0.0074
5.47
5.55
7.99
0.20
0.21
0.30
0.24
300
0.0062
0.0075
0.0082
6.74
8.07
8.93
0.25
0.30
0.33
0.29
400
0.0084
0.0096
0.0099
9.12
10.43
10.78
0.34
0.39
0.40
0.39
500
0.0095
0.0104
0.0114
10.30
11.33
12.39
0.38
0.42
0.46
0.42
600
0.0107
0.0112
0.0119
11.63
12.17
12.91
0.43
0.45
0.48
0.45
800
0.0116
0.0125
0.0134
12.61
13.54
14.55
0.47
0.50
0.54
0.50
1000
0.0132
0.0135
0.0139
14.37
14.58
15.16
0.53
0.54
0.56
0.54
Kinetic parameters were then evaluated by fitting the initial rate data to the
Michaelis-Menten equation using non-linear regression with GraphPad Prism 3
software. Km and Vmax for quinolinic acid were determined as 319 ± 60 M and
0.71 ± 0.06 M min-1, respectively.
Chapter Seven Experimental
238
7.3 Inhibition studies on human brain QPRTase
7.3.1 Inhibition studies (with respect to quinolinic acid as the variable substrate)
Preliminary screening of potential inhibitors was carried out by assessing the
% inhibition of QPRTase activity at a fixed concentration of quinolinic acid and
PRPP (0.1 mM). The inhibition of QPRTase by a number of compounds was then
examined in detail by assaying the activity at various concentrations of quinolinic acid
(10-300 M) and a fixed concentration of PRPP (0.1 mM). The reactions were linear
over the time course studied and the rates were measured in triplicate. The kinetic
parameters, Km and Vmax, were calculated by fitting initial rate data to the
Michaelis-Menten equation using non-linear regression with Graph Pad Prism 3
software on a PC. Each inhibitor was compared to a standard assay at quinolinic acid
concentrations 10-300 M. Ki values were determined using linear regression plots
of Km(app) versus inhibitor concentration (competitive inhibition) or 1/Vmax(app) versus
inhibitor concentration (noncompetitive inhibition).
7.3.2 Inhibition studies (with respect to PRPP as the variable substrate)
Preliminary screening of potential inhibitors was carried out by assessing the
% inhibition of QPRTase activity at a fixed concentration of quinolinic acid and
PRPP (0.1 mM). The inhibition of QPRTase by a number of compounds was then
examined in detail by assaying the activity at various concentrations of PRPP
(10-300 M) and a fixed concentration of quinolinic acid (0.3 mM). The reactions
were linear over the time course studied and the rates were measured in triplicate.
The kinetic parameters, Km and Vmax, were calculated by fitting initial rate data to the
Michaelis-Menten equation using non linear regression with Graph Pad Prism 3
software on a PC. Each inhibitor was compared to a standard assay at PRPP
concentrations 10-300 M. Ki values were determined using linear regression plots
of Km(app) versus inhibitor concentration.
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N-Methylquinolinic acid (41)
N
Me
CO2
CO2H
-
+
.H2O
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.88, 0.88 0.84, 0.84, 0.87 0.80, 0.80, 0.81 0.73, 0.73, 0.76
0.2 0.88, 0.89, 0.89 0.75, 0.75, 0.80 0.73, 0.73, 0.75 0.66, 0.70, 0.71
0.1 0.83, 0.86, 0.86 0.58, 0.60, 0.65 0.50, 0.53, 0.58 0.46, 0.48, 0.50
0.05 0.72, 0.74, 0.75 0.48, 0.49, 0.49 0.35, 0.39, 0.42 0.33, 0.33, 0.35
0.025 0.53, 0.58, 0.59 0.35, 0.37, 0.38 0.26, 0.28, 0.30 0.16, 0.17, 0.23
0.010 0.40, 0.42, 0.44 0.19, 0.20, 0.26 0.12, 0.13, 0.17 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.6  1.2 0.94  0.02
100 42.4  4.1 0.93  0.03
200 74.1  6.7 0.99  0.04
300 106.8  8.6 1.02  0.04
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N-Ethylquinolinic acid (42)
N
Et
CO2
CO2H
-
+
.H2O
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.81, 0.82, 0.82 0.75, 0.76, 0.76 0.67, 0.67, 0.68
0.2 0.79, 0.80, 0.83 0.68, 0.68, 0.79 0.65, 0.66, 0.67 0.45, 0.54, 0.55
0.1 0.69, 0.69, 0.79 0.65, 0.66, 0.67 0.45, 0.47, 0.53 0.38, 0.39, 0.44
0.05 0.71, 0.84, 0.84 0.52, 0.52, 0.56 0.37, 0.42, 0.44 0.29, 0.32, 0.33
0.025 0.50, 0.51, 0.56 0.32, 0.34, 0.38 0.20, 0.22, 0.24 0.16, 0.18, 0.20
0.010 0.36, 0.37, 0.41 0.22, 0.26, 0.27 0.14, 0.17, 0.18 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.6  2.3 0.89  0.05
100 32.1  3.2 0.87  0.03
200 70.5  6.9 0.91  0.04
300 98.0  9.8 0.83  0.08
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5-Ethylquinolinic acid (43)
N
Et CO2H
CO2H
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.6 mM inhibitor)
Rate (M min-1)
( 0.8 mM inhibitor)
Rate (M min-1)
(1.0 mM inhibitor)
0.3 0.85, 0.87, 0.90 0.85, 0.87, 0.89 0.79, 0.82, 0.84 0.72, 0.73, 0.74
0.2 0.82, 0.84, 0.88 0.83, 0.87, 0.89 0.67, 0.70, 0.75 0.53, 0.55, 0.65
0.1 0.79, 0.82, 0.84 0.67, 0.70, 0.74 0.57, 0.60, 0.64 0.44, 0.47, 0.50
0.05 0.72, 0.74, 0.78 0.59, 0.61, 0.64 0.47, 0.47, 0.48 0.34, 0.39, 0.42
0.025 0.55, 0.57, 0.63 0.43, 0.45, 0.47 0.34, 0.41, 0.43 0.20, 0.23, 0.26
0.010 0.36, 0.39, 0.42 0.15, 0.18, 0.22 0.08, 0.12, 0.14 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.4  1.0 0.92  0.01
600 33.2  2.9 0.98  0.04
800 44.9  5.9 0.90  0.06
1000 74.1  12.1 0.86  0.07
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5-Ethyl-N-methylquinolinic acid (46)
N CO2
Et
Me
CO2H
+ -
.H2O
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.6 mM inhibitor)
Rate (M min-1)
( 0.8 mM inhibitor)
Rate (M min-1)
(1.0 mM inhibitor)
0.3 0.85, 0.87, 0.90 0.88, 0.88, 0.89 0.83, 0.84, 0.85 0.77, 0.79, 0.80
0.2 0.82, 0.84, 0.88 0.79, 0.85, 0.87 0.75, 0.77, 0.79 0.62, 0.63, 0.69
0.1 0.79, 0.82, 0.84 0.71, 0.81, 0.83 0.62, 0.63, 0.70 0.55, 0.57, 0.60
0.05 0.72, 0.74, 0.78 0.63, 0.68, 0.70 0.52, 0.55, 0.57 0.40, 0.43, 0.45
0.025 0.55, 0.57, 0.63 0.45, 0.46, 0.46 0.34, 0.38, 0.41 0.25, 0.29, 0.31
0.010 0.36, 0.39, 0.42 0.20, 0.22, 0.27 0.15, 0.19, 0.21 0.11, 0.15, 0.18
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.4  1.0 0.92  0.01
600 26.8  2.5 0.97  0.02
800 37.5  3.3 0.93  0.02
1000 54.6  8.4 0.88  0.04
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Quinolinic acid N-oxide (62)
N
O
CO2H
CO2H
-
+
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.05 mM inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
0.3 0.85, 0.88, 0.89 0.86, 0.86, 0.88 0.83, 0.84, 0.87 0.77, 0.79, 0.81
0.2 0.87, 0.89, 0.90 0.79, 0.80, 0.82 0.75, 0.77, 0.80 0.65, 0.68, 0.72
0.1 0.83, 0.85, 0.87 0.66, 0.69, 0.72 0.58, 0.61, 0.65 0.50, 0.53, 0.55
0.05 0.72, 0.74, 0.77 0.49, 0.50, 0.56 0.40, 0.44, 0.47 0.28, 0.33, 0.35
0.025 0.56, 0.57, 0.59 0.35, 0.39, 0.40 0.27, 0.31, 0.33 0.17, 0.20, 0.24
0.010 0.39, 0.42, 0.46 0.25, 0.27, 0.30 0.15, 0.17, 0.22 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.6 0.94  0.02
50 35.7  3.5 0.94  0.03
100 60.7  5.1 1.00  0.03
200 111.0  10.0 1.07  0.04
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Phthalic acid (25)
CO2H
CO2H
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.05 mM inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.85, 0.85, 0.88 0.78, 0.81, 0.82 0.68, 0.69, 0.72
0.2 0.88, 0.91, 0.93 0.70, 0.71, 0.74 0.64, 0.65, 0.69 0.56, 0.56, 0.58
0.1 0.83, 0.84, 0.87 0.55, 0.55, 0.57 0.44, 0.45, 0.51 0.38, 0.42, 0.43
0.05 0.78, 0.79, 0.88 0.37, 0.43, 0.44 0.31, 0.34, 0.34 0.18, 0.19, 0.26
0.025 0.56, 0.57, 0.62 0.24, 0.29, 0.30 0.22, 0.22, 0.25 0.10, 0.11, 0.17
0.010 0.39, 0.39, 0.42 0.14, 0.15, 0.20 0.09, 0.10, 0.17 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
50 74.0  7.4 1.03  0.04
100 109.7  11.2 1.06  0.06
200 203.0  28.9 1.17  0.09
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2,3-Naphthalene dicarboxylic acid (104)
CO2H
CO2H
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.85, 0.87, 0.88 0.83, 0.84, 0.85 0.80, 0.82, 0.83
0.2 0.88, 0.91, 0.93 0.83, 0.84, 0.86 0.79, 0.80, 0.80 0.76, 0.79, 0.82
0.1 0.83, 0.84, 0.87 0.76, 0.78, 0.80 0.65, 0.67, 0.70 0.59, 0.62, 0.64
0.05 0.78, 0.79, 0.88 0.58, 0.62, 0.66 0.49, 0.53, 0.55 0.42, 0.46, 0.46
0.025 0.56, 0.57, 0.62 0.43, 0.45, 0.48 0.35, 0.37, 0.40 0.27, 0.30, 0.32
0.010 0.39, 0.39, 0.42 0.27, 0.29, 0.32 0.21, 0.24, 0.25 0.16, 0.20, 0.20
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 25.4  2.0 0.95  0.02
200 37.8  3.2 0.94  0.02
300 55.1  4.3 0.98  0.03
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Picolinic acid (26)
N CO2H
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.86, 0.88 0.86, 0.86, 0.87 0.82, 0.83, 0.84 0.78, 0.78, 0.82
0.2 0.88, 0.89, 0.90 0.78, 0.79, 0.85 0.76, 0.78, 0.80 0.71, 0.73, 0.75
0.1 0.82, 0.84, 0.88 0.74, 0.74, 0.76 0.64, 0.65, 0.68 0.59, 0.59, 0.60
0.05 0.73, 0.74, 0.74 0.59, 0.65, 0.66 0.47, 0.57, 0.59 0.37, 0.52, 0.54
0.025 0.53, 0.55, 0.62 0.40, 0.42, 0.44 0.28, 0.30, 0.34 0.20, 0.24, 0.26
0.010 0.39, 0.41, 0.45 0.18, 0.19, 0.22 0.08, 0.09, 0.11 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.1 0.94  0.02
100 30.6  2.5 0.96  0.02
200 51.4  6.1 0.99  0.04
300 69.8  8.9 0.99  0.05
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N-Methylpicolinic acid (50)
N
Me
CO2H+
.HSO4
-
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.86, 0.88 0.88, 0.89, 0.89 0.86, 0.86, 0.87 0.83, 0.84, 0.84
0.2 0.88, 0.89, 0.90 0.84, 0.86, 0.88 0.77, 0.80, 0.85 0.79, 0.80, 0.81
0.1 0.82, 0.84, 0.88 0.78, 0.79, 0.80 0.72, 0.79, 0.81 0.67, 0.75, 0.77
0.05 0.73, 0.74, 0.74 0.66, 0.66, 0.67 0.58, 0.59, 0.60 0.44, 0.47, 0.55
0.025 0.53, 0.55, 0.62 0.45, 0.47, 0.54 0.38, 0.40, 0.44 0.35, 0.37, 0.39
0.010 0.39, 0.41, 0.45 0.27, 0.32, 0.35 0.22, 0.24, 0.26 0.14, 0.16, 0.20
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.1 0.94  0.02
100 22.4  1.3 0.96  0.01
200 30.6  2.5 0.95  0.02
300 43.4  4.4 0.98  0.04
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N-Ethylpicolinic acid (51)
N
Et
CO2H+
.HSO4
-
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.86, 0.88 0.86, 0.87, 0.87 0.84, 0.86, 0.87 0.83, 0.84, 0.87
0.2 0.88, 0.89, 0.90 0.85, 0.86, 0.87 0.82, 0.85, 0.86 0.80, 0.85, 0.87
0.1 0.82, 0.84, 0.88 0.76, 0.77, 0.79 0.70, 0.75, 0.76 0.67, 0.69, 0.71
0.05 0.73, 0.74, 0.74 0.57, 0.60, 0.65 0.52, 0.55, 0.59 0.48, 0.49, 0.55
0.025 0.53, 0.55, 0.62 0.47, 0.51, 0.53 0.42, 0.44, 0.46 0.31, 0.33, 0.37
0.010 0.39, 0.41, 0.45 029, 0.31, 0.33 0.25, 0.27, 0.28 0.19, 0.22, 0.24
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.1 0.94  0.02
100 22.5  1.5 0.94  0.02
200 29.7  2.2 0.95  0.03
300 44.6  3.8 0.99  0.03
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Picolinic acid N-oxide (105)
N
O
CO2H
-
+
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.85, 0.88, 0.89 0.84, 0.84, 0.88 0.81, 0.83, 0.85 0.75, 0.76, 0.78
0.2 0.87, 0.89, 0.90 0.83, 0.85, 0.87 0.75, 0.77, 0.80 0.68, 0.71, 0.74
0.1 0.83, 0.85, 0.87 0.80, 0.85, 0.87 0.59, 0.69, 0.71 0.60, 0.65, 0.66
0.05 0.72, 0.74, 0.77 0.59, 0.63, 0.67 0.50, 0.52, 0.55 0.43, 0.46, 0.48
0.025 0.56, 0.57, 0.59 0.47, 0.50, 0.51 0.36, 0.38, 0.41 0.25, 0.29, 0.33
0.010 0.39, 0.42, 0.46 0.27, 0.28, 0.33 0.18, 0.22, 0.26 0.12, 0.15, 0.17
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.6 0.94  0.02
100 22.6  2.1 0.95  0.02
200 35.6  2.4 0.91  0.02
300 47.0  4.6 0.89  0.03
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Quinoline-2-carboxylic acid (52)
N CO2H
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
Rate (M min-1)
( 0.5 mM inhibitor)
Rate (M min-1)
(0.7 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.90, 0.91, 0.91 0.88, 0.90, 0.91 0.84, 0.85, 0.87
0.2 0.88, 0.91, 0.93 0.88, 0.92, 0.94 0.84, 0.88, 0.90 0.79, 0.84, 0.85
0.1 0.83, 0.84, 0.87 0.76, 0.78, 0.80 0.63, 0.65, 0.72 0.56, 0.60, 0.63
0.05 0.78, 0.79, 0.88 0.55, 0.57, 0.66 0.51, 0.55, 0.60 0.42, 0.45, 0.48
0.025 0.56, 0.57, 0.62 0.42, 0.46, 0.48 0.27, 0.28, 0.36 0.24, 0.26, 0.28
0.010 0.39, 0.39, 0.42 0.20, 0.23, 0.24 0.15, 0.17, 0.20 0.08, 0.11, 0.16
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
300 35.2  2.6 1.04  0.02
500 56.3  5.6 1.09  0.05
700 76.4  6.8 1.10  0.08
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N-Methylquinoline-2-carboxylic acid (55)
N
Me
CO2H+
.HSO4
-
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
Rate (M min-1)
( 0.5 mM inhibitor)
Rate (M min-1)
(0.7 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.90, 0.90, 0.91 0.88, 0.89, 0.91 0.82, 0.86, 0.89
0.2 0.88, 0.91, 0.93 0.89, 0.89, 0.91 0.85, 0.88, 0.90 0.80, 0.84, 0.87
0.1 0.83, 0.84, 0.87 0.78, 0.80, 0.84 0.73, 0.75, 0.77 0.66, 0.69, 0.72
0.05 0.78, 0.79, 0.88 0.62, 0.64, 0.67 0.52, 0.55, 0.60 0.45, 0.48, 0.52
0.025 0.56, 0.57, 0.62 0.50, 0.50, 0.51 0.42, 0.44, 0.48 0.34, 0.37, 0.39
0.010 0.39, 0.39, 0.42 0.26, 0.28, 0.30 0.18, 0.20, 0.24 0.14, 0.16, 0.20
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
300 25.5  1.7 1.00  0.02
500 35.5  2.7 1.01  0.03
700 49.0  4.0 1.02  0.03
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Adenosine 5’-monophosphate (107) - Inhibition with respect to quinolinic acid
N
N
O
OHOH
PiO
N
N
NH2
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
( 0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.77, 0.79, 0.84 0.67, 0.69, 0.70 0.58, 0.65, 0.68
0.2 0.88, 0.91, 0.93 0.70, 0.72, 0.78 0.65, 0.67, 0.69 0.54, 0.57, 0.61
0.1 0.83, 0.84, 0.87 0.68, 0.68, 0.71 0.57, 0.59, 0.63 0.48, 0.50, 0.54
0.05 0.78, 0.79, 0.88 0.57, 0.60, 0.64 0.51, 0.53, 0.55 0.42, 0.44, 0.48
0.025 0.56, 0.57, 0.62 0.47, 0.51, 0.55 0.42, 0.48, 0.52 0.35, 0.36, 0.42
0.010 0.39, 0.39, 0.42 0.34, 0.36, 0.38 0.27, 0.30, 0.33 0.25, 0.28, 0.31
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 13.7  1.8 0.80  0.02
200 13.9  1.4 0.71  0.02
300 15.3  3.3 0.62  0.03
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Adenosine 5’-monophosphate (107) - Inhibition with respect to PRPP
N
N
O
OHOH
PiO
N
N
NH2
[PRPP] (mM) Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
Rate (M min-1)
( 0.5 mM inhibitor)
Rate (M min-1)
(0.7 mM inhibitor)
0.3 0.90, 0.92, 0.94 0.83, 0.85, 0.88 0.79, 0.80, 0.82 0.70, 0.72, 0.75
0.2 0.83, 0.85, 0.91 0.81, 0.81, 0.84 0.74, 0.78, 0.83 0.64, 0.68, 0.71
0.1 0.81, 0.89, 0.91 0.61, 0.62, 0.68 0.55, 0.57, 0.63 0.51, 0.53, 0.54
0.05 0.65, 0.67, 0.71 0.53, 0.55, 0.58 0.43, 0.46, 0.51 0.36, 0.39, 0.41
0.025 0.45, 0.48, 0.53 0.30, 0.32, 0.37 0.24, 0.26, 0.33 0.16, 0.20, 0.24
0.010 0.29, 0.34, 0.37 0.17, 0.19, 0.22 0.11, 0.15, 0.18 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.03
300 44.9  4.0 0.98  0.04
500 58.2  5.9 0.97  0.04
700 73.7  7.6 0.92  0.04
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Guanosine 5’-monophosphate (108) - Inhibition with respect to quinolinic acid
N
N
O
OHOH
PiO
N
NH
O
NH2
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
( 0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.78, 0.82, 0.85 0.68, 0.71, 0.72 0.61, 0.64, 0.66
0.2 0.88, 0.91, 0.93 0.75, 0.77, 0.77 0.64, 0.68, 0.72 0.56, 0.58, 0.60
0.1 0.83, 0.84, 0.87 0.68, 0.70, 0.73 0.58, 0.60, 0.63 0.49, 0.52, 0.55
0.05 0.78, 0.79, 0.88 0.60, 0.62, 0.66 0.51, 0.55, 0.57 0.45, 0.48, 0.50
0.025 0.56, 0.57, 0.62 0.50, 0.53, 0.55 0.45, 0.47, 0.51 0.33, 0.36, 0.43
0.010 0.39, 0.39, 0.42 0.36, 0.38, 0.41 0.29, 0.32, 0.34 0.26, 0.29, 0.31
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 13.0  1.6 0.82  0.02
200 13.1  1.3 0.72  0.02
300 14.9  2.0 0.63  0.03
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Guanosine 5’-monophosphate (108) - Inhibition with respect to PRPP
N
N
O
OHOH
PiO
N
NH
O
NH2
[PRPP] (mM) Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
Rate (M min-1)
( 0.5 mM inhibitor)
Rate (M min-1)
(0.7 mM inhibitor)
0.3 0.90, 0.92, 0.94 0.85, 0.86, 0.88 0.80, 0.83, 0.85 0.75, 0.78, 0.79
0.2 0.83, 0.85, 0.91 0.80, 0.83, 0.84 0.76, 0.78, 0.79 0.70, 0.72, 0.73
0.1 0.81, 0.89, 0.91 0.68, 0.71, 0.74 0.61, 0.64, 0.65 0.55, 0.61, 0.62
0.05 0.65, 0.67, 0.71 0.53, 0.55, 0.58 0.46, 0.49, 0.52 0.40, 0.43, 0.44
0.025 0.45, 0.48, 0.53 0.34, 0.38, 0.40 0.26, 0.30, 0.33 0.21, 0.22, 0.25
0.010 0.29, 0.34, 0.37 0.18, 0.20, 0.23 0.13, 0.16, 0.19 0.08, 0.10, 0.13
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.03
300 39.6  2.1 0.98  0.02
500 53.2  3.4 0.98  0.02
700 69.7  5.7 0.97  0.04
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Cytidine 5’-monophosphate (109) - Inhibition with respect to quinolinic acid
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
( 0.2 mM inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.74, 0.78, 0.80 0.63, 0.63, 0.64 0.51, 0.57, 0.59
0.2 0.88, 0.91, 0.93 0.68, 0.68, 0.74 0.58, 0.60, 0.63 0.50, 0.53, 0.55
0.1 0.83, 0.84, 0.87 0.63, 0.65, 0.68 0.53, 0.56, 0.60 0.48, 0.49, 0.51
0.05 0.78, 0.79, 0.88 0.53, 0.56, 0.58 0.45, 0.47, 0.53 0.40, 0.44, 0.47
0.025 0.56, 0.57, 0.62 0.45, 0.47, 0.49 0.37, 0.40, 0.43 0.29, 0.32, 0.37
0.010 0.39, 0.39, 0.42 0.32, 0.36, 0.39 0.28, 0.32, 0.36 0.24, 0.27, 0.34
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 13.9  2.6 0.76  0.03
200 12.3  2.1 0.63  0.02
300 13.4  2.6 0.56  0.02
N
N
O
OHOH
PiO
O
NH2
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Cytidine 5’-monophosphate (109) - Inhibition with respect to PRPP
N
N
O
OHOH
PiO
O
NH2
[PRPP] (mM) Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
Rate (M min-1)
( 0.5 mM inhibitor)
Rate (M min-1)
(0.7 mM inhibitor)
0.3 0.90, 0.92, 0.94 0.83, 0.86, 0.90 0.79, 0.82, 0.84 0.73, 0.75, 0.78
0.2 0.83, 0.85, 0.91 0.77, 0.80, 0.82 0.69, 0.72, 0.75 0.65, 0.68, 0.70
0.1 0.81, 0.89, 0.91 0.59, 0.60, 0.68 0.55, 0.58, 0.60 0.50, 0.55, 0.56
0.05 0.65, 0.67, 0.71 0.49, 0.53, 0.55 0.42, 0.44, 0.47 0.33, 0.39, 0.41
0.025 0.45, 0.48, 0.53 0.30, 0.33, 0.37 0.21, 0.26, 0.30 0.16, 0.19, 0.21
0.010 0.29, 0.34, 0.37 0.17, 0.19, 0.22 0.08, 0.10, 0.13 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.03
300 48.3  4.4 0.98  0.04
500 70.0  6.0 1.00  0.03
700 88.6  9.0 0.98  0.04
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Thymidine 5’-monophosphate (110) - Inhibition with respect to quinolinic acid
N
NH
O
OHOH
PiO
O
CH3
O
[Quinolinic acid]
(mM)
Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.1 mM inhibitor)
Rate (M min-1)
(0.2 mM inhibitor)
Rate (M min-1)
( 0.3 mM inhibitor)
0.3 0.86, 0.87, 0.87 0.69, 0.74, 0.76 0.64, 0.68, 0.71 0.53, 0.62, 0.64
0.2 0.88, 0.91, 0.93 0.62, 0.65, 0.71 0.54, 0.56, 0.58 0.41, 0.43, 0.50
0.1 0.83, 0.84, 0.87 0.61, 0.63, 0.65 0.48, 0.52, 0.54 0.43, 0.46, 0.48
0.05 0.78, 0.79, 0.88 0.50, 0.52, 0.55 0.44, 0.46, 0.49 0.39, 0.42, 0.44
0.025 0.56, 0.57, 0.62 0.40, 0.42, 0.48 0.33, 0.37, 0.41 0.29, 0.32, 0.35
0.010 0.39, 0.39, 0.42 0.30, 0.31, 0.36 0.26, 0.30, 0.32 0.21, 0.24, 0.28
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 13.5  1.4 0.96  0.02
100 15.6  2.7 0.73  0.02
200 15.9  2.8 0.64  0.02
300 15.6  3.5 0.55  0.03
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Thymidine 5’-monophosphate (110) - Inhibition with respect to PRPP
N
NH
O
OHOH
PiO
O
CH3
O
[PRPP] (mM) Rate (M min-1)
(No inhibitor)
Rate (M min-1)
(0.3 mM inhibitor)
Rate (M min-1)
( 0.5 mM inhibitor)
Rate (M min-1)
(0.7 mM inhibitor)
0.3 0.90, 0.92, 0.94 0.86, 0.88, 0.91 0.81, 0.82, 0.85 0.76, 0.78, 0.80
0.2 0.83, 0.85, 0.91 0.77, 0.79, 0.82 0.73, 0.75, 0.77 0.64, 0.67, 0.69
0.1 0.81, 0.89, 0.91 0.55, 0.58, 0.68 0.58, 0.60, 0.63 0.51, 0.53, 0.54
0.05 0.65, 0.67, 0.71 0.51, 0.51, 0.53 0.41, 0.44, 0.47 0.33, 0.37, 0.41
0.025 0.45, 0.48, 0.53 0.32, 0.33, 0.38 0.24, 0.27, 0.32 0.18, 0.20, 0.24
0.010 0.29, 0.34, 0.37 0.15, 0.17, 0.20 0.08, 0.10, 0.13 -
[Inhibitor] (M) Km(app) (M) Vmax(app) (M min-1)
0 22.1  2.3 0.99  0.04
300 51.2  5.5 1.00  0.03
500 68.6  4.9 1.02  0.03
700 88.8  7.6 1.00  0.03
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7.4 Synthesis of potential inhibitors of human brain QPRTase
7.4.1 General methods
NMR data were collected using a Bruker AV-300 operating at 300 MHz for 1H and
75.46 MHz for 13C. Chemical shifts for proton and carbon resonances are reported in
ppm relative to chloroform (δ 7.25, 77.0 respectively), methanol (δ 3.35, 49.0
respectively), dimethylsulfoxide (δ 2.5, 39.7 respectively) or water (δ 4.70). The
coupling constants are given in Hz. The multiplicity is given as follows, singlet: s,
doublet: d, triplet: t, quartet: q, multiplet: m, doublet of doublets: dd, doublet of
doublets of doublets: ddd, triplet of doublets: td, broad signal: br.
Electrospray mass spectra were recorded on a Micromass LCT spectrometer.
Dominant fractions are reported as percentages of the base peak intensity.
Infrared spectra were recorded on a Perkin-Elmer 1420 spectrophotometer. The
samples were prepared as nujol mulls (solids) or as thin films (liquids) between
sodium chloride plates. Absorption maxima are reported in wavenumbers (cm-1).
Elemental analyses were carried out by the University of St Andrews microanalytical
laboratory.
Melting points were determined using Gallenkamp melting point apparatus and are
uncorrected.
Thin layer chromatography was performed on 0.20 mm silica gel plates (60F 245)
(Allied signal).
Flash chromatography was performed according to the procedure of Still et al. using
sorbisil C60 (40-60 mm mesh) silica gel.4
Solvents were dried and purified according to the methods of Perrin and Armarego.5
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7.4.2 Synthesis of N-substituted compounds
Synthesis of dimethyl quinolinate (38)
N
CO2Me
CO2Me
38
To a suspension of quinolinic acid (12.06 g, 72 mmol) in methanol (100 mL) was
added concentrated sulfuric acid (12 mL), dropwise with stirring. Upon heating,
quinolinic acid dissolved and the resulting solution was heated under reflux overnight.
The reaction was quenched by pouring on to crushed ice. Concentrated ammonia
solution was added until the solution was strongly alkaline (pH 10). The product was
then extracted with diethyl ether (3 × 150 mL). The combined diethyl ether extracts
were dried (MgSO4) and the solvent was removed under reduced pressure to give
a white solid (7.90 g). The crude product was recrystallised from methanol
to give the pure product as a white crystalline solid (7.58 g, 54%); mp 55-56 C
(lit.6 52-53 C); max (nujol / cm-1) 1760 (C=O stretch); δH (300 MHz; CDCl3) 3.94
(3 H, s, CO2CH3), 4.01 (3 H, s, CO2CH3), 7.50 (1 H, dd, J5,6 5 and J4,5 8, H-5),
8.17 (1 H, dd, J4,6 2 and J4,5 8, H-4) and 8.77 (1 H, dd, J4,6 2 and J5,6 5, H-6);
δC (75.46 MHz; CDCl3) 53.4 (CO2CH3), 53.5 (CO2CH3), 125.5 (C-5), 126.9 (C-3),
138.0 (C-4), 151.1 (C-6), 152.2 (C-2), 166.2 (CO2CH3) and 167.0 (CO2CH3);
m/z (ES+) 218 ((M+Na)+, 100%) and 196 ((M+H)+, 8%).
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Synthesis of N-methylquinolinic acid (41)
N
Me
CO2Me
CO2Me
CH3OSO3
N
CO2Me
CO2Me N
Me
CO2
CO2H
+
-
-
+
.H2O
38 39 41
conc. HCl
reflux
(MeO)2SO2
70 oC
Dimethyl sulfate (1.1 mL, 12 mmol) was added slowly, with stirring, to dimethyl
quinolinate 38 (2.33 g, 12 mmol) and the reaction was heated at 70 °C for 2 hours
under a nitrogen atmosphere. Upon cooling, the reaction mixture crystallised,
forming a white solid. 1H and 13C NMR spectroscopy showed the reaction
had reached completion and the desired product 39 had been formed exclusively.
δH (300 MHz; CDCl3) 3.60 (3 H, s, CH3OSO3-), 3.97 (3 H, s, CO2CH3), 4.09 (3 H, s,
CO2CH3), 4.50 (3 H, s, NCH3), 8.42 (1 H, dd, J5,6 6 and J4,5 8, H-5), 9.00 (1 H, dd,
J4,6 1 and J4,5 8, H-4) and 9.77 (1 H, dd, J4,6 1 and J5,6 6, H-6); δC (75.46 MHz; CDCl3)
50.2 (CH3OSO3-), 53.1 (CO2CH3), 53.4 (CO2CH3), 58.0 (NCH3), 131.8 (C-5), 132.2
(C-3), 149.3 (C-4), 150.6 (C-6), 153.1 (C-2), 163.6 (CO2CH3) and 165.1 (CO2CH3).
The intermediate dimethyl N-methylquinolinate 39 (3.75 g) was then dissolved in
concentrated hydrochloric acid (30 mL) and the resulting solution was heated under
reflux (100 °C) for 3 hours. Excess hydrochloric acid was removed under reduced
pressure to give a white solid. Recrystallisation from water gave the product 41 as
white crystals (1.94 g, 81%, over 2 steps); mp 156-158 C; (Found: C 48.55; H 4.60;
N 7.02. Calc. For C8H9NO5: C 48.25; H 4.55; N 7.02%); max (nujol / cm-1) 3000
(O─H stretch) and 1750 (C=O stretch); δH (300 MHz; D2O) 4.36 (3 H, s, NCH3), 8.15
(1 H, dd, J5,6 6 and J4,5 8, H-5), 9.03 (1 H, dd, J4,6 1 and J4,5 8, H-4) and 9.06 (1 H, dd,
J4,6 1 and J5,6 6, H-6); δC (75.46 MHz; d6-DMSO) 49.6 (NCH3), 128.9 (C-5),
131.6 (C-3), 150.1 (C-4), 150.3 (C-6), 150.6 (C-2), 161.1 (CO2H) and 161.9 (CO2H);
m/z (ES+) 182 (M+, 100%).
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Synthesis of N-ethylquinolinic acid (42)
N
CO2Me
CO2Me N
Et
CO2Me
CO2Me N
Et
CO2
CO2H
+
-CH3CH2OSO3
+
.H2O
-
conc. HCl
reflux
(EtO)2SO2
70 oC
38 40 42
Diethyl sulfate (1.5 mL, 12 mmol) was added slowly, with stirring, to dimethyl
quinolinate 38 (2.33 g, 12 mmol) and the reaction was heated at 70 °C overnight
under a nitrogen atmosphere. The reaction was then allowed to cool to room
temperature. 1H and 13C NMR spectroscopy showed the reaction had reached
completion and the desired product 40 had been formed exclusively. δH (300 MHz;
CDCl3) 1.26 (3 H, t, J 7, CH3CH2OSO3-), 1.71 (3 H, t, J 8, CH3CH2N), 3.98 (3 H, s,
CO2CH3), 4.05 (3 H, s, CO2CH3), 4.10 (2 H, q, J 7, CH3CH2OSO3-), 4.78 (2 H, q,
J 8, CH3CH2N), 8.55 (1 H, dd, J5,6 6 and J4,5 8, H-5), 9.10 (1 H, dd, J4,6 1 and
J4,5 8, H-4) and 9.63 (1 H, dd, J4,6 1 and J5,6 6, H-6); δC (75.46 MHz; CDCl3)
15.6 (CH3CH2OSO3-), 17.6 (CH3CH2N), 53.0 (CO2CH3), 53.2 (CO2CH3), 53.4
(CH3CH2OSO3-), 65.6 (CH3CH2N), 129.0 (C-5), 131.1 (C-3), 146.9 (C-4), 147.7
(C-6), 151.0 (C-2), 160.1 (CO2CH3) and 161.1 (CO2CH3).
The intermediate dimethyl N-ethylquinolinate 40 (4.10 g) was then dissolved in
concentrated hydrochloric acid (30 mL) and the resulting solution was heated under
reflux (100 °C) for 3 hours. Excess hydrochloric acid was removed under reduced
pressure to produce a white solid. Recrystallisation from water gave the product 42 as
white crystals (2.02 g, 79%, over 2 steps); mp 145-147 C; (Found: C 50.89; H 5.03;
N 6.47. Calc. For C9H11NO5: C 50.71; H 5.20; N 6.57%); max (nujol / cm-1) 3020
(O─H stretch) and 1720 (C=O stretch); δH (300 MHz; D2O) 1.50 (3 H, t, J 7,
NCH2CH3), 4.53 (2 H, q, J 7, NCH2CH3), 7.96 (1 H, dd, J5,6 6 and J4,5 8, H-5),
8.85 (1 H, dd, J4,6 1 and J4,5 8, H-4) and 8.89 (1 H, dd, J4,6 1 and J5,6 6, H-6);
δC (75.46 MHz; d6-DMSO) 18.8 (NCH2CH3), 58.6 (NCH2CH3), 129.2 (C-5), 129.4
(C-3), 148.5 (C-4), 150.2 (C-6), 150.5 (C-2), 166.0 (CO2H) and 166.7 (CO2H);
m/z (ES+) 196 (M+, 100%).
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Synthesis of dimethyl 5-ethylquinolinate (44)7
N
CO2Me
CO2Me
44
To a suspension of 5-ethylquinolinic acid (2.50 g, 13 mmol) in methanol (30 mL) was
added concentrated sulfuric acid (3 mL), dropwise with stirring. The resulting
solution was heated under reflux overnight. The solution was then cooled and poured
on to crushed ice. Concentrated ammonia solution was added until the solution
was strongly alkaline (pH 10). The product was then extracted with diethyl ether
(3 × 60 mL). The combined diethyl ether extracts were dried (MgSO4) and the
solvent was removed under reduced pressure to give a yellow oil (1.60 g). The crude
product was purified by column chromatography on silica with dichloromethane /
ethyl acetate (4:1) as the eluting solvent. This gave the desired product as a colourless
oil (1.38 g, 48%); max (nujol / cm-1) 1750 (C=O stretch); δH (300 MHz; CDCl3) 1.28
(3H, t, J 8, CH3CH2), 2.74 (2 H, q, J 8, CH3CH2), 3.91 (3 H, s, CO2CH3), 3.97 (3 H,
s, CO2CH3), 7.92 (1 H, d, J4,6 2, H-4) and 8.56 (1 H, d, J4,6 2, H-6); δC (75.46 MHz;
CDCl3) 15.2 (CH3CH2), 26.1 (CH3CH2), 53.3 (CO2CH3), 53.4 (CO2CH3), 127.4 (C-5),
136.8 (C-3), 141.9 (C-4), 147.8 (C-6), 151.7 (C-2), 166.8 (CO2CH3) and 166.9
(CO2CH3); m/z (ES+) 246 ((M+Na)+, 100%) and 224 ((M+H)+, 8%).
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Synthesis of 5-ethyl-N-methylquinolinic acid (46)
N
CO2Me
CO2Me
Et
N
CO2Me
CO2Me
Et
Me
CH3OSO3
N CO2
Et
Me
CO2H
+
-
+ -
.H2O
conc. HCl
reflux
(MeO)2SO2
70 oC
44 45 46
Dimethyl sulfate (0.4 mL, 4.5 mmol) was added slowly, with stirring, to dimethyl
5-ethylquinolinate 44 (1.00 g, 4.5 mmol) and the reaction was heated at 70 °C
overnight under a nitrogen atmosphere. The reaction was then allowed to cool to
room temperature. 1H and 13C NMR spectroscopy showed the reaction had reached
completion and the desired product 45 had been formed exclusively. δH (300 MHz;
CDCl3) 1.19 (3H, t, J 8, CH3CH2), 2.83 (2 H, q, J 8, CH3CH2), 3.59 (3H, s,
CH3OSO3-), 3.89 (3 H, s, CO2CH3), 4.01 (3 H, s, CO2CH3), 4.23 (3 H, s, NCH3), 8.85
(1 H, d, J4,6 2, H-4) and 8.89 (1 H, d, J4,6 2, H-6); δC (75.46 MHz; CDCl3) 13.6
(CH3CH2), 25.8 (CH3CH2), 47.0 (CH3OSO3-), 54.6 (CO2CH3), 55.6 (CO2CH3), 56.7
(NCH3), 128.8 (C-5), 136.2 (C-3), 146.7 (C-4), 147.1 (C-6), 149.3 (C-2), 161.9
(CO2CH3) and 163.3 (CO2CH3).
The intermediate dimethyl 5-ethyl-N-methylquinolinate 45 (1.50 g) was then
dissolved in concentrated hydrochloric acid (20 mL) and the resulting solution was
heated under reflux (100 °C) for 3 hours. Excess hydrochloric acid was removed
under reduced pressure to give a white solid. Recrystallisation from water
gave the product 46 as white crystals (0.91 g, 89%, over 2 steps); mp 177-179 C;
(Found: C 52.98; H 5.70; N 6.07. Calc. For C10H13NO5: C 52.86; H 5.73; N 6.17%);
max (nujol / cm-1) 3000 (O─H stretch) and 1710 (C=O stretch); δH (300 MHz; D2O)
1.15 (3H, t, J 8, CH3CH2), 2.74 (2 H, q, J 8, CH3CH2), 4.14 (3 H, s, NCH3), 8.59
(1 H, d, J4,6 2, H-4) and 8.72 (1 H, d, J4,6 2, H-6); δC (75.46 MHz; d6-DMSO) 13.7
(CH3CH2), 25.4 (CH3CH2), 46.3 (NCH3), 127.5 (C-5), 137.0 (C-3), 143.8 (C-4), 147.1
(C-6), 151.3 (C-2), 165.3 (CO2CH3) and 165.8 (CO2CH3); m/z (ES+) 210 (M+, 100%).
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Synthesis of methyl picolinate (47)8
N CO2Me
47
To a suspension of picolinic acid (8.85 g, 72 mmol) in methanol (100 mL) was added
concentrated sulfuric acid (12 mL), dropwise with stirring. Upon heating, picolinic
acid dissolved and the resulting solution was heated under reflux overnight. The
reaction was quenched by pouring on to crushed ice. Concentrated ammonia solution
was added until the solution was strongly alkaline (pH 10). The product was then
extracted with diethyl ether (3 × 150 mL). The combined diethyl ether extracts were
dried (MgSO4) and the solvent was removed under reduced pressure to give a yellow
oil (7.03 g). The crude product was purified by column chromatography on silica
with dichloromethane / ethyl acetate (4:1) as the eluting solvent. This gave the
desired product as a colourless oil (6.80g, 69%); max (nujol / cm-1) 1710 (C=O
stretch); δH (300 MHz; CD3OD) 3.58 (3 H, s, CO2CH3), 7.20 (1 H, ddd, J3,5 1.5, J5,6 5
and J4,5 8, H-5), 7.48 (1 H, td, J4,6 2 and J3,4 = J4,5 8, H-4), 7.53 (1 H, ddd, J3,6 1, J3,5 1.5
and J3,4 8, H-3) and 7.97 (1 H, ddd, J3,6 1, J4,6 2 and J5,6 5, H-6); δC (75.46 MHz;
CDCl3) 52.9 (CO2CH3), 128.9 (C-5), 129.7 (C-3), 138.0 (C-4), 151.1 (C-6), 152.2
(C-2) and 167.0 (CO2CH3); m/z (ES+) 160 ((M+Na)+, 100%) and 138 ((M+H)+, 10%).
Chapter Seven Experimental
267
Synthesis of N-methylpicolinic acid (50)
N CO2Me N
Me
CO2Me
CH3OSO3
N
Me
CO2H+
-
+
.HSO4
-conc. HCl
reflux
(MeO)2SO2
70 oC
47 48 50
Dimethyl sulfate (1.1 mL, 12 mmol) was added slowly, with stirring, to methyl
picolinate 47 (1.64 g, 12 mmol) and the reaction was heated at 70 °C for 6 hours
under a nitrogen atmosphere. Upon cooling, the reaction mixture crystallised,
forming a white solid. 1H and 13C NMR spectroscopy showed the reaction had
reached completion and the desired product 48 had been formed exclusively.
δH (300 MHz; CDCl3) 3.49 (3 H, s, CH3OSO3-), 4.11 (3 H, s, CO2CH3), 4.60 (3 H, s,
NCH3), 7.38-7.40 (1 H, m, H-5), 7.73 (1 H, dd, J3,5 1 and J3,4 8, H-3), 8.04 (1 H, td,
J4,6 1 and J3,4 = J4,5 8, H-4) and 8.65 (1 H, dd, J4,6 1 and J5,6 6, H-6); δC (75.46 MHz;
CDCl3) 49.1 (CH3OSO3-), 53.1 (CO2CH3), 54.0 (NCH3), 130.3 (C-5), 130.8 (C-3),
142.5 (C-4), 147.2 (C-6), 150.0 (C-2) and 159.6 (CO2CH3).
The intermediate methyl N-methylpicolinate 48 (3.10 g) was then dissolved in
concentrated hydrochloric acid (25 mL) and the resulting solution was heated under
reflux (100 °C) for 2 hours. Excess hydrochloric acid was removed under reduced
pressure to give a white solid. Recrystallisation from methanol gave the product 50
as white crystals (2.59 g, 92%, over 2 steps); mp 169-172 C (lit.9 170-173 C);
(Found: C 35.64; H 3.74; N 5.91. Calc. For C7H9NSO6: C 35.74; H 3.85; N 5.95%);
max (nujol / cm-1) 3050 (O─H stretch) and 1760 (C=O stretch); δH (300 MHz; D2O)
4.24 (3 H, s, NCH3), 7.83-7.86 (1 H, m, H-5), 7.99 (1 H, dd, J3,5 1 and J3,4 8, H-3),
8.39 (1 H, td, J4,6 1 and J3,4 = J4,5 8, H-4) and 8.59 (1 H, dd, J4,6 1 and J5,6 6, H-6);
δC (75.46 MHz; d6-DMSO) 50.7 (NCH3), 131.6 (C-5), 132.0 (C-3), 147.5 (C-4), 149.1
(C-6), 150.5 (C-2) and 164.9 (CO2H); m/z (ES+) 138 (M+, 100%).
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Synthesis of N-ethylpicolinic acid (51)
N CO2Me N
Et
CO2Me
CH3CH2OSO3
N
Et
CO2H+
-
+
.HSO4
-conc. HCl
reflux
(EtO)2SO2
70 oC
47 49 51
Diethyl sulfate (1.5 mL, 12 mmol) was added slowly, with stirring, to methyl
picolinate 47 (1.64 g, 12 mmol) and the reaction was heated at 70 °C overnight under
a nitrogen atmosphere. The reaction was then allowed to cool to room temperature.
1H and 13C NMR spectroscopy showed the reaction had reached completion and the
desired product 49 had been formed exclusively. δH (300 MHz; CDCl3) 1.47 (3 H, t,
J 8, CH3CH2OSO3-), 1.68 (3 H, t, J 8, CH3CH2N), 3.97 (3 H, s, CO2CH3), 4.54 (2 H,
q, J 8, CH3CH2OSO3-), 5.06 (2 H, q, J 8, CH3CH2N), 8.38-8.41 (1 H, m, H-5), 8.47
(1 H, dd, J3,5 1 and J3,4 8, H-3), 8.76 (1 H, td, J4,6 1 and J3,4 = J4,5 8, H-4) and 9.50
(1 H, dd, J4,6 1 and J5,6 6, H-6); δC (75.46 MHz; CDCl3) 15.4 (CH3CH2OSO3-), 17.4
(CH3CH2N), 53.1 (CO2CH3), 58.5 (CH3CH2OSO3-), 65.1 (CH3CH2N), 131.1 (C-5),
132.0 (C-3), 142.5 (C-4), 147.8 (C-6), 149.3 (C-2) and 159.9 (CO2CH3).
The intermediate methyl N-ethylpicolinate 49 (3.40 g) was then dissolved in
concentrated hydrochloric acid (25 mL) and the resulting solution was heated under
reflux (100 °C) for 2 hours. Excess hydrochloric acid was removed under reduced
pressure to give a white solid. Recrystallisation from methanol gave the product 51 as
white crystals (2.00 g, 67%, over 2 steps); 230-232 C; (Found: C 38.45; H 4.52;
N 5.66. Calc. For C8H11NSO6: C 38.55; H 4.42; N 5.62%); max (nujol / cm-1) 3000
(O─H stretch) and 1720 (C=O stretch); δH (300 MHz; D2O) 1.42 (3 H, t, J 7,
NCH2CH3), 4.58 (2 H, q, J 7, NCH2CH3) 7.84-7.87 (1 H, m, H-5), 7.92 (1 H, dd, J3,5 1
and J3,4 8, H-3), 8.37 (1 H, td, J4,6 1 and J3,4 = J4,5 8, H-4) and 8.64 (1 H, dd, J4,6 1 and
J5,6 6, H-6); δC (75.46 MHz; d6-DMSO) 18.6 (CH3CH2N), 58.6 (CH3CH2N), 130.8
(C-5), 131.5 (C-3), 148.3 (C-4), 149.0 (C-6), 150.9 (C-2) and 166.6 (CO2H);
m/z (ES+) 152 (M+, 100%).
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Synthesis of methyl quinoline-2-carboxylate (53)
N CO2Me
53
To a suspension of quinoline-2-carboxylic acid (5.00 g, 29 mmol) in methanol
(40 mL) was added concentrated sulfuric acid (4 mL), dropwise with stirring. The
resulting solution was heated under reflux overnight. The solution was then cooled
and poured on to crushed ice. Upon addition of concentrated ammonia solution, a
white solid precipitated from solution and was collected by filtration. The crude
product was recrystallised from methanol to give the pure product as a white
crystalline solid (4.50 g, 83%); mp 81-83 C (lit.10 78 C); max (nujol / cm-1) 1740
(C=O stretch); δH (300 MHz; CDCl3) 4.03 (3 H, s, CO2CH3), 7.56-7.63 (1 H, m, H-6),
7.70-7.77 (1 H, m, H-7), 8.14 (1 H, d, J3,4 8, H-3), 8.20 (1 H, dd, J5,7 1.5 and J5,6 8,
H-5), 8.26 (1 H, dd, J6,8 1.5 and J7,8 8, H-8) and 8.42 (1 H, d, J3,4 8, H-4);
δC (75.46 MHz; CDCl3) 53.3 (CO2CH3), 121.0 (C-3), 127.6 (C-6), 128.7 (C-5), 129.4
(C-4a), 130.4 (C-8), 130.7 (C-7), 137.4 (C-4), 147.5 (C-8a), 147.9 (C-2) and 165.9
(CO2CH3); m/z (ES+) 210 ((M+Na)+, 100%) and 188 ((M+H)+, 10%).
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Synthesis of N-methylquinoline-2-carboxylic acid (55)11
N CO2Me
CH3OSO3
N CO2Me
Me
N
Me
CO2H+
-
+
.HSO4
-conc. HCl
reflux
(MeO)2SO2
70 oC
53 54 55
Dimethyl sulfate (1.0 mL, 10.7 mmol) was added slowly, with stirring, to methyl
quinoline-2-carboxylate 53 (2.00 g, 10.7 mmol) and the reaction was heated at 70 °C
overnight under a nitrogen atmosphere. The reaction was then allowed to cool to
room temperature. 1H and 13C NMR spectroscopy showed the reaction had reached
completion and the desired product 54 had been formed exclusively. δH (300 MHz;
CDCl3) 3.27 (3 H, s, CH3OSO3-), 3.55 (3 H, s, CO2CH3), 4.40 (3 H, s, NCH3), 7.80-
7.85 (1 H, m, H-6), 8.00-8.06 (1 H, m, H-7), 8.18 (1 H, d, J3,4 8, H-3), 8.20-8.28
(2 H, m, H-5 and H-8) and 8.50 (1 H, d, J3,4 8, H-4); δC (75.46 MHz; CDCl3) 48.8
(CH3OSO3-), 54.6 (CO2CH3), 55.3 (NCH3), 121.3 (C-3), 129.0 (C-6), 130.6 (C-5),
130.9 (C-4a), 136.2 (C-8), 138.6 (C-7), 141.1 (C-4), 148.3 (C-8a), 149.2 (C-2) and
165.4 (CO2CH3).
The intermediate methyl N-methylquinoline-2-carboxylate 54 (3.20 g) was then
dissolved in concentrated hydrochloric acid (25 mL) and the resulting solution
was heated under reflux (100 °C) for 3 hours. Excess hydrochloric acid was
removed under reduced pressure to give a yellow solid. Recrystallisation from
methanol gave the product 55 as white crystals (1.89 g, 62%, over 2 steps);
mp 105-107 C; (Found: C 46.47; H 3.91; N 4.83. Calc. For C11H11NSO6: C 46.32;
H 3.86; N 4.91%); max (nujol / cm-1) 3050 (O─H stetch) and 1720 (C=O stretch);
δH (300 MHz; D2O) 4.35 (3 H, s, NCH3), 7.75-7.87 (1 H, m, H-6), 7.98-8.07 (1 H, m,
H-7), 8.17 (1 H, d, J3,4 8, H-3), 8.20-8.29 (2 H, m, H-5 and H-8) and 8.54 (1 H, d,
J3,4 8, H-4); δC (75.46 MHz; d6-DMSO) 47.9 (NCH3), 120.7 (C-3), 129.0 (C-6), 130.8
(C-5), 131.2 (C-4a), 136.0 (C-8), 138.8 (C-7), 141.2 (C-4), 147.8 (C-8a), 148.4 (C-2)
and 166.0 (CO2H); m/z (ES+) 188 (M+, 100%).
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Synthesis of methyl nicotinate (56)
N
CO2Me
56
To a suspension of nicotinic acid (8.85 g, 72 mmol) in methanol (100 mL) was added
concentrated sulfuric acid (12 mL), dropwise with stirring. Upon heating, nicotinic
acid dissolved and the resulting solution was heated under reflux overnight. The
reaction was quenched by pouring on to crushed ice. Concentrated ammonia solution
was added until the solution was strongly alkaline (pH 10). The product was then
extracted with diethyl ether (3 × 150 mL). The combined diethyl ether extracts were
dried (MgSO4) and the solvent was removed under reduced pressure to give an off-
white solid (7.93 g). The crude product was recrystallised from methanol to give the
pure product as a white crystalline solid (7.49 g, 76%); mp 40-43 C (lit.12 37-39 C);
max (nujol / cm-1) 1720 (C=O stretch); δH (300 MHz; CDCl3) 3.84 (3 H, s, CO2CH3),
7.43 (1 H, ddd, J2,5 1, J5,6 6 and J4,5 8, H-5), 8.19 (1 H, ddd, J4,6 1.5, J2,4 2 and J4,5 8,
H-4), 8.47 (1 H, dd, J4,6 1.5 and J5,6 6, H-6) and 8.85 (1 H, dd, J2,5 1 and J2,4 2, H-2);
δC (75.46 MHz; CDCl3) 52.4 (CO2CH3), 128.3 (C-5), 130.7 (C-3), 139.1 (C-4), 149.0
(C-6), 151.5 (C-2) and 164.1 (CO2CH3); m/z (ES+) 160 ((M+Na)+, 100%) and 138
((M+H)+, 8%).
Chapter Seven Experimental
272
Synthesis of N-methylnicotinic acid (59)
N
CO2Me
N
Me
CO2Me
CH3OSO3
N
Me
CO2H
+
-
+
.HSO4
-conc. HCl
reflux
(MeO)2SO2
70 oC
56 57 59
Dimethyl sulfate (1.1 mL, 12 mmol) was added slowly, with stirring, to methyl
nicotinate 56 (1.64 g, 12 mmol) and the reaction was heated at 70 °C for 6 hours
under a nitrogen atmosphere. Upon cooling, the reaction mixture crystallised,
forming a white solid. 1H and 13C NMR spectroscopy showed the reaction had
reached completion and the desired product 57 had been formed exclusively.
δH (300 MHz; CDCl3) 3.29 (3 H, s, CH3OSO3-), 4.24 (3 H, s, CO2CH3), 4.38 (3 H, s,
NCH3), 8.08 (1 H, ddd, J2,5 1, J5,6 6 and J4,5 8, H-5), 8.73 (1 H, ddd, J4,6 1.5, J2,4 2 and
J4,5 8, H-4), 8.97 (1 H, dd, J4,6 1.5 and J5,6 6, H-6) and 9.19 (1 H, dd, J2,5 1 and J2,4 2,
H-2); δC (75.46 MHz; CDCl3) 49.5 (CH3OSO3-), 53.4 (CO2CH3), 54.6 (NCH3), 128.9
(C-5), 130.7 (C-3), 145.1 (C-4), 147.0 (C-6), 149.5 (C-2) and 162.1 (CO2CH3).
The intermediate methyl N-methylnicotinate 57 (3.10 g) was then dissolved in
concentrated hydrochloric acid (25 mL) and the resulting solution was heated under
reflux (100 °C) for 2 hours. Excess hydrochloric acid was removed under reduced
pressure to give a white solid. Recrystallisation from methanol gave the product 59
as white crystals (2.54 g, 90%, over 2 steps); mp 166-168 C; (Found: C 36.14;
H 3.90; N 6.00. Calc. For C7H9NSO6: C 35.74; H 3.85; N 5.95%); max (nujol / cm-1)
3050 (O─H stretch) and 1760 (C=O stretch); δH (300 MHz; D2O) 4.32 (3 H, s,
NCH3), 8.02 (1 H, dd, J5,6 6 and J4,5 8, H-5), 8.81-8.86 (2 H, m, H-4 and H-6) and 9.22
(1 H, br s, H-2); δC (75.46 MHz; d6-DMSO) 51.3 (NCH3), 130.9 (C-5), 147.7 (C-3),
148.3 (C-4), 149.5 (C-6), 150.8 (C-2) and 164.2 (CO2H); m/z (ES+) 138 (M+, 100%).
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Synthesis of N-ethylnicotinic acid (60)
N
CO2Me
N
Et
CO2Me
CH3CH2OSO3
N
Et
CO2H
+
-
+
.HSO4
-conc. HCl
reflux
(EtO)2SO2
70 oC
56 58 60
Diethyl sulfate (1.5 mL, 12 mmol) was added slowly, with stirring, to methyl
nicotinate 56 (1.64 g, 12 mmol) and the reaction was heated at 70 °C overnight under
a nitrogen atmosphere. The reaction was then allowed to cool to room temperature.
1H and 13C NMR spectroscopy showed the reaction had reached completion and the
desired product 58 had been formed exclusively. δH (300 MHz; CDCl3) 1.21 (3 H, t,
J 8, CH3CH2OSO3-), 1.68 (3 H, t, J 8, CH3CH2N), 3.97 (3 H, s, CO2CH3), 4.03 (2 H,
q, J 8, CH3CH2OSO3-), 4.88 (2 H, q, J 8, CH3CH2N), 8.27 (1 H, ddd, J2,5 1, J5,6 6 and
J4,5 8, H-5), 8.90 (1 H, ddd, J4,6 1.5, J2,4 2 and J4,5 8, H-4), 9.33 (1 H, dd, J4,6 1.5 and
J5,6 6, H-6) and 9.36 (1 H, dd, J2,5 1 and J2,4 2, H-2); δC (75.46 MHz; CDCl3) 15.7
(CH3CH2OSO3-), 17.4 (NCH2CH3), 53.5 (CO2CH3), 58.8 (CH3CH2OSO3-), 63.8
(NCH2CH3), 129.6 (C-5), 131.5 (C-3), 145.4 (C-4), 145.9 (C-6), 149.2 (C-2) and
161.7 (CO2CH3).
The intermediate methyl N-ethylnicotinate 58 (3.40 g) was then dissolved in
concentrated hydrochloric acid (25 mL) and the resulting solution was heated under
reflux (100 °C) for 2 hours. Excess hydrochloric acid was removed under reduced
pressure to give a white solid. Recrystallisation from methanol gave the product 60
as white crystals (2.15 g, 72%, over 2 steps); mp 234-236 C; (Found: C 38.46;
H 4.51; N 5.67. Calc. For C8H11NSO6: C 38.55; H 4.42; N 5.62%); max (nujol / cm-1)
3000 (O─H stretch) and 1730 (C=O stretch); δH (300 MHz; D2O) 1.49 (3 H, t, J 7,
NCH2CH3), 4.54 (2 H, q, J 7, NCH2CH3), 8.05 (1 H, dd, J5,6 6 and J4,5 8, H-5),
8.85-8.89 (2 H, m, H-4 and H-6) and 9.19 (1 H, br s, H-2); δC (75.46 MHz;
d6-DMSO) 18.3 (NCH2CH3), 60.6 (NCH2CH3), 131.2 (C-5), 134.0 (C-3), 148.0 (C-4),
148.4 (C-6), 149.8 (C-2) and 167.1 (CO2H); m/z (ES+) 152 (M+, 100%).
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Attempted synthesis of quinolinic acid N-oxide (62)
N
CO2Me
CO2Me N
O
CO2Me
CO2Me N
O
CO2H
+
-
+
-
peracetic acid
acetic acid
Conc. HCl
reflux
DCM
reflux
38 61 63
Peroxyacetic acid (15 mL of a 32 wt% solution in dilute acetic acid, 63 mmol) was
added to dichloromethane (40 mL) and the solution was stirred at 0 C. To this
solution was added a solution of dimethyl quinolinate 38 (1.00g, 5 mmol) in
dichloromethane (10 mL) dropwise, with stirring. The resulting solution was allowed
to slowly warm to room temperature and was then heated under reflux for 6 hours.
The reaction was then cooled to room temperature and the solvent was removed
under reduced pressure to give a colourless oil. To the residue was added
dichloromethane (50 mL) followed by water (50 mL). The organic layer was washed
with water (50 mL), dried (MgSO4) and the solvent was removed under reduced
pressure to give a white solid. Recrystallisation from methanol gave the desired
product 61 as a white solid (0.25 g, 24%); mp 141-143 C (lit.13 (140-141 C);
max (nujol/cm-1) 1760 (C=O stretch) and 1300 (N+─O- stretch); δH (300 MHz; CDCl3)
3.88 (3 H, s, CO2CH3), 3.99 (3 H, s, CO2CH3), 7.35 (1 H, dd, J5,6 6 and J4,5 8, H-5),
7.82 (1 H, dd, J4,6 1 and J4,5 8, H-4) and 8.30 (1 H, dd, J4,6 1 and J5,6 6, H-6);
δC (75.46 MHz; d6-DMSO) 54.6 (CO2CH3), 55.6 (CO2CH3), 127.4 (C-5), 129.7 (C-3),
132.7 (C-4), 141.6 (C-6), 143.0 (C-2), 161.8 (CO2CH3) and 163.9 (CO2CH3);
m/z (ES+) 212 ((M+H)+, 100%).
A solution of dimethyl quinolinate N-oxide 61 (0.14 g, 0.7 mmol) in concentrated
hydrochloric acid (10 mL) was heated under reflux for 6 hours. The excess
hydrochloric acid was removed under reduced pressure. The product was
recrystallised from water to give a white solid (85 mg, 88%). The product was
identified as nicotinic acid N-oxide 63; mp 249-252 C (dec.) (lit.14 249 C (dec.));
max (nujol / cm-1) 3000 (O─H stretch), 1720 (C=O stretch) and 1295 (N+─O- stretch);
δH (300 MHz; D2O) 7.62 (1 H, ddd, J2,5 1, J5,6 6 and J4,5 8, H-5), 8.18 (1 H, ddd,
J4,6 1.5, J2,4 2 and J4,5 8, H-4), 8.42 (1 H, dd, J4,6 1.5 and J5,6 6, H-6) and 8.75 (1 H, dd,
J2,5 1 and J2,4 2, H-2); δC (75.46 MHz; d6-DMSO) 127.5 (C-5), 131.2 (C-3), 139.5
(C-4), 142.1 (C-6), 142.5 (C-2) and 164.2 (CO2H); m/z (ES+) 140 ((M+H)+, 100%).
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Synthesis of quinolinic acid N-oxide (62)
N
CO2H
CO2H
O
+
-
62
A mixture of quinolinic acid (0.50 g, 3 mmol) and peroxyacetic acid (10 mL of a
32 wt% solution in dilute acetic acid, 42 mmol) was gently heated. Upon heating,
quinolinic acid dissolved and the resulting solution was heated at 60 C. After
4 hours, a white precipitate began to separate. The reaction was heated at 60 C for a
further 2 hours and was then allowed to cool to room temperature. The white
precipitate was collected by suction filtration. Recrystallisation from water gave the
desired product 62 as a white solid (0.16 g, 30%); mp 263-265 C (dec.) (lit.15 mp
260-262 C (dec.)); (Found: C 45.95; H 2.75; N 7.70. Calc. For C7H5NO5: C 45.90;
H 2.73; N 7.65%); max (nujol / cm-1) 3000 (O─H stretch), 1730 (C=O stretch) and
1250 (N+─O- stretch); δH (300 MHz; D2O) 7.58 (1 H, dd, J5,6 6 and J4,5 8, H-5),
8.16 (1 H, dd, J4,6 1 and J4,5 8, H-4) and 8.38 (1 H, dd, J4,6 1 and J5,6 6, H-6);
δC (75.46 MHz; d6-DMSO) 126.4 (C-5), 126.7 (C-3), 127.8 (C-4), 142.0 (C-6), 143.3
(C-2), 162.0 (CO2H) and 163.9 (CO2H); m/z (ES+) 184 ((M+H)+, 100%).
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Attempted synthesis of N-(2-hydroxyethyl)quinolinic acid (64)
N
CO2Me
CO2Me N
OH
CO2Me
CO2Me
O CO2H
N
O
O
+
THF, -78 oC
BF3.Et2O
conc. HCl
reflux
+
38 65 66
To a solution of dimethyl quinolinate 38 (1.28 g, 6.6 mmol) in dry tetrahydrofuran
(20 mL) was added boron trifluoride diethyl etherate (2.5 mL, 20 mmol). The
resulting solution was cooled to -78 C and ethylene oxide (0.5 g, 11.4 mmol) was
swiftly decanted to the flask. After stirring at -78 C under a nitrogen bubbler for
2 hours, the reaction was allowed to slowly warm to room temperature overnight.
The solvent was removed under reduced pressure. Water (50 mL) was added to the
residue and the insoluble white solid was removed by filtration. The water
was removed under reduced pressure to give a pale yellow solid (1.32 g, 82%);
δH (300 MHz; D2O) 3.38 (2 H, t, J 7, CH2), 3.82 (3 H, s, CO2CH3), 3.87 (3 H, s,
CO2CH3), 4.05 (2 H, t, J 7, CH2O), 7.62 (1 H, dd, J5,6 5 and J4,5 8, H-5), 8.20 (1 H, dd,
J4,6 1.5 and J4,5 8, H-4) and 8.60 (1 H, dd, J4,6 1.5 and J5,6 5, H-6); δC (75.46 MHz;
d6-DMSO) 51.2 (CO2CH3), 52.7 (CO2CH3), 60.8 (CH2), 62.4 (CH2), 126.8 (C-5),
129.2 (C-3), 145.9 (C-4), 149.0 (C-6), 151.7 (C-2), 158.6 (CO2CH3) and 161.1
(CO2CH3); m/z (ES+) 240 (M+, 100%).
A solution of dimethyl N-(2-hydroxyethyl)quinolinate 65 (1.20 g) in concentrated
hydrochloric acid (20 mL) was heated under reflux for 6 hours. The reaction was then
cooled to room temperature and the excess hydrochloric acid was removed under
reduced pressure to give a pale brown solid (0.95 g). All attempts to purify
the product failed. The product was identified as the bicyclic compound 66;
δH (300 MHz; D2O) 3.45 (2 H, t, J 7, CH2), 4.10 (2 H, t, J 7, CH2), 7.97 (1 H, dd,
J5,6 5 and J4,5 8, H-5), 8.70 (1 H, dd, J4,6 1.5 and J4,5 8, H-4) and 8.74 (1 H, dd, J4,6 1.5
and J5,6 5, H-6); δC (75.46 MHz; d6-DMSO) 57.7 (CH2), 58.9 (CH2), 127.0 (C-5),
130.3 (C-3), 148.2 (C-4), 149.5 (C-6), 152.4 (C-2), 157.8 (C=O) and 163.0 (CO2H);
m/z (ES+) 194 (M+, 100%).
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7.4.3 Routes to 4-substituted quinolinic acid derivatives
7.4.3.1 Route 1 – Directed ortho-metalation
Synthesis of diisopropyl quinolinate (69)16
N
CO2
CO2iPr
iPr
69
To a suspension of quinolinic acid (4.98 g, 29.8 mmol) in isopropanol (40 mL) was
added concentrated sulfuric acid (6 mL), dropwise with stirring. Upon heating,
quinolinic acid dissolved and the resulting solution was heated under reflux overnight.
The solution was then cooled and poured on to crushed ice. Concentrated ammonia
solution was added until the solution was strongly alkaline (pH 10). The product was
then extracted with diethyl ether (3 × 100 mL). The combined diethyl ether extracts
were dried (MgSO4) and the solvent was removed under reduced pressure to give a
yellow oil (3.46 g). The crude product was purified by column chromatography on
silica with dichloromethane / ethyl acetate (4:1) as the eluting solvent. This gave the
desired product as a colourless oil (3.02 g, 40%); max (nujol / cm-1) 1740 (C=O
stretch); δH (300 MHz; CD3OD) 1.36 (6 H, d, J 5, 2 × CH3), 1.39 (6 H, d, J 5,
2 × CH3), 5.17-5.31 (2 H, m, 2 × CH(CH3)2), 7.63 (1 H, dd, J5,6 5 and J4,5 8, H-5),
8.28 (1 H, dd, J4,6 1.5 and J4,5 8, H-4) and 8.72 (1 H, dd, J4,6 1.5 and J5,6 5, H-6);
δC (75.46 MHz; CDCl3) 23.6 (2 × CH3), 23.7 (2 × CH3), 71.4 (CH (iPr)), 71.9
(CH (iPr)), 124.9 (C-5), 126.8 (C-3), 138.0 (C-4), 152.0 (C-6), 152.1 (C-2), 165.0
(CO2iPr) and 166.3 (CO2iPr); m/z (ES+) 290 ((M+K)+, 5%), 274 ((M+Na)+, 100%) and
252 ((M+H)+, 10%).
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Attempted synthesis17 of diisopropyl 4-trimethylsilylquinolinate (70)
N
CO2
CO2
SiMe3
iPr
iPr
70
To a solution of 2,2,6,6-tetramethylpiperidine (1.0 mL, 6.0 mmol) in dry
tetrahydrofuran (10 mL) was added n-butyllithium (4.2 mL of a 1.6 M solution in
hexane, 6.6 mmol) with stirring at -78 °C, under a nitrogen atmosphere. After
25 minutes, a solution of trimethylsilyl chloride (3.8 mL, 30.0 mmol) in dry
tetrahydrofuran (5 mL) was added, followed by the dropwise addition of a solution of
diisopropyl quinolinate (0.77 g, 3.0 mmol) in dry tetrahydrofuran (10 mL) over
15 minutes. After stirring at -78 °C for 2 hours, the solution was allowed to gradually
warm up to room temperature. The reaction was quenched by pouring the reaction
mixture over 5% aqueous sodium hydrogen carbonate solution (10 mL). The organic
material was extracted with diethyl ether (3 × 50 mL), washed with water (15 mL)
and brine (2 × 20 mL) and dried (K2CO3). Removal of the solvent under reduced
pressure gave a brown oil (0.84 g). An attempt was made to separate the components
of the crude product by column chromatography on silica, employing gradient elution
5:1 hexane / ethyl acetate to 1:1 hexane / ethyl acetate. The major product isolated
was identified as diisopropyl 4,6-di(trimethylsilyl)quinolinate 71 (0.18 g, 15%);
δH (300 MHz; CDCl3) 0.25 (9 H, s, Si(CH3)3), 0.27 (9 H, s, Si(CH3)3), 1.29 (6 H, d,
J 6, 2 × CH3), 1.34 (6 H, d, J 6, 2 × CH3), 5.13-5.24 (2 H, m, 2 × CH(CH3)2) and 7.66
(1 H, s, H-5); δC (75.46 MHz; CDCl3) 0.0 (2 × Si(CH3)3), 22.1 (4 × CH3 (iPr)),
70.3 (CH (iPr)), 70.4 (CH (iPr)), 124.9 (C-5), 126.9 (C-3), 134.2 (C-4), 149.1 (C-6),
152.0 (C-2), 165.0 (CO2iPr) and 166.5 (CO2iPr); m/z (ES+) 418 ((M+Na)+, 100%) and
396 ((M+H)+, 25%).
N
CO2
CO2
SiMe3
Me3Si
iPr
iPr
71
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7.4.3.2 Route 2 - Addition to N-acylpyridinium salts18
N
CO2
CO2 N
CO2
CO2
H
O OEt
Ph
iPr
iPriPr
iPr
1. 5% CuI
2. EtOCOCl
3. PhMgBr
69 78
To a solution of diisopropyl quinolinate 69 (1.00 g, 4.0 mmol) in dry tetrahydrofuran
(20 mL) under nitrogen was added CuI (57 mg, 0.3 mmol) and the mixture was stirred
at room temperature until it became homogeneous. The reaction was cooled to
approximately -30 oC (dry ice / xylene) then ethyl chloroformate (0.6 mL, 6.0 mmol)
was added, with stirring. After 10 minutes, phenyl magnesium bromide (2 mL of a
3 M solution in diethyl ether, 6.0 mmol) in dry tetrahydrofuran (10 mL) was added
slowly via cannula. The resulting orange solution was stirred for 2 hours at
approximately -30 oC (dry ice / xylene) and then at room temperature for 2 hours.
The reaction was quenched by addition of 20% aqueous ammonium chloride solution
(20 mL) followed by diethyl ether (25 mL). The organic layer was separated and
washed sequentially with 20% aqueous ammonium chloride / ammonium hydroxide
solution (50:50, 20 mL), water (20 mL), 10% HCl (20 mL), water (20 mL) and brine
(20 mL). After drying (MgSO4), the solution was filtered and evaporated to yield a
yellow oil (2.69 g). TLC and 1H NMR analysis of the crude product showed no
reaction had occurred.
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7.4.3.3 Route 3 – Oxidation of 4-substituted quinolines
7.4.3.3.1 Synthesis of 4-substituted quinolines
Attempted synthesis19 of 4-isobutylquinoline (87) (I)
N
87
To a solution of n-butyllithium (2.8 mL of a 2.5 M solution in hexane, 7.0 mmol) in
dry diethyl ether (20 mL) was added a solution of 4-methylquinoline 84 (1.00 g,
7.0 mmol) in diethyl ether (5 mL), under nitrogen. The reaction mixture turned bright
red/orange. After 10 minutes, a solution of isopropyl bromide (0.33 mL, 3.5 mmol) in
dry diethyl ether (3 mL) was added slowly over 20 minutes. The resulting solution
was heated under reflux, under nitrogen, for 1 hour. The reaction mixture was
allowed to cool to room temperature and was then poured over crushed ice. The two
phases were separated and the aqueous layer was extracted with diethyl ether
(3 x 75 mL). The combined diethyl ether extracts were dried (Na2SO4) and the
solvent was removed under reduced pressure to give a yellow oil (0.98 g). No attempt
was made to purify the crude product. The major product was identified as 2-butyl-4-
methyl-1,2-dihydroquinoline 88; δH (300 MHz; CDCl3) 0.83 (3 H, t, J 7, CH3),
1.18-1.33 (4 H, m, 2 x CH2), 1.43-1.52 (2 H, m, CH2), 1.90 (3 H, s, 4-CH3), 3.68 (1 H,
br s, NH), 4.03-4.09 (1 H, m, H-2), 5.30-5.33 (1 H, m, H-3), 6.32 (1 H, dd, J5,7 1 and
J5,6 8, H-5), 6.49-6.55 (1 H, m, H-6), 6.85-6.90 (1 H, m, H-7) and 6.93 (1 H, dd, J6,8 1
and J7,8 8, H-8); m/z (ES+) 202 ((M+H)+, 10%). The minor product was identified as
2-butyl-4-methylquinoline 89; δH (300 MHz; CDCl3) 0.88 (3 H, t, J 7, CH3), 1.10-
1.18 (2 H, m, CH2), 1.31-1.40 (2 H, m, CH2), 1.66-1.76 (2 H, m, CH2), 2.59 (3 H, s,
4-CH3), 7.06 (1 H, s, H-3), 7.38-7.44 (1 H, m, H-6), 7.56-7.61 (1 H, m, H-7), 7.85-
7.88 (1 H, m, H-5) and 7.95-7.99 (1 H, m, H-8); m/z (ES+) 200 ((M+H)+, 100%).
N
CH3
N
H
CH3
nBu
89
nBu
88
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Attempted synthesis19 of 4-isobutylquinoline (87) (II)
N
87
To a solution of methyllithium (4.4 mL of a 1.6 M solution in diethyl ether, 7.0 mmol)
in dry diethyl ether (20 mL) was added a solution of 4-methylquinoline 84 (1.00 g, 7.0
mmol) in diethyl ether (5 mL), under nitrogen. The resulting solution was heated
under reflux for 30 minutes. A solution of isopropyl bromide (0.33 mL, 3.5 mmol) in
dry diethyl ether (3 mL) was then added slowly and the resulting solution was heated
under reflux, under nitrogen, for 2.5 hours. The reaction mixture was allowed to cool
to room temperature and was then poured over crushed ice. The two phases were
separated and the aqueous layer was extracted with diethyl ether (3 x 75 mL). The
combined ether extracts were dried (Na2SO4) and the solvent was removed under
reduced pressure to give a yellow oil (0.72 g). No attempt was made to purify the
crude product. The product was identified as 2,4-dimethyl-1,2-dihydroquinoline 90;
δH (300 MHz; CDCl3) 1.17 (3 H, d, J 6, 2-CH3), 1.89 (3 H, s, 4-CH3), 3.68 (1H, br s,
NH), 4.20-4.28 (1 H, m, H-2), 5.26-5.29 (1 H, m, H-3), 6.33 (1 H, dd, J5,7 1 and J5,6 8,
H-5), 6.51-6.57 (1 H, m, H-6), 6.85-6.91 (1 H, m, H-7) and 6.93 (1 H, dd, J6,8 1 and
J7,8 8, H-8); m/z (ES+) 160 ((M+H)+, 100%).
N
H
CH3
CH3
90
Chapter Seven Experimental
282
Attempted synthesis of 4-isobutylquinoline (87) (III)
N
87
Dry diisopropylamine (1.00 mL, 7.0 mmol) was stirred under nitrogen in dry
tetrahydrofuran (25 mL) at -78 °C for 10 minutes. n-Butyllithium (2.8 mL of a 2.5 M
solution in hexane, 7.0 mmol) was added and the mixture was allowed to slowly reach
room temperature. The resulting lithium diisopropylamide solution was then cooled
to -78 °C and transferred slowly via cannula to a solution of 4-methylquinoline 84
(1.00 g, 7.0 mmol) in dry tetrahydrofuran (25 mL) that was also previously cooled to
-78 °C. The mixture was left to stir at -30 °C for 1 hour then the resulting red solution
was again cooled to -78 °C. A solution of isopropyl bromide (0.65 mL, 6.7 mmol) in
dry tetrahydrofuran (8 mL) that was previously cooled to -78 °C was then added
slowly via cannula. The resulting solution was stirred under nitrogen overnight,
slowly allowing the reaction to warm to room temperature. The reaction mixture was
then added to water (100 mL) and stirred for 10 minutes before extracting with diethyl
ether (3  100 mL). The diethyl ether extracts were washed with water (100 mL),
dried (Na2SO4) and evaporated under reduced pressure. This gave the crude product
as a brown oil (1.54 g). TLC and 1H NMR analysis of the crude product showed no
reaction had occurred.
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Synthesis20,21 of 4-isobutylquinoline (87)
N
87
To liquid ammonia (120 mL) was added iron (III) nitrate (0.05 g) with vigorous
stirring. To the resulting orange solution was added clean sodium (1.21 g,
52.5 mmol) in small pieces over a period of 30 minutes. Stirring was continued until
the initial dark blue colour was replaced by a grey suspension of sodium amide.
4-Methylquinoline 84 (5.02 g, 35.1 mmol) was then added dropwise. After stirring
the resulting solution for 30 minutes, isopropyl bromide (6.46 g, 52.5 mmol) was
added at such a rate that the reaction did not become unduly vigorous. The reaction
was stirred for 1 hour and then ammonium chloride was added to quench the reaction.
The ammonia was allowed to evaporate overnight. To the resulting orange residue
was added diethyl ether (100 mL) followed by water (100 mL). The two phases were
separated and the aqueous phase was extracted further with diethyl ether (100 mL).
The combined diethyl ether extracts were extracted with 6N hydrochloric acid
solution (4 x 25 mL). The acid extracts were then made strongly alkaline by the
addition of solid sodium hydroxide. A brown oil formed on the surface and was
separated. The aqueous layer was extracted with diethyl ether (3 x 100 mL). The
combined upper layer (brown oil) and diethyl ether extracts were dried (sodium
sulfate) and the solvent was removed under reduced pressure to give a dark brown oil
(5.04 g). The crude product was purified by column chromatography on silica
employing gradient elution 3:1 petroleum ether / ethyl acetate to 1:1 petroleum ether /
ethyl acetate. This gave the desired product 87 as a pale yellow oil (2.79 g, 43%);
max/cm-1 3025, 1600 and 1510; δH (300 MHz; CDCl3) 0.90 (6 H, d, J 7, 2 x CH3),
1.94-2.07 (1 H, m, CH), 2.84 (2 H, d, J 7, CH2), 7.11 (1 H, d, J2,3 5, H-3), 7.43-7.49
(1 H, m, H-6), 7.58-7.64 (1 H, m, H-7), 7.94 (1 H, ddd, J5,6 8, J5,7 1.5 and J5,8 0.5,
H-5), 8.03 (1 H, ddd, J7,8 8, J6,8 1.5 and J5,8 0.5, H-8) and 8.71 (1 H, d, J2,3 5, H-2);
δC (75.46 MHz; CDCl3) 23.0 (2 x CH3), 29.6 (CH), 41.8 (CH2), 122.1 (C-3), 124.2
(C-6), 126.4 (C-5), 128.2 (C-4a), 129.2 (C-8), 130.4 (C-7), 147.9 (C-4), 148.7 (C-8a)
and 150.2 (C-2); m/z (ES+) 208 ((M+Na)+, 15%) and 186 ((M+H)+, 100%).
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Synthesis20,21 of 4-benzylquinoline (91)
N
91
To liquid ammonia (120 mL) was added iron (III) nitrate (0.04 g) with vigorous
stirring. To the resulting orange solution was added clean sodium (1.21 g,
52.5 mmol) in small pieces over a period of 30 minutes. Stirring was continued until
the initial dark blue colour was replaced by a grey suspension of sodium amide.
4-Methylquinoline 84 (5.02 g, 35.1 mmol) was then added dropwise. After stirring
the resulting solution for 30 minutes, bromobenzene (8.24 g, 52.5 mmol) was added at
such a rate that the reaction did not become unduly vigorous. After stirring for
1 hour, the reaction was quenched by addition of ammonium chloride and the
ammonia was allowed to evaporate overnight. To the resulting orange residue was
added diethyl ether (100 mL) followed by water (100 mL). The two phases were
separated and the aqueous phase was extracted further with diethyl ether (100 mL).
The combined diethyl ether extracts were extracted with 6N hydrochloric acid
solution (4 x 25 mL). The acid extracts were then made strongly alkaline by the
addition of solid sodium hydroxide. A brown oil formed on the surface and was
separated. The aqueous layer was extracted with diethyl ether (3 x 100 mL). The
combined upper layer (brown oil) and diethyl ether extracts were dried (Na2SO4) and
the solvent was removed under reduced pressure to give a dark brown oil (4.24 g).
The crude product was purified by column chromatography on silica employing
gradient elution 3:1 petroleum ether / ethyl acetate to 1:1 petroleum ether / ethyl
acetate. This gave the desired product 91 as a pale yellow oil (1.66 g, 22%); max/cm-1
3029, 1591 and 1508; δH (300 MHz; CDCl3) 4.44 (2 H, s, CH2), 7.13 (1 H, d, J2,3 5,
H-3), 7.19-7.34 (5 H, m, 5  Ar-H), 7.50-7.56 (1 H, m, H-6), 7.67-7.73 (1 H, m, H-7),
8.03 (1 H, ddd, J5,6 8, J5,7 1.5 and J5,8 0.5, H-5), 8.15 (1 H, ddd, J7,8 8, J6,8 1.5 and
J5,8 0.5, H-8) and 8.83 (1 H, d, J2,3 5, H-2); δC (75.46 MHz; CDCl3) 38.6 (CH2), 122.3
(C-3), 124.3 (C-6), 127.0 (C-5), 127.1 (C-4’), 128.0 (C-4a), 129.1, 129.3 (C-2’, C-3’,
C-5’ and C-6’), 129.6 (C-8), 130.6 (C-7), 139.0 (C-1’), 147.0 (C-4), 148.8 (C-8a) and
150.7 (C-2); m/z (ES+) 220 ((M+H)+, 100%).
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Synthesis20,21 of 4-phenethylquinoline (94)
N
94
To liquid ammonia (50 mL) was added iron (III) nitrate (0.02 g) with vigorous
stirring. To the resulting orange solution was added clean sodium (0.24 g,
10.5 mmol) in small pieces over a period of 30 minutes. Stirring was continued until
the initial dark blue colour was replaced by a grey suspension of sodium amide.
4-Methylquinoline 84 (1.00 g, 7.0 mmol) was then added dropwise. After stirring the
resulting solution for 30 minutes, benzyl bromide (1.80 g, 10.5 mmol) was added at
such a rate that the reaction did not become unduly vigorous. The reaction mixture
was stirred for a further 1 hour and then ammonium chloride was added to quench the
reaction and the ammonia was allowed to evaporate overnight. To the orange residue
was added diethyl ether (50 mL) followed by water (50 mL). The two phases were
separated and the diethyl ether phase was extracted with 6N hydrochloric acid
solution (4 x 20 mL). The acid extracts were then made strongly alkaline by the
addition of solid sodium hydroxide. A brown oil formed on the surface and was
separated. The aqueous layer was extracted with diethyl ether (3 x 50 mL). The
combined upper layer (brown oil) and diethyl ether extracts were dried (Na2SO4) and
the solvent was removed under reduced pressure to give a dark brown oil (0.73 g).
The crude product was purified by column chromatography on silica employing
gradient elution 3:1 petroleum ether / ethyl acetate to 1:1 petroleum ether / ethyl
acetate. This gave the desired product 94 as a pale yellow solid (0.40 g, 24%); mp 98-
100 C (lit.22 mp 101-103 C); max/cm-1 3030, 1595 and 1510; δH (300 MHz; CDCl3)
3.01 (2 H, t, J 8, CH2), 3.32 (2 H, t, J 8, CH2), 7.10-7.27 (6 H, m, 6 x Ar-H), 7.48-7.54
(1 H, m, H-6), 7.62-7.68 (1 H, m, H-7), 8.01 (1 H, ddd, J5,6 8, J5,7 1.5 and J5,8 0.5,
H-5), 8.07 (1 H, ddd, J7,8 8, J6,8 1.5 and J5,8 0.5, H-8) and 8.72 (1 H, d, J2,3 5, H-2);
δC (75.46 MHz; CDCl3) 34.5 (CH2), 36.6 (CH2), 121.3 (C-3), 123.8 (C-6), 126.7
(C-5), 126.8 (C-4’), 128.0 (C-4a), 128.8, 129.0 (C-2’, C-3’, C-5’ and C-6’), 129.5
(C-8), 130.7 (C-7), 141.4 (C-1’), 147.8 (C-4), 148.8 (C-8a) and 150.6 (C-2); m/z (ES+)
256 ((M+Na)+, 5%) and 234 ((M+H)+, 100%).
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7.4.3.3.2 Oxidation of 4-substituted quinolines
Synthesis23 of 4-methylquinolinic acid (95)
N
CH3
CO2H
CO2H
95
To a biphasic mixture of dichloromethane (75 mL) and sodium hypochlorite solution
(50 mL diluted with 155 mL of water, 1.0 mol) was added ruthenium (IV) oxide
(24 mg, 175 mol) under vigorous stirring at room temperature. When the reaction
mixture was yellow, 4-methylquinoline 84 (1.00 g, 7.0 mmol) was added dropwise.
After stirring at room temperature for 7.5 hours, the mixture became black. TLC
analysis (dichloromethane:methanol, 95:5) showed that the conversion was not
complete and an additional amount of sodium hypochlorite solution (20 mL, 0.4 mol)
was added. After stirring overnight at room temperature, the aqueous phase was
separated, washed with diethyl ether (2 x 100 mL) and acidified to pH 1 with 37%
hydrochloric acid. Evaporation to dryness gave the crude product as a yellow
solid (23.20 g). Desalinisation of the crude product was attempted by adding
N,N-dimethylformamide (100 mL), then removing the insoluble salt by filtration.
The filtrate was evaporated and the resulting orange solid was washed with toluene
(4 x 50 mL) followed by chloroform (3 x 50 mL). Recrystallisation from ethanol
gave the product 95 as an orange solid (0.88 g, 69%, impure); mp 180 C (dec.)
(lit.24 mp 188–190 C); max(H2O)/nm 276 (log  1.96) (lit.24 276 (log  3.69));
max/cm-1 3000 (O─H stretch) and 1725 (C=O stretch); δH (300 MHz; D2O)
2.52 (3 H, s, 4-CH3), 7.91 (1 H, d, J5,6 6, H-5) and 8.49 (1 H, d, J5,6 6, H-6);
δC (75.46 MHz; CD3OD) 19.6 (CH3), 130.0 (C-5), 135.0 (C-3), 146.5 (C-4), 149.2
(C-6), 152.0 (C-2), 167.5 (CO2H) and 171.4 (CO2H); m/z (ES+) 182 ((M+H)+, 100%).
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